ACC/AHA Appendix Code	ACC/AHA Appendix PT	ACC/AHA Concept PT	ACC/AHA Header Subset Code	ACC/AHA Header PT	ACC/AHA Definition	NCIt Concept Code	NCIt PT	NCIt SY	NCIt Definition	Row
C191382	COVID-19 Diagnosis	Acute COVID-19 case				C171133	COVID-19 Infection	2019-nCoV Infection || COVID-19 || COVID-19 Virus Infection || HCoV-19 Infection || Human Coronavirus 2019 Infection || SARS Coronavirus 2 Infection || SARS-2 Infection || SARS-CoV-2 Disease || SARS-CoV-2 Infection || SARS-CoV2 Disease || SARS-CoV2 Infection || SARS2 Infection || Severe Acute Respiratory Syndrome Coronavirus 2 Infection	An acute infection of the respiratory tract that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on currently available information, SARS-CoV-2 is thought to mainly spread from person to person through respiratory droplets. Typically, there is a two- to 14-day incubation period and infected persons can present with no symptoms or mild to severe fever, dry cough, fatigue, and difficulty breathing. Dysgeusia, anosmia, and gastrointestinal and flu-like symptoms have also been reported. Older adults and persons of any age who have serious underlying medical conditions may be of higher risk for severe illness, including secondary infections, respiratory failure, and multi-organ dysfunction.	2
C191382	COVID-19 Diagnosis	Confirmed acute COVID-19 case			Requires detection of SARS-CoV-2 RNA in a clinical or autopsy specimen using a molecular amplification test (e.g., RT-PCR)	C191513	Confirmed Acute COVID-19 Case		An acute COVID-19 infection that is verified by detection of SARS-CoV-2 RNA in a clinical or autopsy specimen using a molecular amplification test (e.g., RT-PCR).	3
C191382	COVID-19 Diagnosis	Probable acute COVID-19 case			Detection of SARS-CoV-2 by antigen test in a respiratory specimen OR Meets clinical criteria and epidemiological linkage criteria for COVID-19 with no confirmatory laboratory testing performed OR A death certificate that lists COVID-19 disease or SARS-CoV-2 as an underlying cause of death or a significant condition contributing to death with no confirmatory laboratory evidence of SARS-CoV-2	C191609	Probable Acute COVID-19 Case		A presumed acute COVID-19 infection as evidenced by detection of SARS-CoV-2 by antigen test in a respiratory specimen, by meeting clinical criteria and epidemiological linkage criteria for COVID-19 with no confirmatory laboratory testing performed, or by a death certificate that lists COVID-19 disease or SARS-CoV-2 as an underlying cause of death or a significant condition contributing to death with no confirmatory laboratory evidence of SARS-CoV-2.	4
C191382	COVID-19 Diagnosis	Suspected acute COVID-19 case			Requires detection of specific antibody in serum, plasma, or whole blood, or detection of specific antigen by immunocytochemistry in an autopsy specimen.	C191515	Suspected Acute COVID-19 Case		A likely acute COVID-19 infection as evidenced by detection of specific antibody in serum, plasma, or whole blood, or detection of specific antigen by immunocytochemistry in an autopsy specimen.	5
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	6
C191382	COVID-19 Diagnosis	No			COVID-19 test negative and no symptoms to suggest COVID-19	C38757	Negative Finding	Negative	A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.	7
C191382	COVID-19 Diagnosis	COVID-19 symptom status			Presence or absence of symptoms due to acute COVID-19	C191554	COVID-19 Symptom Status		The presence or absence of symptoms due to acute COVID-19.	8
C191382	COVID-19 Diagnosis	Symptomatic				C171549	Symptomatic COVID-19 Infection Laboratory-Confirmed	COVID-19 Symptomatic Laboratory-Confirmed || Symptomatic SARS-CoV-2 Infection Laboratory-Confirmed	An infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is symptomatic at the time of testing.	9
C191382	COVID-19 Diagnosis	Asymptomatic				C171547	Asymptomatic COVID-19 Infection Laboratory-Confirmed	Asymptomatic SARS-CoV-2 Infection Laboratory-Confirmed || COVID-19 Asymptomatic Laboratory-Confirmed	An infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is asymptomatic at the time of testing.	10
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	11
C191382	COVID-19 Diagnosis	Exposure to infectious COVID-19 case			Being in close contact, as defined by the CDC, with a person with a probable or confirmed acute COVID-19 case while the person was in the presumptive infectious period	C171571	Exposed to COVID-19	Exposed to SARS-CoV-2	A finding indicating that an individual has been exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	12
C191382	COVID-19 Diagnosis	Yes				C49488	Yes		The affirmative response to a question.	13
C191382	COVID-19 Diagnosis	No				C49487	No		The non-affirmative response to a question.	14
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	15
C191382	COVID-19 Diagnosis	Persistently positive SARS-CoV-2 antigen or molecular test			Persistently positive virological test (molecular amplification or antigen test) in a patient who is out of the presumptive infectious period of acute COVID-19	C191618	Persistent SARS Coronavirus 2 Positive	Persistently SARS Coronavirus 2 Positive	An indication that SARS-CoV-2 continued to be detected in a patient's biological samples beyond the presumptive infectious period of acute COVID-19.	16
C191382	COVID-19 Diagnosis	Yes				C49488	Yes		The affirmative response to a question.	17
C191382	COVID-19 Diagnosis	No				C49487	No		The non-affirmative response to a question.	18
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	19
C191382	COVID-19 Diagnosis	Postacute sequelae of SARS-CoV-2 infection (PASC)			Symptoms that significantly impair quality of life, which started during or after probable or confirmed acute COVID-19 and have persisted 4 wk to 3 mo after the initial diagnosis of COVID-19	C179263	Post-Acute Sequelae of COVID-19	Long COVID || Long COVID-19 Syndrome	A constellation of signs and symptoms that can persist for weeks or months after acute infection with SARS-CoV-2, or appear weeks after infection. This condition may be characterized by fatigue, shortness of breath, difficulty focusing or concentrating ("brain fog"), sleep disorders, fevers, gastrointestinal symptoms, anxiety, and depression.	20
C191382	COVID-19 Diagnosis	Yes				C49488	Yes		The affirmative response to a question.	21
C191382	COVID-19 Diagnosis	No				C49487	No		The non-affirmative response to a question.	22
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	23
C191382	COVID-19 Diagnosis	Multisystem inflammatory syndrome in children (MIS-C)			The occurrence of fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization with multisystem (greater than or equal to 2) organ involvement AND No plausible alternative diagnoses AND Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test OR exposure to a suspected or confirmed COVID-19 case within 4 wk prior to symptom onset in an individual aged <21 y	C172127	Multisystem Inflammatory Syndrome in Children	COVID-19-Related Pediatric Inflammatory Multisystem Syndrome || Multisystem Inflammatory Syndrome in Children Associated with COVID-19 || Pediatric Inflammatory Multisystem Syndrome || Pediatric Multi-System Inflammatory Syndrome Potentially Associated with COVID-19 || Pediatric Multisystem Inflammatory Syndrome	A rare syndrome temporally associated with COVID-19 in children, marked by persistent fever, inflammation (neutrophilia, elevated C-reactive protein (CRP), and lymphopenia), poor function in one or more organs, and other specific clinical and laboratory features not attributable to other infections. The characteristics of this syndrome appear to be similar to toxic shock syndrome and Kawasaki disease. The following variable signs and symptoms have been most commonly reported to date: coagulopathy, cardiac dysfunction, diarrhea, abdominal distension, other GI symptoms (with some children having positive stool tests for SARS-CoV-2), and acute kidney injury. Respiratory symptoms are not always a prominent feature in these cases.	24
C191382	COVID-19 Diagnosis	Yes				C49488	Yes		The affirmative response to a question.	25
C191382	COVID-19 Diagnosis	No				C49487	No		The non-affirmative response to a question.	26
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	27
C191382	COVID-19 Diagnosis	Multisystem inflammatory syndrome in adults (MIS-A)			A patient aged greater than or equal to 21 y hospitalized for greater than or equal to 24 h, or with an illness resulting in death, who meets the following clinical and laboratory criteria. The patient should not have a more likely alternative diagnosis for the illness (e.g., bacterial sepsis, exacerbation of a chronic medical condition). I. Clinical Criteria: Subjective fever or documented fever (greater than or equal to 38.0 degrees C) for greater than or equal to 24 h prior to hospitalization or within the first 3 d of hospitalization* and at least 3 of the following clinical criteria occurring prior to hospitalization or within the first 3 d of hospitalization*. At least 1 must be a primary clinical criterion: A. Primary clinical criteria: 1. Severe cardiac illness includes myocarditis, pericarditis, coronary artery dilatation/aneurysm, or new-onset right or left ventricular dysfunction (LVEF <50%), 2nd/3rd degree AV block, or ventricular tachycardia. (Note: cardiac arrest alone does not meet this criterion) 2. Rash and nonpurulent conjunctivitis B. Secondary clinical criteria: 1. New-onset neurological signs and symptoms: includes encephalopathy in a patient without prior cognitive impairment, seizures, meningeal signs, or peripheral neuropathy (including Guillain-Barr� syndrome) 2. Shock or hypotension not attributable to medical therapy (e.g., sedation, renal replacement therapy) 3. Abdominal pain, vomiting, or diarrhea 4. Thrombocytopenia (platelet count <150,000/microliter) II. Laboratory evidence: The presence of laboratory evidence of inflammation and SARS-CoV-2 infection. A. Elevated levels of at least 2 of the following: C-reactive protein, ferritin, IL-6, erythrocyte sedimentation rate, procalcitonin B. A positive SARS-CoV-2 test for current or recent infection by RT-PCR, serology, or antigen detection NOTE: *These criteria must be met by the end of hospital day 3, where the date of hospital admission is hospital day 0.	C178502	Multisystem Inflammatory Syndrome in Adults		A rare syndrome found in adults with positive test results for SARS-CoV-2 by polymerase chain reaction or antibody assays indicating recent infection that is marked by cardiovascular, gastrointestinal, dermatologic, and neurologic symptoms without severe respiratory illness. The most common signs and symptoms that have been reported to date include fever, low blood pressure, abdominal pain, vomiting, diarrhea, neck pain, rash, chest pain, and tiredness not attributable to other infections.	28
C191382	COVID-19 Diagnosis	Yes				C49488	Yes		The affirmative response to a question.	29
C191382	COVID-19 Diagnosis	No				C49487	No		The non-affirmative response to a question.	30
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	31
C191382	COVID-19 Diagnosis	Prior COVID-19			Prior evidence of COVID-19 in an individual who is no longer in the infectious period	C191430	Prior COVID-19 Infection		A finding indicating that there is prior evidence of COVID-19 in an individual who is no longer in the infectious period.	32
C191382	COVID-19 Diagnosis	Prior COVID-19 without residual sequelae of postacute COVID-19				C191608	Prior COVID-19 Infection Without Residual Sequelae of Post-Acute COVID-19		A finding indicating that there is prior evidence of COVID-19 in an individual who has no residual sequelae of post-acute COVID-19.	33
C191382	COVID-19 Diagnosis	Prior COVID-19 with residual sequelae of postacute COVID-19				C191607	Prior COVID-19 Infection With Residual Sequelae of Post-Acute COVID-19		A finding indicating that there is prior evidence of COVID-19 in an individual who has residual sequelae of post-acute COVID-19.	34
C191382	COVID-19 Diagnosis	COVID-19 reinfection			New discrete episode of acute COVID-19 in person with a prior history of probable/confirmed COVID-19. Other information can provide supporting but not definitive evidence for reinfection, such as culture or subgenomic mRNA analysis (to detect the presence of replication-competent virus) or serology, which could be useful to document a serological response to SARS-CoV-2. The following should be enumerated as a new case: SARS-CoV-2 sequencing results from the new positive specimen and a positive specimen from the most recent previous case demonstrate a different lineage. OR Person was most recently enumerated as a confirmed or probable case with onset date (if available) or first positive specimen collection date for that classification >90 d prior. OR Person was previously reported but not enumerated as a confirmed or probable case (i.e., suspect), but now meets the criteria for a confirmed or probable case. Repeat suspect cases should not be enumerated.	C191512	COVID Reinfection		A new, discrete episode of acute COVID-19 in an individual with a prior history of probable/confirmed COVID-19.	35
C191382	COVID-19 Diagnosis	Yes				C49488	Yes		The affirmative response to a question.	36
C191382	COVID-19 Diagnosis	No				C49487	No		The non-affirmative response to a question.	37
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	38
C191382	COVID-19 Diagnosis	Date of acute COVID-19 diagnosis			Date that viral testing confirming a diagnosis of acute COVID-19 was obtained	C191536	SARS-CoV-2 Diagnosis Date	COVID-19 Virus Diagnosis Date || Severe Acute Respiratory Syndrome Coronavirus 2 Diagnosis Date	The date that SARS-CoV-2 testing resulted in a diagnosis.	39
C191382	COVID-19 Diagnosis	Hospitalization due to COVID-19			Hospitalization due to COVID-19	C191557	Hospitalization due to COVID-19		Admission to a hospital due the health effects caused by COVID-19 infection.	40
C191382	COVID-19 Diagnosis	Yes				C49488	Yes		The affirmative response to a question.	41
C191382	COVID-19 Diagnosis	No				C49487	No		The non-affirmative response to a question.	42
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	43
C191382	COVID-19 Diagnosis	Hospitalization for any reason with incidental diagnosis of SARS-CoV-2 infection			Hospitalization for any non-COVID-19-related indication with incidental diagnosis of SARS-CoV-2 infection	C191558	Hospitalization with Incidental Diagnosis of SARS-CoV-2 Infection		A hospitalization for a reason not related to COVID-19 infection during which a diagnosis of COVID-19 infection is made.	44
C191382	COVID-19 Diagnosis	Yes				C49488	Yes		The affirmative response to a question.	45
C191382	COVID-19 Diagnosis	No				C49487	No		The non-affirmative response to a question.	46
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	47
C191382	COVID-19 Diagnosis	Date of first COVID-19-related hospitalization			Date that the first COVID-19-related hospitalization occurred	C191528	Date of First COVID-19-related Hospitalization		The date that the first COVID-19-related hospitalization occurred.	48
C191382	COVID-19 Diagnosis	Date of first hospitalization with incidental diagnosis of SARS-CoV-2 infection			Date that hospitalization for any non-COVID-19-related indication occurred with incidental first diagnosis of SARS-CoV-2 infection	C191529	Date of First Hospitalization with Incidental Diagnosis of SARS-CoV-2 Infection		The date of the hospitalization when an incidental finding of SARS-CoV-2 infection was first diagnosed.	49
C191382	COVID-19 Diagnosis	Coinfection of COVID-19 with other respiratory infections			Other respiratory infection in patient an episode of acute illness caused by SARS-CoV-2	C191500	Coinfection of COVID-19 with Other Respiratory Infections		A respiratory infection that is diagnosed concurrently during an episode of acute illness caused by SARS-CoV-2.	50
C191382	COVID-19 Diagnosis	Influenza				C53482	Influenza		An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system.	51
C191382	COVID-19 Diagnosis	Other viral infection				C3439	Viral Infection	Viral Disease || Viral Disorder	Any disease caused by a virus.	52
C191382	COVID-19 Diagnosis	Bacterial infection				C2890	Bacterial Infection	Bacterial Disorder	An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.	53
C191382	COVID-19 Diagnosis	Fungal infection				C3245	Fungal Infection		An infection caused by a fungus.	54
C191382	COVID-19 Diagnosis	SARS CoV-2 variant			Variant lineage of SARS-CoV-2	C189004	SARS-CoV-2 Variant	SARS CoV-2 Variant	A genetic variant of SARS CoV-2 as designated by the World Health Organization.	55
C191382	COVID-19 Diagnosis	Alpha (B.1.1.7 and Q lineages)				C179573	SARS Coronavirus 2 B.1.1.7	B.1.1.7 || SARS Coronavirus 2 Variant Lineage B.1.1.7 || SARS-CoV-2 B.1.1.7 || SARS2 B.1.1.7	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 69, 70 and 144 and amino acid substitutions N501Y, A570D, D614G, P681H, T716I, S982A and D1118H. The substitutions E484K, S494P and K1191N have also been detected in some but not all sequences for this lineage.	56
C191382	COVID-19 Diagnosis	Beta (B.1.351 and descendant lineages)				C179575	SARS Coronavirus 2 B.1.351	B.1.351 || SARS Coronavirus 2 Variant Lineage B.1.351 || SARS-CoV-2 B.1.351 || SARS2 B.1.351	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 241-242 and amino acid substitutions D80A, D215G, K417N, E484K, N501Y, D614G and A701V.	57
C191382	COVID-19 Diagnosis	Delta (B.1.617.2 and AY lineages)				C179586	SARS Coronavirus 2 B.1.617.2	B.1.617.2 || SARS Coronavirus 2 Variant Lineage B.1.617.2 || SARS-CoV-2 B.1.617.2 || SARS2 B.1.617.2	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 156 and 157 and amino acid substitutions T19R, R158G, L452R, T478K, D614G, P681R and D950N. The substitution G142D has also been detected in some but not all sequences for this lineage.	58
C191382	COVID-19 Diagnosis	Delta (AY1)				C180977	SARS Coronavirus 2 AY.1	AY.1 || B.1.617.2.1 || SARS Coronavirus 2 B.1.617.2.1 || SARS Coronavirus 2 Variant Lineage AY.1 || SARS Coronavirus 2 Variant Lineage B.1.617.2.1 || SARS-CoV-2 AY.1 || SARS-CoV-2 B.1617.2.1 || SARS2 AY.1 || SARS2 B.1.617.2.1	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions T19R, W258L, K417N, L452R, T478K, D614G, P681R and D950N.	59
C191382	COVID-19 Diagnosis	Delta (AY3)				C181075	SARS Coronavirus 2 AY.3	AY.3 || B.1.617.2.3 || SARS Coronavirus 2 B.1.617.2.3 || SARS Coronavirus 2 Variant Lineage AY.3 || SARS Coronavirus 2 Variant Lineage B.1.617.2.3 || SARS-CoV-2 AY.3 || SARS-CoV-2 B.1617.2.3 || SARS2 AY.3 || SARS2 B.1.617.2.3	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletion of amino acids 157 and 158 and amino acid substitutions T19R, E156G, L452R, T478K, D614G, P681R and D950N.	60
C191382	COVID-19 Diagnosis	Gamma (P.1 and descendant lineages)				C179599	SARS Coronavirus 2 P.1	B.1.1.28.1 || B.1.128.1 || P.1 || SARS Coronavirus 2 Variant Lineage P.1 || SARS-CoV-2 B.1.128.1 || SARS-CoV-2 P.1 || SARS2 P.1	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I and V1176F.	61
C191382	COVID-19 Diagnosis	Epsilon (B.1.427 and B.1.429)				C179576	SARS Coronavirus 2 B.1.427	B.1.427 || SARS Coronavirus 2 Variant Lineage B.1.427 || SARS-CoV-2 B.1.427 || SARS2 B.1.427	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions L452R and D614G.	62
C191382	COVID-19 Diagnosis	Epsilon (B.1.429)				C179577	SARS Coronavirus 2 B.1.429	B.1.429 || SARS Coronavirus 2 Variant Lineage B.1.429 || SARS-CoV-2 B.1.429 || SARS2 B.1.429	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions S13I, W152C, L452R and D614G.	63
C191382	COVID-19 Diagnosis	Eta (B.1.525)				C179579	SARS Coronavirus 2 B.1.525	B.1.525 || SARS Coronavirus 2 Variant Lineage B.1.525 || SARS-CoV-2 B.1.525 || SARS2 B.1.525	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 69, 70 and 144 and amino acid substitutions A67V, E484K, D614G, Q677H and F888L.	64
C191382	COVID-19 Diagnosis	Iota (B.1.526)				C179580	SARS Coronavirus 2 B.1.526	B.1.526 || SARS Coronavirus 2 Variant Lineage B.1.526 || SARS-CoV-2 B.1.526 || SARS2 B.1.526	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions T95I, D253G and D614G. The substitutions L5F, S477N, E484K and A701V have also been detected in some but not all sequences for this lineage.	65
C191382	COVID-19 Diagnosis	Kappa (B.1.617.1)				C179585	SARS Coronavirus 2 B.1.617.1	B.1.617.1 || SARS Coronavirus 2 Variant Lineage B.1.617.1 || SARS-CoV-2 B.1.617.1 || SARS2 B.1.617.1	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The substitution T95I has also been detected in some but not all sequences for this lineage.	66
C191382	COVID-19 Diagnosis	B.1.617.3				C179596	SARS Coronavirus 2 B.1.617.3	B.1.617.3 || SARS Coronavirus 2 Variant Lineage B.1.617.3 || SARS-CoV-2 B.1.617.3 || SARS2 B.1.617.3	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions T19R, G142D, L452R, E484Q, D614G, P681R, D950N.	67
C191382	COVID-19 Diagnosis	Mu (B.1.621, B.1.621.1)				C180913	SARS Coronavirus 2 B.1.621	B.1.621 || SARS Coronavirus 2 Variant Lineage B.1.621 || SARS-CoV-2 B.1.621 || SARS2 B.1.621	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: an amino acid insertion 146N and amino acid substitutions T95I, Y144T, Y145S, R346K, E484K, N501Y, D614G, P681H and D950N.	68
C191382	COVID-19 Diagnosis	Mu (B.1.621.1)				C188869	SARS Coronavirus 2 B.1.621.1	B.1.621.1 || SARS Coronavirus 2 Variant Lineage B.1.621.1 || SARS-CoV-2 B.1.621.1 || SARS2 B.1.621.1	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H and D950N.	69
C191382	COVID-19 Diagnosis	Zeta (P.2)				C179598	SARS Coronavirus 2 P.2	B.1.1.28.2 || B.1.128.2 || P.2 || SARS Coronavirus 2 Variant Lineage P.2 || SARS-CoV-2 B.1.128.2 || SARS-CoV-2 P.2 || SARS2 P.2	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: amino acid substitutions E484K, D614G and V1176F. The substitution F565L has also been detected in some but not all sequences for this lineage.	70
C191382	COVID-19 Diagnosis	Omicron (B.1.1.529 and BA lineages)				C184327	SARS Coronavirus 2 B.1.1.529	B.1.1.529 || SARS Coronavirus 2 Variant Lineage B.1.1.529 || SARS-CoV-2 B.1.1.529 || SARS2 B.1.1.529	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 69/70, 143/145 and 212 and amino acid substitutions A67V, T95I, G142D, N211I, G339D, S371L, S373P, S375F, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, D796Y, N856K, Q954H, N969K and L981F.	71
C191382	COVID-19 Diagnosis	Omicron (BA.1)				C187221	SARS Coronavirus 2 BA.1	B.1.1.529.1 || BA.1 || SARS Coronavirus 2 Variant Lineage BA.1 || SARS-CoV-2 BA.1 || SARS2 BA.1	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 69/70, 143/145 and 212 and amino acid substitutions A67V, T95I, G142D, N211I, G339D, S371L, S373P, S375F, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F.	72
C191382	COVID-19 Diagnosis	Omicron (BA.1,1)				C185726	SARS Coronavirus 2 BA.1.1	B.1.1.529.1.1 || BA.1.1 || SARS Coronavirus 2 Variant Lineage BA.1.1 || SARS-CoV-2 BA.1.1 || SARS2 BA.1.1	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 69/70, 143/145 and 212 and amino acid substitutions A67V, T95I, G142D, N211I, G339D, R346K, S371L, S373P, S375F, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F.	73
C191382	COVID-19 Diagnosis	Omicron (BA.1)				C185727	SARS Coronavirus 2 BA.2	B.1.1.529.2 || BA.2 || SARS Coronavirus 2 Variant Lineage BA.2 || SARS-CoV-2 BA.2 || SARS2 BA.2	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 25/27 and amino acid substitutions T19I, L24S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and N969K.	74
C191382	COVID-19 Diagnosis	Omicron (BA.1)				C187220	SARS Coronavirus 2 BA.2.12.1	B.1.1.529.2.12.1 || BA.2.12.1 || SARS Coronavirus 2 Variant Lineage BA.2.12.1 || SARS-CoV-2 BA.2.12.1 || SARS2 BA.2.12.1	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 25/27 and amino acid substitutions T19I, L24S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, S704L, N764K, D796Y, Q954H and N969K.	75
C191382	COVID-19 Diagnosis	Omicron (BA.1)				C187219	SARS Coronavirus 2 BA.3	B.1.1.529.3 || BA.3 || SARS Coronavirus 2 Variant Lineage BA.3 || SARS-CoV-2 BA.3 || SARS2 BA.3	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 69/70, 143/145 and 212 and amino acid substitutions A67V, G142D, N211I, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and N969K.	76
C191382	COVID-19 Diagnosis	Omicron (BA.1)				C187218	SARS Coronavirus 2 BA.4	B.1.1.529.4 || BA.4 || SARS Coronavirus 2 Variant Lineage BA.4 || SARS-CoV-2 BA.4 || SARS2 BA.4	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 25/27 and 69/70 and amino acid substitutions T19I, L24S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and N969K. This variant has two novel amino acid variations, a D61L substitution in the ORF6 protein and a L11F in the ORF7b protein.	77
C191382	COVID-19 Diagnosis	Omicron (BA.1)				C187217	SARS Coronavirus 2 BA.5	B.1.1.529.5 || BA.5 || SARS Coronavirus 2 Variant Lineage BA.5 || SARS-CoV-2 BA.5 || SARS2 BA.5	A variant lineage of SARS coronavirus 2 where the following variations in the spike glycoprotein sequence have been identified: deletions of the amino acids at positions 25/27 and 69/70 and amino acid substitutions T19I, L24S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and N969K.	78
C191382	COVID-19 Diagnosis	Other, specify				C157106	Specify Other		A directive to indicate a response not listed.	79
C191382	COVID-19 Diagnosis	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	80
C191383	COVID-19 Cardiovascular Complications	Acute myocardial injury related to acute COVID-19	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C191419	Acute Myocardial Injury Related to Acute COVID-19		Acute myocardial injury in an individual with probable or confirmed COVID-19 infection and no alternative explanation for acute myocardial injury.	81
C191383	COVID-19 Cardiovascular Complications	Acute myocardial injury without ischemia, HF, ventricular dysfunction, or myocarditis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute myocardial injury, without evidence of a newly reduced LVEF or RVEF, HF, cardiogenic shock, myocarditis, or acute ischemia in a patient with probable or confirmed acute COVID-19	C191442	Acute Myocardial Injury without Ischemia, Heart Failure, Ventricular Dysfunction, or Myocarditis Related to COVID-19		Acute myocardial injury, without evidence of acute ischemia, heart failure, a newly reduced left or right ventricular ejection fraction, cardiogenic shock, or myocarditis in a patient with probable or confirmed acute COVID-19.	82
C191383	COVID-19 Cardiovascular Complications	Acute myocardial injury with type I myocardial infarction	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute myocardial injury with clinical presentation suggestive of type I myocardial infarction with detection of a rise or fall of cardiac troponin values with at least 1 value above the 99th percentile upper reference limit and with at least 1 of the following: 1. Symptoms of acute myocardial ischemia; 2. New ischemic ECG changes; 3. Development of pathological Q waves; 4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology; 5. Identification of a coronary thrombus by angiography including intracoronary imaging or by autopsy, occurring in a patient with probable or confirmed acute COVID-19	C191441	Acute Myocardial Injury with Type I Myocardial Infarction Related to COVID-19		Acute myocardial injury with clinical presentation suggestive of type I myocardial infarction with detection of a rise or fall of cardiac troponin values with at least one value above the 99th percentile upper reference limit and with at least 1 of the following: 1. Symptoms of acute myocardial ischemia; 2. New ischemic ECG changes; 3. Development of pathological Q waves; 4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology; 5. Identification of a coronary thrombus by angiography including intracoronary imaging or by autopsy, occurring in a patient with probable or confirmed acute COVID-19.	83
C191383	COVID-19 Cardiovascular Complications	Acute myocardial injury with myocarditis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute myocardial injury with clinical, imaging, and or pathology evidence supporting inflammation and myocarditis in a patient with probable or confirmed acute COVID-19	C191439	Acute Myocardial Injury with Myocarditis Related to COVID-19		Acute myocardial injury with clinical, imaging, and or pathology evidence supporting myocarditis in a patient with probable or confirmed acute COVID-19.	84
C191383	COVID-19 Cardiovascular Complications	Acute myocardial injury with LV dysfunction	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute myocardial injury with evidence of new systolic dysfunction with reduced LVEF (LVEF <50%) in a patient with probable or confirmed acute COVID-19	C191438	Acute Myocardial Injury with Left Ventricular Dysfunction Related to COVID-19		Acute myocardial injury with evidence of new systolic dysfunction with reduced left ventricular ejection (LVEF less than 50%) in a patient with probable or confirmed acute COVID-19.	85
C191383	COVID-19 Cardiovascular Complications	Acute myocardial injury with RV dysfunction	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute myocardial injury with evidence of newly reduced RV function in a patient with probable or confirmed acute COVID-19	C191440	Acute Myocardial Injury with Right Ventricular Dysfunction Related to COVID-19		Acute myocardial injury with evidence of newly reduced right ventricular function in a patient with probable or confirmed acute COVID-19.	86
C191383	COVID-19 Cardiovascular Complications	Acute myocardial injury with HF	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute myocardial injury with evidence of new or worsening signs and symptoms of HF in a patient with probable or confirmed acute COVID-19	C191437	Acute Myocardial Injury with Heart Failure Related to COVID-19		Acute myocardial injury with evidence of new or worsening signs and symptoms of heart failure in a patient with probable or confirmed acute COVID-19.	87
C191383	COVID-19 Cardiovascular Complications	Acute myocardial injury with cardiogenic shock	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute myocardial injury with evidence of cardiogenic shock defined as clinical evidence of low cardiac index (e.g., <2.2 L/min/m2) accompanied by impaired tissue perfusion in a patient with probable or confirmed acute COVID-19	C191436	Acute Myocardial Injury with Cardiogenic Shock Related to COVID-19		Acute myocardial injury with evidence of cardiogenic shock defined as clinical evidence of low cardiac index (e.g., less than 2.2 L/min/m2) accompanied by impaired tissue perfusion in a patient with probable or confirmed acute COVID-19.	88
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	89
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	90
C191383	COVID-19 Cardiovascular Complications	Acute heart failure	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	HF with new or worsening signs and symptoms in a patient with probable or confirmed acute COVID-19. Acute HF can be in the setting of either a preserved or reduced LVEF. This can be the first presentation of HF, or it can reflect an acute decompensation in a patient with history of chronic HF.	C191556	Acute Heart Failure Related to COVID-19		New or worsening signs of heart failure in a patient with probable or confirmed acute COVID-19. This can be the first presentation or it can reflect an acute decompensation in a patient with history of chronic heart failure.	91
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	92
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	93
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	94
C191383	COVID-19 Cardiovascular Complications	Acute pericarditis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Inflammatory process involving the pericardium, can occur with or without the new development of a pericardial effusion, in a patient with probable or confirmed acute COVID-19	C191443	Acute Pericarditis Related to COVID-19		Acute pericarditis in a patient with probable or confirmed acute COVID-19.	95
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	96
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	97
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	98
C191383	COVID-19 Cardiovascular Complications	Pericardial effusion	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Inflammatory process involving the pericardium with the new development of a pericardial effusion in a patient with probable or confirmed acute COVID-19	C191594	Pericardial Effusion Related to COVID-19		Pericardial effusion in a patient with probable or confirmed acute COVID-19.	99
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	100
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	101
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	102
C191383	COVID-19 Cardiovascular Complications	Sustained ventricular arrhythmia	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Sustained ventricular tachycardia (greater than or equal to 30 s or requiring DCCV) or ventricular fibrillation in a patient with probable or confirmed acute COVID-19	C191643	Sustained Ventricular Arrhythmia Related to COVID-19		Ventricular tachycardia or ventricular fibrillation lasting greater than or equal to 30 seconds, or requiring direct current cardioversion (DCCV) in a patient with probable or confirmed acute COVID-19.	103
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	104
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	105
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	106
C191383	COVID-19 Cardiovascular Complications	New-onset AF	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Newly occurring AF in a patient with probable or confirmed acute COVID-19, further categorized as: 1) first detected AF, 2) paroxysmal AF: AF that is self-terminating within 7 d of recognized onset, 3) persistent AF: AF that is not self-terminating within 7 d	C191454	New Onset Atrial Fibrillation Related to COVID-19		Newly occurring atrial fibrillation (AF) in a patient with probable or confirmed acute COVID-19. It is further categorized as first detected AF, paroxysmal AF (self-terminating within seven days of recognized onset), or persistent AF (not self-terminating within seven days).	107
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	108
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	109
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	110
C191383	COVID-19 Cardiovascular Complications	New-onset atrial flutter	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Newly occurring atrial flutter in a patient with probable or confirmed acute COVID-19	C191456	New Onset Atrial Flutter Related to COVID-19		Newly occurring atrial flutter in a patient with probable or confirmed acute COVID-19.	111
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	112
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	113
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	114
C191383	COVID-19 Cardiovascular Complications	Sustained atrial tachyarrhythmia other than AF or atrial flutter	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Other types of supraventricular tachycardia, including AV nodal reentry, orthodromic re-entrant tachycardia, multifocal atrial tachycardia, other atrial tachycardia, in a patient with probable or confirmed acute COVID-19	C191631	Sustained Atrial Tachyarrhythmia Related to COVID-19 other than Atrial Fibrillation or Atrial Flutter		A supraventricular tachycardia, including AV nodal re-entry, orthodromic re-entrant tachycardia, multifocal atrial tachycardia, other atrial tachycardia that lasts more then 30 seconds in a patient with probable or confirmed acute COVID-19.	115
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	116
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	117
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	118
C191383	COVID-19 Cardiovascular Complications	Bradyarrhythmia requiring temporary or permanent pacing	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Bradycardia (ventricular rate <60 bpm) that is symptomatic reflecting signs of hypoperfusion and that requires temporary or permanent pacemaker intervention in a patient with probable or confirmed acute COVID-19	C191452	Bradyarrhythmia Related to COVID-19 Requiring Temporary or Permanent Pacing		Bradycardia (ventricular rate less than 60 bpm) showing signs of hypoperfusion and that requires temporary or permanent pacemaker intervention in a patient with probable or confirmed acute COVID-19.	119
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	120
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	121
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	122
C191383	COVID-19 Cardiovascular Complications	Deep venous thrombosis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Thrombus formation within deep veins in a patient with probable or confirmed acute COVID-19	C191541	Deep Venous Thrombosis Related to COVID-19	DVT Related to COVID-19	Deep vein thrombosis in a patient with probable or confirmed acute COVID-19.	123
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	124
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	125
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	126
C191383	COVID-19 Cardiovascular Complications	Pulmonary embolus	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Thrombus formation or lodging in an artery in the lung in a patient with probable or confirmed acute COVID-19	C191612	Pulmonary Embolism Related to COVID-19		Pulmonary embolism in a patient with probable or confirmed acute COVID-19.	127
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	128
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	129
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	130
C191383	COVID-19 Cardiovascular Complications	Intracardiac thrombus	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Thrombus formation in the left or right ventricle or atria of the heart in a patient with probable or confirmed acute COVID-19	C191457	Intracardiac Thrombus Related to COVID-19		Thrombus formation in the chambers of the heart in a patient with probable or confirmed acute COVID-19.	131
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	132
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	133
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	134
C191383	COVID-19 Cardiovascular Complications	Acute ischemic limb	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute decrease in limb perfusion, usually producing new or worsening symptoms or signs, and often threatening limb viability or resulting in limb amputation in a patient with probable or confirmed acute COVID-19	C191596	Acute Ischemic Limb Related to COVID-19		A sudden or severe decrease in limb perfusion in a patient with probable or confirmed acute COVID-19, usually producing new or worsening symptoms or signs, and often threatening limb viability or resulting in limb amputation.	135
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	136
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	137
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	138
C191383	COVID-19 Cardiovascular Complications	Sudden cardiac death with ROSC	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Unexpected death caused by sudden cardiac arrest with asystole, pulseless electrical activity, sustained ventricular tachycardia, or ventricular fibrillation with successful ROSC in a patient with probable or confirmed acute COVID-19	C191627	Sudden Cardiac Death with Return of Spontaneous Circulation Related to COVID-19		Unexpected death caused by sudden cardiac arrest with asystole, pulseless electrical activity, sustained ventricular tachycardia, or ventricular fibrillation in a patient with probable or confirmed acute COVID-19 despite successful return of spontaneous circulation (ROSC).	139
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	140
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	141
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	142
C191383	COVID-19 Cardiovascular Complications	Cardiogenic shock with or without comorbid distributive shock	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Clinical evidence of low cardiac index (e.g., <2.2 L/min/m2) accompanied by impaired tissue perfusion in a patient with probable or confirmed acute COVID-19	C191420	Cardiogenic Shock Related to COVID-19		Cardiogenic shock in a patient with probable or confirmed acute COVID-19.	143
C191383	COVID-19 Cardiovascular Complications	Stage A	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	At risk: A patient who is not currently experiencing signs or symptoms of cardiogenic shock but is at risk for its development. These patients may include those with large acute myocardial infarction or prior infarction, acute or acute on chronic HF symptoms.	C191473	Cardiogenic Shock Stage A Related to COVID-19		Clinical signs of warmth and perfusion without volume overload or hypoperfusion and with a normal cardiac index in a patient with probable or confirmed acute COVID-19 that is not currently experiencing signs or symptoms of cardiogenic shock but is at risk for its development. These patients may include those with large acute myocardial infarction or prior infarction, or those with acute or acute on chronic heart failure symptoms.	144
C191383	COVID-19 Cardiovascular Complications	Stage B	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Beginning cardiogenic shock: A patient who has clinical evidence of relative hypotension or tachycardia without hypoperfusion	C191474	Cardiogenic Shock Stage B Related to COVID-19		Clinical signs of shock or compensated shock in a patient with probable or confirmed acute COVID-19 wherein they may be volume overloaded, tachycardic, and/or hypotensive but no evidence of hypoperfusion on physical exam or laboratory studies.	145
C191383	COVID-19 Cardiovascular Complications	Stage C	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Classic cardiogenic shock: A patient that manifests with hypoperfusion that requires intervention (inotrope, pressor or mechanical support, including ECMO) beyond volume resuscitation to restore perfusion. These patients typically present with relative hypotension.	C191475	Cardiogenic Shock Stage C Related to COVID-19		Clinical signs of cardiogenic shock with clinical evidence of hypotension and hypoperfusion (cold and wet) on physical examination that requires intervention (inotrope, pressor or mechanical support, including extracorporeal membrane oxygenation (ECMO)) beyond volume resuscitation to restore normal perfusion in a patient with probable or confirmed acute COVID-19. Invasive hemodynamics may demonstrate the classic depressed cardiac index associated with cardiogenic shock.	146
C191383	COVID-19 Cardiovascular Complications	Stage D	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Deteriorating/doom: A patient that is similar to category C but is getting worse. They have failure to respond to initial interventions.	C191476	Cardiogenic Shock Stage D Related to COVID-19		Clinical signs of deteriorating cardiogenic shock in a patient with probable or confirmed acute COVID-19. Failure to respond to initial interventions to restore adequate perfusion after 30 minutes. Further more intensive therapies are required, including the addition of mechanical circulatory support.	147
C191383	COVID-19 Cardiovascular Complications	Stage E	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Extremis: A patient that is experiencing cardiac arrest with ongoing CPR or ECMO, being supported by multiple interventions	C191477	Cardiogenic Shock Stage E Related to COVID-19		Clinical signs of extremis in a patient with cardiogenic shock and probable or confirmed acute COVID-19. Highly unstable, often with circulatory collapse and/or refractory cardiac arrest with ongoing cardiopulmonary resuscitation (CPR). They are being supported by multiple simultaneous acute interventions including extracorporeal membrane oxygenation (ECMO)-facilitated CPR (eCPR).	148
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	149
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	150
C191383	COVID-19 Cardiovascular Complications	Acute stroke	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	An acute neurological deficit attributed to an acute focal injury of the central nervous system by a vascular cause in a patient with probable or confirmed acute COVID-19, accompanied with neuropathological, neuroimaging, or clinical evidence of permanent injury	C191520	Acute Stroke Related to COVID-19		The sudden or severe onset of neurological deficit(s) attributable to an acute focal vascular injury of the central nervous system in a patient with probable or confirmed acute COVID-19.	151
C191383	COVID-19 Cardiovascular Complications	Acute ischemic stroke || Ischemic stroke	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Acute onset of neurological deficits resulting from a loss of blood supply to brain tissue in an area of arterial distribution.	C95802	Ischemic Stroke	Ischemic Cerebrovascular Accident	An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of brain tissue.	152
C191383	COVID-19 Cardiovascular Complications	Intracerebral hemorrhage	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Rapidly developing clinical signs of neurological dysfunction attributable to a focal collection of blood within the brain parenchyma or ventricular system that is not caused by trauma	C50485	Cerebral Hemorrhage	Intracerebral Hemorrhage || Parenchymatous Hemorrhage	Bleeding within the cerebrum.	153
C191383	COVID-19 Cardiovascular Complications	Subarachnoid hemorrhage	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Rapidly developing signs of neurological dysfunction or headache because of bleeding into the subarachnoid space (the space between the arachnoid membrane and the pia mater of the brain or spinal cord), which is not caused by trauma	C50757	Subarachnoid Hemorrhage		Intracranial hemorrhage into the subarachnoid space.	154
C191383	COVID-19 Cardiovascular Complications	Epidural hemorrhage	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Intracranial hemorrhage into the epidural space	C50555	Epidural Hemorrhage	Extradural Hemorrhage	Intracranial hemorrhage into the epidural space.	155
C191383	COVID-19 Cardiovascular Complications	Subdural hemorrhage	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Bleeding between the dura mater and the brain, usually secondary to a tear of the bridging vein	C50759	Subdural Hemorrhage		Bleeding between the dura mater and the brain, usually secondary to a tear of the bridging vein.	156
C191383	COVID-19 Cardiovascular Complications	Cerebral venous sinus thrombosis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Stroke because of thrombosis of a cerebral venous structure	C116715	Venous Stroke		Ischemic or hemorrhagic stroke resulting from cerebral venous thrombosis.	157
C191383	COVID-19 Cardiovascular Complications	Stroke || Stroke not otherwise specified	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	An episode of acute neurological dysfunction presumed to be caused by ischemia or hemorrhage, persisting greater than or equal to 24 h or until death but without sufficient evidence to be classified as one of the above	C3390	Stroke	Cerebrovascular Accident || Stroke Syndrome	A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.	158
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	159
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	160
C191383	COVID-19 Cardiovascular Complications	Transient ischemic attack	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A brief episode of neurological dysfunction, caused by focal brain or retinal ischemia without imaging evidence of acute infarction	C50781	Transient Ischemic Attack		A brief attack (from a few minutes to an hour) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.	161
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	162
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	163
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	164
C191383	COVID-19 Cardiovascular Complications	Left ventricular thrombus	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	New diagnosis of left ventricular thrombus in a patient with probable or confirmed acute COVID-19	C191458	Left Ventricular Thrombus Related to COVID-19		A blood clot that has formed in the left ventricle of the heart in a patient with probable or confirmed acute COVID-19.	165
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	166
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	167
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	168
C191383	COVID-19 Cardiovascular Complications	Coronary ectasia	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Diffuse dilation of coronary artery segment (greater than or equal to 1.5' the adjacent normal segment) in a patient with probable or confirmed acute COVID-19	C191509	Coronary Artery Ectasia Related to COVID-19		Coronary artery ectasia in a patient with probable or confirmed acute COVID-19.	169
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	170
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	171
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	172
C191383	COVID-19 Cardiovascular Complications	Coronary artery aneurysm	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Focal dilation of a coronary artery (greater than or equal to 1.5' the adjacent normal segment) in a patient with probable or confirmed acute COVID-19	C191502	Coronary Artery Aneurysm Related to COVID-19		Coronary artery aneurysm in a patient with probable or confirmed acute COVID-19.	173
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	174
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	175
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	176
C191383	COVID-19 Cardiovascular Complications	Microvascular thrombosis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Blood clotting that is occurring in small blood vessels in the body in a patient with probable or confirmed acute COVID-19	C191642	Microvascular Thrombosis Related to COVID-19		Blood clot formation in the small blood vessels of the body in a patient with probable or confirmed acute COVID-19.	177
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	178
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	179
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	180
C191383	COVID-19 Cardiovascular Complications	Thrombophilia	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A condition characterized by an abnormally high level of thrombi. Causes include thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, bone marrow disorders, and antiphospholipid antibody syndrome in a patient with probable or confirmed acute COVID-19.	C191638	Thrombophilia Related to COVID-19		Thrombophilia in a patient with probable or confirmed acute COVID-19.	181
C191383	COVID-19 Cardiovascular Complications	Yes	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49488	Yes		The affirmative response to a question.	182
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	183
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	184
C191383	COVID-19 Cardiovascular Complications	Cardiovascular adverse events related to medications aimed at COVID-19	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Cardiovascular adverse events attributable to or associated with medications used for COVID-19	C191447	Cardiovascular Adverse Events Related to Medications Aimed at COVID-19		A cardiovascular adverse event that is attributable to or associated with medications used to treat COVID-19.	185
C191383	COVID-19 Cardiovascular Complications	Arrhythmia	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C2881	Arrhythmia	Cardiac Arrhythmia	Any variation from the normal rate or rhythm (which may include the origin of the impulse and/or its subsequent propagation) in the heart.	186
C191383	COVID-19 Cardiovascular Complications	Coronary artery disorder	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C26732	Coronary Artery Disease	Coronary Disease	Narrowing of the coronary arteries due to fatty deposits inside the arterial walls. The diagnostic criteria may include documented history of any of the following: documented coronary artery stenosis greater than or equal to 50% (by cardiac catheterization or other modality of direct imaging of the coronary arteries); previous coronary artery bypass surgery (CABG); previous percutaneous coronary intervention (PCI); previous myocardial infarction. (ACC)	187
C191383	COVID-19 Cardiovascular Complications	HF || Heart failure	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A clinical condition in which the function of the heart is inadequate to meet the metabolic needs of the body.	C50577	Heart Failure	Cardiac Failure	Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.	188
C191383	COVID-19 Cardiovascular Complications	Blood pressure disorder || Hypotension	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A condition in which the blood pressure is less than the below the fifth percentile or below 2 standard deviations of the mean for age and sex.	C3128	Hypotension	Low Blood Pressure || Vascular Hypotensive Disorder	Blood pressure that is abnormally low.	189
C191383	COVID-19 Cardiovascular Complications	Shock	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C35016	Shock	Circulatory Collapse	A life-threatening condition that requires immediate medical intervention. It is characterized by reduced blood flow that may result in damage of multiple organs. Types of shock include cardiogenic, hemorrhagic, septic, anaphylactic, and traumatic shock.	190
C191383	COVID-19 Cardiovascular Complications	Embolism	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C26759	Embolism		The blockage of a blood vessel lumen by air or solid material such as blood clot or other tissues (e.g., adipose tissue, cancer cells) that have migrated from another anatomic site.	191
C191383	COVID-19 Cardiovascular Complications	Thrombosis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C26891	Thrombosis		The formation of a blood clot in the lumen of a vessel or heart chamber; causes include coagulation disorders and vascular endothelial injury.	192
C191383	COVID-19 Cardiovascular Complications	Vascular hypertensive disorder	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C3117	Hypertension	High Blood Pressure || Vascular Hypertensive Disorder	Blood pressure that is abnormally high.	193
C191383	COVID-19 Cardiovascular Complications	Other	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	194
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	195
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	196
C191383	COVID-19 Cardiovascular Complications	Cardiovascular adverse effects from vaccines to prevent COVID-19	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	Cardiovascular adverse events associated with COVID-19 vaccinations	C191446	Cardiovascular Adverse Effects from Vaccines to Prevent COVID-19		A cardiovascular adverse effect that is attributable to or associated with vaccines used to prevent COVID-19.	197
C191383	COVID-19 Cardiovascular Complications	Myocarditis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C34831	Myocarditis		Inflammation of the muscle tissue of the heart.	198
C191383	COVID-19 Cardiovascular Complications	Thrombocytopenia	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C3408	Thrombocytopenia		A laboratory test result indicating that there is an abnormally small number of platelets in the circulating blood.	199
C191383	COVID-19 Cardiovascular Complications	Thrombosis	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C26891	Thrombosis		The formation of a blood clot in the lumen of a vessel or heart chamber; causes include coagulation disorders and vascular endothelial injury.	200
C191383	COVID-19 Cardiovascular Complications	Other	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	201
C191383	COVID-19 Cardiovascular Complications	No	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection		C49487	No		The non-affirmative response to a question.	202
C191383	COVID-19 Cardiovascular Complications	Unknown	C191396	Acute Cardiovascular Complications Related to COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	203
C191383	COVID-19 Cardiovascular Complications	PASC HF	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	New-onset HF with clinical syndrome of dyspnea, fatigue, fluid retention/peripheral edema that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191555	New-onset Heart Failure Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Heart Failure || Post-Acute Sequelae of COVID-19 Heart Failure	New onset of heart failure with a clinical syndrome of dyspnea, fatigue, fluid retention/peripheral edema that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	204
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	205
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	206
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	207
C191383	COVID-19 Cardiovascular Complications	PASC ischemic cardiomyopathy	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Reduced LV function with LVEF <50% in a patient with history of suspected or confirmed myocardial ischemia or ACS with acute COVID-19 that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191478	Ischemic Cardiomyopathy Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Ischemic Cardiomyopathy || Post-Acute Sequelae of COVID-19 Ischemic Cardiomyopathy	Reduced left ventricular function with less than 50% ejection fraction in a patient with history of suspected or confirmed myocardial ischemia or acute coronary syndrome (ACS) that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	208
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	209
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	210
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	211
C191383	COVID-19 Cardiovascular Complications	PASC nonischemic cardiomyopathy	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Reduced LV function with LVEF <50% without evidence of myocardial ischemia that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191479	Non-Ischemic Cardiomyopathy Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Non-Ischemic Cardiomyopathy || Post-Acute Sequelae of COVID-19 Non-Ischemic Cardiomyopathy	Reduced left ventricular function with less than 50% ejection fraction but without evidence of myocardial ischemia that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	212
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	213
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	214
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	215
C191383	COVID-19 Cardiovascular Complications	PASC inappropriate sinus tachycardia	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Inappropriate sinus tachycardia at rest with heart rate >100 bpm that cannot be explained by any identifiable cause, including anemia, hypoxia, hypotension, or fever that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191565	Inappropriate Sinus Tachycardia Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Inappropriate Sinus Tachycardia || Post-Acute Sequelae of COVID-19 Inappropriate Sinus Tachycardia	Inappropriate sinus tachycardia at rest with heart rate greater than 100 bpm that cannot be explained by any identifiable cause, including anemia, hypoxia, hypotension, or fever that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	216
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	217
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	218
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	219
C191383	COVID-19 Cardiovascular Complications	PASC POTS	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	PASC POTS is a clinical syndrome that started during probable or confirmed acute COVID-19 and lasts greater than or equal to 3 mo. POTS is defined as 1) sustained heart rate increment greater than or equal to 30 bpm within 10 min of standing or head-up tilt (for individuals who are age 12-19 y, the required heart rate increment is greater than or equal to 40 bpm); 2) absence of orthostatic hypotension (i.e., no sustained systolic blood pressure drop of greater than or equal to 20 mm Hg); 3) frequent symptoms of orthostatic intolerance during standing, with rapid improvement upon return to a supine position. Symptoms may include lightheadedness, palpitations, tremulousness, generalized weakness, blurred vision, and fatigue; 4) duration of symptoms for at least 3 mo; and 5) absence of other conditions explaining sinus tachycardia such as anorexia nervosa, primary anxiety disorders, hyperventilation, anemia, fever, pain, infection, dehydration, hyperthyroidism, pheochromocytoma, use of cardioactive drugs (e.g., sympathomimetics, anticholinergics) or severe deconditioning caused by prolonged bed rest.	C191603	Postural Orthostatic Tachycardia Syndrome Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC POTS || PASC Postural Orthostatic Tachycardia Syndrome || Post-Acute Sequelae of COVID-19 Postural Orthostatic Tachycardia Syndrome	Postural orthostatic tachycardia syndrome (POTS) that started during probable or confirmed acute COVID-19 and persisted at least three months after the initial diagnosis of COVID-19.	220
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	221
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	222
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	223
C191383	COVID-19 Cardiovascular Complications	PASC AF	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	AF in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191453	Atrial Fibrillation Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Atrial Fibrillation || Post-Acute Sequelae of COVID-19 Atrial Fibrillation	Atrial fibrillation in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	224
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	225
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	226
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	227
C191383	COVID-19 Cardiovascular Complications	PASC atrial flutter	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Atrial flutter in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191455	Atrial Flutter Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Atrial Flutter || Post-Acute Sequelae of COVID-19 Atrial Flutter	Atrial flutter in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	228
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	229
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	230
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	231
C191383	COVID-19 Cardiovascular Complications	PASC supraventricular tachyarrhythmia other than AF or atrial flutter	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Supraventricular tachycardia other than AF or atrial flutter in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191630	Supraventricular Tachyarrhythmia Other than Atrial Fibrillation or Atrial Flutter Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Supraventricular Tachyarrhythmia Other than Atrial Fibrillation or Atrial Flutter || Post-Acute Sequelae of COVID-19 Supraventricular Tachyarrhythmia Other than Atrial Fibrillation or Atrial Flutter	Supraventricular tachycardia other than atrial fibrillation or atrial flutter in a patient without prior history of atrial tachyarrhythmias that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	232
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	233
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	234
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	235
C191383	COVID-19 Cardiovascular Complications	PASC pericarditis	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Pericarditis characterized by chest pain, electrocardiographic changes or pericardial effusion, that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191595	Pericarditis Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Pericarditis || Post-Acute Sequelae of COVID-19 Pericarditis	Pericarditis that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	236
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	237
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	238
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	239
C191383	COVID-19 Cardiovascular Complications	PASC pericardial effusion	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Pericardial effusion that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191593	Pericardial Effusion Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Pericardial Effusion || Post-Acute Sequelae of COVID-19 Pericardial Effusion	Pericardial effusion that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	240
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	241
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	242
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	243
C191383	COVID-19 Cardiovascular Complications	PASC cardiac structural abnormalities	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Cardiac structural changes or abnormalities characterized by myocardial systolic dysfunction or myocardial edema or fibrosis on noninvasive cardiac imaging that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191625	Cardiac Structural Abnormalities Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Cardiac Structural Abnormalities || Post-Acute Sequelae of COVID-19 Cardiac Structural Abnormalities	Cardiac structural changes or abnormalities characterized by myocardial systolic dysfunction or myocardial edema or fibrosis on non-invasive cardiac imaging that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	244
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	245
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	246
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	247
C191383	COVID-19 Cardiovascular Complications	PASC deep venous thrombosis	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Formation of greater than or equal to 1 blood clots or thrombi in large veins of the body, diagnosed with Doppler ultrasound, occurring most frequently in lower extremities or upper extremities that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191540	Deep Venous Thrombosis Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC DVT || PASC Deep Venous Thrombosis || Post-Acute Sequelae of COVID-19 Deep Venous Thrombosis	Formation of multiple thrombi in the large veins of the body, diagnosed with Doppler ultrasound, occurring most frequently in lower extremities or upper extremities, that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	248
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	249
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	250
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	251
C191383	COVID-19 Cardiovascular Complications	PASC pulmonary thromboembolic disease	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Intravascular migration of a venous thrombus or embolus to the pulmonary arterial circulation, microvascular thrombosis in the pulmonary capillaries, or pulmonary artery thrombus in situ diagnosed by a positive pulmonary angiogram, an unequivocally positive helical CT scan, a high-probability ventilation-perfusion scan, or autopsy that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191611	Pulmonary Thromboembolic Disease Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Pulmonary Thromboembolic Disease || Post-Acute Sequelae of COVID-19 Pulmonary Thromboembolic Disease	Intravascular migration of a venous embolus to the pulmonary arterial circulation, microvascular thrombosis in the pulmonary capillaries, or pulmonary artery thrombus in situ diagnosed by a positive pulmonary angiogram, an unequivocally positive helical CT scan, a high-probability ventilation-perfusion scan, or autopsy that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	252
C191383	COVID-19 Cardiovascular Complications	Yes	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49488	Yes		The affirmative response to a question.	253
C191383	COVID-19 Cardiovascular Complications	No	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C49487	No		The non-affirmative response to a question.	254
C191383	COVID-19 Cardiovascular Complications	Unknown	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	255
C191383	COVID-19 Cardiovascular Complications	PASC neurovascular disorder	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Disorder of the nervous system related to a vascular etiology that started during probable or confirmed acute COVID-19 and persisted beyond 4 wk after the initial diagnosis of COVID-19. Preexisting cardiovascular conditions, or those that did not develop until after COVID-19 had resolved, should not be listed here.	C191581	Neurovascular Disorder Associated with Post-Acute Sequelae of SARS-CoV-2 Infection	PASC Neurovascular Disorder || Post-Acute Sequelae of COVID-19 Neurovascular Disorder	A disorder of the nervous system related to a vascular etiology that started during probable or confirmed acute COVID-19 and persisted beyond four weeks after the initial diagnosis of COVID-19.	256
C191383	COVID-19 Cardiovascular Complications	Acute ischemic stroke || Ischemic stroke	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Acute onset of neurological deficits resulting from a loss of blood supply to brain tissue in an area of arterial distribution.	C95802	Ischemic Stroke	Ischemic Cerebrovascular Accident	An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of brain tissue.	257
C191383	COVID-19 Cardiovascular Complications	Hemorrhagic stroke	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	Brain tissue necrosis due to an intracerebral bleed	C95803	Hemorrhagic Stroke	Hemorrhagic Cerebrovascular Accident	An acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage.	258
C191383	COVID-19 Cardiovascular Complications	Cerebral venous thrombosis	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C132727	Cerebral Vein Thrombosis		The formation of a blood clot in a cerebral vein.	259
C191383	COVID-19 Cardiovascular Complications	Myalgic encephalomyelitis/chronic fatigue syndrome	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19		C3037	Chronic Fatigue Syndrome	Myalgic Encephalomyelitis	A syndrome of unknown etiology. Chronic fatigue syndrome (CFS) is a clinical diagnosis characterized by an unexplained persistent or relapsing chronic fatigue that is of at least six months' duration, is not the result of ongoing exertion, is not substantially alleviated by rest, and results in substantial reduction of previous levels of occupational, educational, social, or personal activities. Common concurrent symptoms of at least six months duration include impairment of memory or concentration, diffuse pain, sore throat, tender lymph nodes, headaches of a new type, pattern, or severity, and nonrestorative sleep. The etiology of CFS may be viral or immunologic. Neurasthenia and fibromyalgia may represent related disorders. Also known as myalgic encephalomyelitis.	260
C191383	COVID-19 Cardiovascular Complications	Other	C191403	Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	261
C191383	COVID-19 Cardiovascular Complications	Death due to acute MI	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	Death by any cardiovascular mechanism (e.g., arrhythmia, sudden death, HF, stroke, pulmonary embolus, peripheral arterial disease) less than or equal to 30 d after a MI, related to the immediate consequences of the MI, such as progressive HF or recalcitrant arrhythmia in a patient with probable or confirmed acute COVID-19. There may be assessable mechanisms of cardiovascular death during this time period, but for simplicity, if the cardiovascular death occurs less than or equal to 30 d of the MI, it will be considered a death due to MI.	C191480	Death due to Acute Myocardial Infarction Related to COVID-19		Death by any cardiovascular mechanism (e.g., arrhythmia, sudden death, heart failure (HF), stroke, pulmonary embolus, peripheral arterial disease) less than or equal to 30 days after a myocardial infarction (MI), related to the immediate consequences of the MI, such as progressive HF or recalcitrant arrhythmia in a patient with probable or confirmed acute COVID-19.	262
C191383	COVID-19 Cardiovascular Complications	Yes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49488	Yes		The affirmative response to a question.	263
C191383	COVID-19 Cardiovascular Complications	No	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49487	No		The non-affirmative response to a question.	264
C191383	COVID-19 Cardiovascular Complications	Unknown	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	265
C191383	COVID-19 Cardiovascular Complications	Sudden cardiac death	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	Death that occurs unexpectedly and suddenly without ROSC in a patient with probable or confirmed acute COVID-19 and not within 30 d of an acute MI. Sudden cardiac death includes the following scenarios: a. Death witnessed and occurring without new or worsening symptoms b. Death witnessed within 60 min of the onset of new or worsening cardiac symptoms, unless the symptoms suggest acute MI c. Death witnessed and attributed to an identified arrhythmia (e.g., captured on an ECG recording, witnessed on a monitor, with asystole, pulseless electrical activity, ventricular tachycardia, or ventricular fibrillation, or unwitnessed but found on implantable cardioverter-defibrillator review) d. Unwitnessed death in a subject seen alive and clinically stable less than or equal to 24 h prior to being found dead without any evidence supporting a specific noncardiovascular cause of death (information regarding the patient's clinical status preceding death should be provided, if available)	C191626	Sudden Cardiac Death Related to COVID-19	SCD Related to COVID-19	Sudden cardiac death in a patient with probable or confirmed acute COVID-19.	266
C191383	COVID-19 Cardiovascular Complications	Yes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49488	Yes		The affirmative response to a question.	267
C191383	COVID-19 Cardiovascular Complications	No	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49487	No		The non-affirmative response to a question.	268
C191383	COVID-19 Cardiovascular Complications	Unknown	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	269
C191383	COVID-19 Cardiovascular Complications	Death due to HF	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	Death in association with clinically worsening symptoms or signs of HF regardless of HF etiology in a patient with probable or confirmed acute COVID-19. Deaths due to HF with COVID-19 can have various etiologies, including myocarditis, myocardial injury, cardiogenic shock, cardiomyopathy, MI, ischemic or nonischemic cardiomyopathy.	C191537	Death due to Heart Failure Related to COVID-19		Death in association with clinically worsening symptoms or signs of heart failure regardless of etiology in a patient with probable or confirmed acute COVID-19.	270
C191383	COVID-19 Cardiovascular Complications	Yes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49488	Yes		The affirmative response to a question.	271
C191383	COVID-19 Cardiovascular Complications	No	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49487	No		The non-affirmative response to a question.	272
C191383	COVID-19 Cardiovascular Complications	Unknown	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	273
C191383	COVID-19 Cardiovascular Complications	Death due to stroke	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	Death after a stroke that is either a direct consequence of the stroke or a complication of the stroke in a patient with probable or confirmed acute COVID-19. Acute stroke should be verified to the extent possible by the diagnostic criteria outlined for stroke.	C191539	Death due to Stroke Related to COVID-19		Death following a stroke that is either a direct consequence of the stroke or a complication of the stroke in a patient with probable or confirmed acute COVID-19.	274
C191383	COVID-19 Cardiovascular Complications	Yes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49488	Yes		The affirmative response to a question.	275
C191383	COVID-19 Cardiovascular Complications	No	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49487	No		The non-affirmative response to a question.	276
C191383	COVID-19 Cardiovascular Complications	Unknown	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	277
C191383	COVID-19 Cardiovascular Complications	Death due to cardiovascular procedure	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	Death caused by the immediate complications of a cardiovascular procedure in a patient with probable or confirmed acute COVID-19	C191464	Death due to Cardiovascular Procedure Related to COVID-19		Death caused by complications of a cardiovascular procedure in a patient with probable or confirmed acute COVID-19.	278
C191383	COVID-19 Cardiovascular Complications	Yes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49488	Yes		The affirmative response to a question.	279
C191383	COVID-19 Cardiovascular Complications	No	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49487	No		The non-affirmative response to a question.	280
C191383	COVID-19 Cardiovascular Complications	Unknown	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	281
C191383	COVID-19 Cardiovascular Complications	Death due to cardiovascular hemorrhage	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	Death related to hemorrhage such as a nonstroke intracranial hemorrhage (e.g., subdural hematoma), nonprocedural or nontraumatic vascular rupture (e.g., aortic aneurysm), or hemorrhage causing cardiac tamponade in a patient with probable or confirmed acute COVID-19	C191463	Death due to Cardiovascular Hemorrhage Related to COVID-19		Death related to hemorrhage such as a non-stroke intracranial hemorrhage, non-procedural or non-traumatic vascular rupture, or hemorrhage causing cardiac tamponade in a patient with probable or confirmed acute COVID-19.	282
C191383	COVID-19 Cardiovascular Complications	Yes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49488	Yes		The affirmative response to a question.	283
C191383	COVID-19 Cardiovascular Complications	No	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49487	No		The non-affirmative response to a question.	284
C191383	COVID-19 Cardiovascular Complications	Unknown	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	285
C191383	COVID-19 Cardiovascular Complications	Death due to pulmonary embolus	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	Death caused by pulmonary embolus in a patient with probable or confirmed acute COVID-19	C191538	Death due to Pulmonary Embolus Related to COVID-19		Death as a consequence of pulmonary embolism in a patient with probable or confirmed acute COVID-19.	286
C191383	COVID-19 Cardiovascular Complications	Yes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49488	Yes		The affirmative response to a question.	287
C191383	COVID-19 Cardiovascular Complications	No	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49487	No		The non-affirmative response to a question.	288
C191383	COVID-19 Cardiovascular Complications	Unknown	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	289
C191383	COVID-19 Cardiovascular Complications	Death due to other cardiovascular causes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	Cardiovascular death not included in the above categories but with a specific, known cause (e.g., peripheral arterial disease)	C191465	Death due to Other Cardiovascular Cause Related to COVID-19		Death from a cardiovascular cause not otherwise noted but with a specific, known cause in a patient with probable or confirmed acute COVID-19.	290
C191383	COVID-19 Cardiovascular Complications	Yes	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49488	Yes		The affirmative response to a question.	291
C191383	COVID-19 Cardiovascular Complications	No	C191397	Cardiovascular Mortality During Acute COVID-19 Infection		C49487	No		The non-affirmative response to a question.	292
C191383	COVID-19 Cardiovascular Complications	Unknown	C191397	Cardiovascular Mortality During Acute COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	293
C191384	COVID-19 Noncardiovascular Complications	ARDS			ARDS meeting standard clinical criteria in a patient with probable or confirmed COVID-19 and felt to be secondary to COVID-19	C171551	COVID-19-Associated Acute Respiratory Distress Syndrome	SARS-CoV-2-Associated Acute Respiratory Distress Syndrome	Acute respiratory distress syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	294
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	295
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	296
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	297
C191384	COVID-19 Noncardiovascular Complications	Pneumonia			Clinical pneumonia or asymptomatic pulmonary infiltrates in a patient with probable or confirmed COVID-19 and felt to be secondary to COVID-19	C171550	COVID-19-Associated Pneumonia	SARS-CoV-2 -Associated Pneumonia	Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is characterized by the presence of ground glass opacities on CT scan images.	298
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	299
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	300
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	301
C191384	COVID-19 Noncardiovascular Complications	Distributive shock			Distributive shock (e.g., due to sepsis or SIRS), defined as an inadequate supply of oxygen at the tissue level to meet metabolic needs in a vasodilated state in a patient with probable or confirmed COVID-19	C191620	Distributive Shock Related to COVID-19	Vasodilatory Shock Related to COVID-19	Systemic vasodilation leading to decreased blood flow to organs in a patient with probable or confirmed acute COVID-19.	302
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	303
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	304
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	305
C191384	COVID-19 Noncardiovascular Complications	Acute kidney injury with renal replacement therapy			Abrupt reduction in kidney function in a patient with probable or confirmed COVID-19, measured by urine output and renal biomarkers requiring any renal replacement therapy	C191516	Acute Kidney Injury with Renal Replacement Therapy Related to COVID-19		Abrupt reduction in kidney function as measured by urine output and renal biomarkers requiring any renal replacement therapy in a patient with probable or confirmed acute COVID-19.	306
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	307
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	308
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	309
C191384	COVID-19 Noncardiovascular Complications	Acute kidney injury without renal replacement therapy			Abrupt reduction in kidney function in a patient with probable or confirmed COVID-19, measured by urine output and renal biomarkers not requiring temporary or permanent renal replacement therapy	C191517	Acute Kidney Injury without Renal Replacement Therapy Related to COVID-19		Abrupt reduction in kidney function as measured by urine output and renal biomarkers but not requiring any renal replacement therapy in a patient with probable or confirmed acute COVID-19.	310
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	311
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	312
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	313
C191384	COVID-19 Noncardiovascular Complications	Acute liver injury with fulminant failure			Acute liver injury manifested by abnormalities in liver enzymes in a patient with probable or confirmed COVID-19. A minority of patients experience severe liver injury that can result in hepatic failure, defined as rapid loss of liver function during acute COVID-19, which is associated with coagulopathy or encephalopathy, and often multiorgan failure.	C191518	Acute Liver Injury with Fulminant Failure Related to COVID-19		Acute liver injury manifested by rapid loss of liver function associated with abnormal liver enzyme levels, coagulopathy or encephalopathy, and often multiorgan failure in a patient with probable or confirmed acute COVID-19.	314
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	315
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	316
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	317
C191384	COVID-19 Noncardiovascular Complications	Acute liver injury without fulminant failure			Acute liver injury in a patient with probable or confirmed COVID-19, defined as abnormal liver chemistries >2' ULN in the absence of signs of hepatic failure (e.g., no coagulopathy or encephalopathy), is usually mild, transient, and does not require intervention.	C191519	Acute Liver Injury without Fulminant Failure Related to COVID-19		Acute liver injury associated with abnormal liver chemistries (greater than two times the upper limit of normal) in the absence of signs of hepatic failure (e.g., no coagulopathy or encephalopathy) in a patient with probable or confirmed acute COVID-19. This is usually mild, transient, and does not require intervention.	318
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	319
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	320
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	321
C191384	COVID-19 Noncardiovascular Complications	Disseminated intravascular coagulation			Abnormalities in coagulation and fibrinolysis, resulting in a condition in which blood clots form throughout the body, thereby causing clotting in small blood vessels and increasing risk for hemorrhage, in a patient with probable or confirmed COVID-19	C191542	Disseminated Intravascular Coagulation Related to COVID-19	DIC Related to COVID-19	Disseminated intravascular coagulation in a patient with probable or confirmed acute COVID-19.	322
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	323
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	324
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	325
C191384	COVID-19 Noncardiovascular Complications	Rhabdomyolysis			Destruction or degeneration of muscle tissue accompanied by the release of breakdown products from muscle cells into the bloodstream (e.g., creatine kinase, aldolase) that may lead to acute kidney injury in a patient with probable or confirmed COVID-19	C191617	Rhabdomyolysis Related to COVID-19		Rhabdomyolysis in a patient with probable or confirmed acute COVID-19.	326
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	327
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	328
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	329
C191384	COVID-19 Noncardiovascular Complications	Seizures			Convulsions, sensory, cognitive disturbances, or loss of consciousness resulting from abnormal electrical discharges in the brain in a patient with probable or confirmed COVID-19	C191619	Seizure Related to COVID-19	Convulsion Related to COVID-19	Seizure in a patient with probable or confirmed acute COVID-19.	330
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	331
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	332
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	333
C191384	COVID-19 Noncardiovascular Complications	Encephalopathy			A functional or structural disorder of the brain	C191549	Encephalopathy Related to COVID-19		Encephalopathy in a patient with probable or confirmed acute COVID-19.	334
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	335
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	336
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	337
C191384	COVID-19 Noncardiovascular Complications	Loss of smell (anosmia)			Loss or impairment of olfactory function during COVID-19	C171558	COVID-19-Associated Anosmia	SARS-CoV-2-Associated Anosmia	Anosmia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	338
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	339
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	340
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	341
C191384	COVID-19 Noncardiovascular Complications	Loss of taste (ageusia)			Loss or impairment of gustatory function during COVID-19	C173629	COVID-19-Associated Ageusia	COVID-19 Associated Loss of Taste	Ageusia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	342
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	343
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	344
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	345
C191384	COVID-19 Noncardiovascular Complications	Pregnancy loss or other adverse pregnancy outcome			Pregnancy loss or other adverse pregnancy outcome (hypertensive disorders of pregnancy, preterm delivery, small for gestational age birth, gestational diabetes) in a patient with probable or confirmed COVID-19	C191604	Pregnancy Complication Related to COVID-19		A pregnancy complication in a patient with probable or confirmed acute COVID-19.	346
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	347
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	348
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	349
C191384	COVID-19 Noncardiovascular Complications	Syncope			Abrupt, transient, complete loss of consciousness, associated with the inability to maintain postural tone and rapid, spontaneous recovery in a patient with probable or confirmed COVID-19	C191629	Syncope Related to COVID-19		Syncope in a patient with probable or confirmed acute COVID-19.	350
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	351
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	352
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	353
C191384	COVID-19 Noncardiovascular Complications	Presyncope			The symptoms before syncope. These symptoms could include extreme lightheadedness; visual sensations, such as "tunnel vision" or "graying out"; and variable degrees of altered consciousness without complete loss of consciousness. Presyncope could progress to syncope, or it could abort without syncope.	C191606	Presyncope Related to COVID-19		Presyncope in a patient with probable or confirmed acute COVID-19.	354
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	355
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	356
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	357
C191384	COVID-19 Noncardiovascular Complications	Cerebral vein thrombosis			The formation of a blood clot in a cerebral vein	C191485	Cerebral Venous Thrombosis Related to COVID-19			358
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	359
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	360
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	361
C191384	COVID-19 Noncardiovascular Complications	Other noncardiovascular complication			Other noncardiovascular symptom(s) in a patient with probable or confirmed COVID-19 such as peripheral neuropathy, gastrointestinal distress or diarrhea, de novo or acute worsening of chronic hyperglycemia, ocular symptoms, and livedo reticularis, which may be related to direct viral tissue damage or systemic inflammation and immunopathological damage	C191511	Non-Cardiovascular Complication Related to COVID-19		A complication in a patient with probable or confirmed acute COVID-19 that is not associated with a cardiovascular cause.	362
C191384	COVID-19 Noncardiovascular Complications	Yes				C49488	Yes		The affirmative response to a question.	363
C191384	COVID-19 Noncardiovascular Complications	No				C49487	No		The non-affirmative response to a question.	364
C191384	COVID-19 Noncardiovascular Complications	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	365
C191385	Symptoms and Signs	Cough || Coughing	C191398	Current Symptoms and Signs: Clinical Symptoms	A sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs, and usually accompanied by a distinctive sound	C37935	Cough		A sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs, and usually accompanied by a distinctive sound.	366
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	367
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	368
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	369
C191385	Symptoms and Signs	Dyspnea || Presence and severity of dyspnea	C191398	Current Symptoms and Signs: Clinical Symptoms	An uncomfortable sensation of difficulty breathing. It may present as an acute or chronic sign of an underlying respiratory or heart disorder.	C2998	Dyspnea	Shortness of Breath	An uncomfortable sensation of difficulty breathing. It may present as an acute or chronic sign of an underlying respiratory or heart disorder.	370
C191385	Symptoms and Signs	No limitation of physical activity by dyspnea	C191398	Current Symptoms and Signs: Clinical Symptoms		C191548	Dyspnea with No Physical Activity Limitation		Dyspnea that does not interfere with their physical activity.	371
C191385	Symptoms and Signs	Dyspnea with moderate physical activity	C191398	Current Symptoms and Signs: Clinical Symptoms		C191547	Dyspnea with Moderate Physical Activity		Dyspnea experienced during moderate exertion.	372
C191385	Symptoms and Signs	Dyspnea with mild physical activity	C191398	Current Symptoms and Signs: Clinical Symptoms		C191546	Dyspnea with Mild Physical Activity		Dyspnea experienced during minimal exertion.	373
C191385	Symptoms and Signs	Dyspnea at rest	C191398	Current Symptoms and Signs: Clinical Symptoms		C191545	Dyspnea at Rest		Dyspnea experienced while at rest.	374
C191385	Symptoms and Signs	Orthopnea	C191398	Current Symptoms and Signs: Clinical Symptoms	Uncomfortable awareness of breathing while in a supine position, improved by sitting upright or standing	C191448	Orthopnea		Shortness of breath while lying down and which is relived by sitting or standing.	375
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	376
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	377
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	378
C191385	Symptoms and Signs	Paroxysmal nocturnal dyspnea	C191398	Current Symptoms and Signs: Clinical Symptoms	Sudden awakening from sleep with uncomfortable awareness of breathing, relieved by sitting upright or standing. A reported duration >5 min is considered positive.	C34561	Paroxysmal Nocturnal Dyspnea	Cardiac Asthma	Sudden onset of shortness of breath that causes one to awaken coughing or wheezing; it may be associated with congestive heart failure or chronic obstructive pulmonary disease.	379
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	380
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	381
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	382
C191385	Symptoms and Signs	Fatigue || Fatigue (lassitude)	C191398	Current Symptoms and Signs: Clinical Symptoms	A state of exhaustion usually caused by various etiologies such as a period of mental or bodily activity, sleep deprivation, medications, chronic disease, or other factors.	C3036	Fatigue	Lack of Energy	Overall tiredness and lack of energy.	383
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	384
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	385
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	386
C191385	Symptoms and Signs	Syncope	C191398	Current Symptoms and Signs: Clinical Symptoms	Abrupt, transient, complete loss of consciousness, associated with inability to maintain postural tone, with rapid and spontaneous recovery	C35053	Syncope		A spontaneous loss of consciousness caused by insufficient blood supply to the brain.	387
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	388
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	389
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	390
C191385	Symptoms and Signs	Presyncope	C191398	Current Symptoms and Signs: Clinical Symptoms	The symptoms before syncope. These symptoms could include extreme lightheadedness; visual sensations, such as "tunnel vision" or "graying out"; and variable degrees of altered consciousness without complete loss of consciousness. Presyncope could progress to syncope, or it could abort without syncope.	C80100	Presyncope		An episode of lightheadedness and dizziness which may precede an episode of syncope.	391
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	392
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	393
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	394
C191385	Symptoms and Signs	Acute pulmonary edema	C191398	Current Symptoms and Signs: Clinical Symptoms	Acute onset or rapid progression of pulmonary edema causing significant hypoxemia or need for supplemental oxygen	C191610	Acute Pulmonary Edema		Rapid or severe onset or rapid progression of pulmonary edema causing significant hypoxemia or the need for supplemental oxygen.	395
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	396
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	397
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	398
C191385	Symptoms and Signs	Fever	C191398	Current Symptoms and Signs: Clinical Symptoms	Temperature greater than or equal to 100.4 degrees F (38.0 degrees C)	C3038	Fever		Elevation of body temperature above normal due to inflammatory or immune responses.	399
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	400
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	401
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	402
C191385	Symptoms and Signs	Loss of smell (anosmia)	C191398	Current Symptoms and Signs: Clinical Symptoms	Loss or impairment of olfactory function during COVID-19	C171558	COVID-19-Associated Anosmia	SARS-CoV-2-Associated Anosmia	Anosmia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	403
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	404
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	405
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	406
C191385	Symptoms and Signs	Loss of taste (ageusia)	C191398	Current Symptoms and Signs: Clinical Symptoms	Loss or impairment of gustatory function during COVID-19	C173629	COVID-19-Associated Ageusia	COVID-19 Associated Loss of Taste	Ageusia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	407
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	408
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	409
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	410
C191385	Symptoms and Signs	Diarrhea	C191398	Current Symptoms and Signs: Clinical Symptoms	Passage of greater than or equal to 3 loose or liquid stools per day (or more frequent passage than is normal for the individual)	C2987	Diarrhea		Watery bowel movements.	411
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	412
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	413
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	414
C191385	Symptoms and Signs	Nausea	C191398	Current Symptoms and Signs: Clinical Symptoms	The inclination to vomit	C3258	Nausea		Upper abdominal discomfort associated with an urge to vomit.	415
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	416
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	417
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	418
C191385	Symptoms and Signs	Vomiting	C191398	Current Symptoms and Signs: Clinical Symptoms	Vomiting	C3442	Vomiting	Emesis	Forceful ejection of the contents of the stomach through the mouth.	419
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	420
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	421
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	422
C191385	Symptoms and Signs	Seizure || Seizures	C191398	Current Symptoms and Signs: Clinical Symptoms	Convulsions, sensory, cognitive disturbances, or loss of consciousness resulting from abnormal electrical discharges in the brain in a patient with probable or confirmed COVID-19	C2962	Seizure	Convulsion	Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.	423
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	424
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	425
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	426
C191385	Symptoms and Signs	Rash || Skin rash	C191398	Current Symptoms and Signs: Clinical Symptoms	Any change in the skin that affects its appearance or texture. A rash may be localized to one part of the body or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked, or blistered, swell, and may be painful.	C39594	Skin Rash	Cutaneous Eruption	Any change in the skin which affects its appearance or texture. A rash may be localized to one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful.	427
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	428
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	429
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	430
C191385	Symptoms and Signs	Limb edema || Peripheral Edema	C191398	Current Symptoms and Signs: Clinical Symptoms	Increased tissue fluid indicated by perceptible indentation on lower leg or foot after palpation	C78262	Edema Limbs	Limb Edema || Peripheral Edema	Swelling due to an excessive accumulation of fluid in the upper or lower extremities.	431
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	432
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	433
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	434
C191385	Symptoms and Signs	Myalgias	C191398	Current Symptoms and Signs: Clinical Symptoms	Painful sensation originating from a muscle or group of muscles	C27009	Myalgia	Muscle Ache	Painful sensation originating from a muscle or group of muscles.	435
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	436
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	437
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	438
C191385	Symptoms and Signs	Headache	C191398	Current Symptoms and Signs: Clinical Symptoms	Pain in any region of the head	C34661	Headache	Cephalalgia || Cephalgia	Pain in various parts of the head, not confined to the area of distribution of any nerve.	439
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	440
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	441
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	442
C191385	Symptoms and Signs	Altered mental state	C191398	Current Symptoms and Signs: Clinical Symptoms	A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline	C121628	Altered Mental Status		A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline.	443
C191385	Symptoms and Signs	Yes	C191398	Current Symptoms and Signs: Clinical Symptoms		C49488	Yes		The affirmative response to a question.	444
C191385	Symptoms and Signs	No	C191398	Current Symptoms and Signs: Clinical Symptoms		C49487	No		The non-affirmative response to a question.	445
C191385	Symptoms and Signs	Unknown	C191398	Current Symptoms and Signs: Clinical Symptoms	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	446
C191385	Symptoms and Signs	Heart rate || Vital Signs - Heart Rate	C191402	Physical Examination	A measurement that describes the frequency of rate of contractions of the systemic (often left) ventricle measured within a unit time.	C49677	Heart Rate	HR	The number of heartbeats per unit of time, usually expressed as beats per minute.	447
C191385	Symptoms and Signs	bpm	C191402	Physical Examination		C49673	Beats per Minute	Beats/Minute || Heart Beats per Minute	The number of heartbeats measured per minute time.	448
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	449
C191385	Symptoms and Signs	Systolic blood pressure	C191402	Physical Examination	Systolic blood pressure value recorded closest to the time of presentation to the health care facility	C25298	Systolic Blood Pressure	Systolic Pressure	The maximum pressure exerted into the systemic arterial circulation during the contraction of the left ventricle of the heart.	450
C191385	Symptoms and Signs	mmHg	C191402	Physical Examination		C49670	Millimeter of Mercury	Torr	A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.	451
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	452
C191385	Symptoms and Signs	Diastolic blood pressure	C191402	Physical Examination	Diastolic blood pressure value recorded closest to the time of presentation to the health care facility	C25299	Diastolic Blood Pressure	Diastolic Pressure	The minimum pressure exerted into the systemic arterial circulation during cardiac ventricular relaxation and filling.	453
C191385	Symptoms and Signs	mmHg	C191402	Physical Examination		C49670	Millimeter of Mercury	Torr	A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.	454
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	455
C191385	Symptoms and Signs	Pulse pressure	C191402	Physical Examination	The force of a heart contraction measured by the difference between the diastolic and systolic blood pressure measurements	C100945	Pulse Pressure		The force of a heart contraction measured by the difference between the diastolic and systolic blood pressure measurements.	456
C191385	Symptoms and Signs	mmHg	C191402	Physical Examination		C49670	Millimeter of Mercury	Torr	A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.	457
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	458
C191385	Symptoms and Signs	Respiratory rate || Vital Signs - Respiratory Rate	C191402	Physical Examination	A measurement that describes the rate of breathing (inhalation and exhalation) measured within a unit time (typically 1 min)	C49678	Respiratory Rate		The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute.	459
C191385	Symptoms and Signs	cycles/min	C191402	Physical Examination		C49674	Breaths per Minute	Breaths/Minute	The number of breaths (inhalation and exhalation) taken per minute time.	460
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	461
C191385	Symptoms and Signs	Height	C191402	Physical Examination	A measurement that describes the vertical measurement or distance from the base, or bottom, of the patient, to the top of the patient; this can be taken as the dimension of extension of a patient who cannot stand.	C164634	Body Height		The vertical measurement or distance from the base to the top of a subject or participant.	462
C191385	Symptoms and Signs	cm	C191402	Physical Examination		C49668	Centimeter		A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.	463
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	464
C191385	Symptoms and Signs	Vital Signs - Weight || Weight at encounter	C191402	Physical Examination	A measurement that describes the vertical force exerted by a mass of the patient as a result of gravity	C81328	Body Weight		The weight of a subject.	465
C191385	Symptoms and Signs	kg	C191402	Physical Examination		C28252	Kilogram		A basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds.	466
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	467
C191385	Symptoms and Signs	Body mass index || Vital Signs - BMI	C191402	Physical Examination	A measurement that is used to indicate the body fat an individual is carrying based on the ratio of weight to height as measured in kilograms per square meters	C16358	Body Mass Index	Quetelet Index	An individual's weight in kilograms divided by the square of the height in meters.	468
C191385	Symptoms and Signs	kg/mg2	C191402	Physical Examination		C49671	Kilogram per Square Meter	Kilogram per Meter Squared || Kilogram/Square Meter	The SI derived unit of spread rate of a substance by mass, used also as a measure of area density and as a dose calculation unit.	469
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	470
C191385	Symptoms and Signs	Jugular venous pressure	C191402	Physical Examination	The estimated height of the mean jugular venous waveform above the right atrium, measured at a 45 degree angle. When expressed in cm without further description, the number should be recorded as written. When it is expressed as cm above the sternal angle, 5 cm should be added to the number recorded.	C191459	Jugular Venous Pressure	JVP	The estimated height of the mean jugular venous waveform above the right atrium, as measured by observation of the bifid pulsation while the patient is supine and their neck is inclined at a 45 degree angle.	471
C191385	Symptoms and Signs	cm	C191402	Physical Examination		C49668	Centimeter		A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch.	472
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	473
C191385	Symptoms and Signs	Jugular venous distension	C191402	Physical Examination	Increased pressure of the superior vena cava causing the jugular vein to bulge, making it visualized at a level of the neck that is higher than normal	C191482	Jugular Venous Distension	JVD	Bulging of the jugular vein secondary to increased pressure of the superior vena cava, causing it to be visualized at a level of the neck that is higher than normal.	474
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	475
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	476
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	477
C191385	Symptoms and Signs	Hepatojugular reflex	C191402	Physical Examination	Distension of the neck veins precipitated by the maneuver of firm sustained pressure over the liver. Also referred to as abdomino-jugular reflux.	C191481	Hepatojugular Reflex	Abdominojugular Reflex	Distension of the neck veins precipitated by sustained pressure over the liver while patient is semi-recumbent. With normal heart function, pressure on the liver does not elevate the venous blood level in the neck veins.	478
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	479
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	480
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	481
C191385	Symptoms and Signs	S3 || Third heart sound (S3)	C191402	Physical Examination	An auscultated finding describing a low-frequency sound that follows A2 in early diastole and corresponds with the first phase of rapid ventricular filling, signifying the third heart sound. It is normal in children and young adults, but abnormal in others.	C61455	S3 Gallop	S3 Heart Sound || Third Heart Sound || Ventricular Gallop	A finding which can be heard on auscultation of the heart in the setting of congestive heart failure. The sound of the S3 gallop, which immediately follows the second heart sound (S2) is thought to be produced by the sound of blood flowing into a noncompliant ventricle.	482
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	483
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	484
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	485
C191385	Symptoms and Signs	Fourth heart sound (S4) || S4	C191402	Physical Examination	An auscultated finding that describes a low-frequency sound, heard late in diastole just before S1, caused by forceful atrial contractions, signifying the fourth heart sound. It is typically abnormal, except in highly trained athletes and the elderly.	C168026	S4 Heart Sound		An auscultated finding that describes a low-frequency sound, heard late in diastole just before S1, caused by forceful atrial contractions, signifying the fourth heart sound. It is typically abnormal, except in highly trained athletes and the elderly. (ACC/AHA)	486
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	487
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	488
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	489
C191385	Symptoms and Signs	Rub	C191402	Physical Examination	An auscultated finding describing high or medium pitched and scratchy sound, generated by inflammation of the pericardial sac	C168025	Pericardial Rub		An auscultated finding describing high or medium pitched and scratchy sound, generated by inflammation of the pericardial sac. (ACC/AHA)	490
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	491
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	492
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	493
C191385	Symptoms and Signs	Heart murmur || Murmur	C191402	Physical Examination	An auscultated finding describing a series of audible vibrations of varying intensity (loudness), frequency (pitch), quality, configuration, and duration created by turbulent blood flow in the heart or surrounding vessels	C84480	Heart Murmur	Cardiac Murmur	A periodic humming or blowing sound heard on auscultation of the heart that can indicate the presence of cardiac disease; murmurs are the result of vibrations caused by the turbulent flow of blood in the heart or great vessels. Murmurs are characterized according to the area of generation (mitral, aortic, tricuspid, or pulmonary) and according to the period of the cycle (systolic or diastolic).	494
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	495
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	496
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	497
C191385	Symptoms and Signs	Cardiac Examination - Heart Sounds, Phase of Murmur || Heart murmur timing	C191402	Physical Examination	The classification of a heart murmur based on the phase of the cardiac cycle or timing of its occurrence	C167438	Heart Murmur Categorized by Phase or Timing		The classification of a heart murmur based on the phase of the cardiac cycle or timing of its occurrence.	498
C191385	Symptoms and Signs	Systolic	C191402	Physical Examination	The phase of time during ventricular ejection in which the semilunar valve(s) are open.	C167437	Systolic Heart Murmur	Systolic Murmur	A heart murmur that occurs during ventricular ejection, while the semilunar valves are open.	499
C191385	Symptoms and Signs	Diastolic	C191402	Physical Examination	The phase of time between ventricular ejection, in which the semilunar valve(s) are closed.	C167445	Diastolic Heart Murmur	Diastolic Murmur	A heart murmur that occurs between ventricular ejection, while the semilunar valves are closed.	500
C191385	Symptoms and Signs	Cardiac Examination - Heart Sounds, Location (Including Murmurs) || Heart sounds - location (including murmurs)	C191402	Physical Examination	The classification of a heart murmur based on location	C168320	Location of Heart Sound Auscultation		The location on the anterior chest wall where auscultation is undertaken.	501
C191385	Symptoms and Signs	Apex	C191402	Physical Examination	The location on the precordium that corresponds to the location of the blunt extremity of the heart formed by the left ventricle.	C168234	Heart Sound Auscultation at Apex		Heart sounds are auscultated on the precordial location corresponding to the blunt extremity of the heart formed by the left ventricle.	502
C191385	Symptoms and Signs	Left lower sternal border	C191402	Physical Examination	The location on the precordium that corresponds to the tricuspid region, between the fifth and sixth intercostal spaces at the left sternal border	C168238	Heart Sound Auscultation at Left Lower Sternal Border		Heart sounds are auscultated on the precordial location corresponding to the tricuspid region, between the fifth, and sixth intercostal spaces at the left sternal border.	503
C191385	Symptoms and Signs	Left middle sternal border	C191402	Physical Examination	The location on the precordium that corresponds to the region between the third and fifth intercostal spaces at the left sternal border	C168240	Heart Sound Auscultation at Left Middle Sternal Border		Heart sounds are auscultated on the precordial location corresponding to the region between the third and fifth intercostal spaces at the left sternal border.	504
C191385	Symptoms and Signs	Left upper sternal border	C191402	Physical Examination	The location on the precordium that corresponds to the pulmonic region, between the second and third intercostal spaces at the left sternal border	C168241	Heart Sound Auscultation at Left Upper Sternal Border		Heart sounds are auscultated on the precordial location corresponding to the pulmonic region, between the second and third intercostal spaces at the left sternal border.	505
C191385	Symptoms and Signs	Right upper sternal border	C191402	Physical Examination	The location on the precordium that corresponds to the aortic region, between the second and third intercostal spaces at the right sternal border	C168247	Heart Sound Auscultation at Right Upper Sternal Border		Heart sounds are auscultated on the precordial location corresponding to the aortic region, between the second and third intercostal spaces at the right sternal border.	506
C191385	Symptoms and Signs	Lung (pulmonary) examination findings	C191402	Physical Examination	Findings on auscultation of the lungs	C191427	Lung Examination Finding	Pulmonary Examination Finding	A finding noted on auscultation of the lungs.	507
C191385	Symptoms and Signs	Clear or normal	C191402	Physical Examination	Lungs are normal on auscultation.	C191568	Lungs Clear on Auscultation		Normal breath sounds noted during auscultation.	508
C191385	Symptoms and Signs	Rales	C191402	Physical Examination	Abnormal breath sounds (crackles) heard on auscultation indicating inflammation, fluid, or infection of the lung	C119216	Rales	Pulmonary Rales	Abnormal breath sounds (crackles) heard on auscultation, indicating inflammation, fluid, or infection of the lung.	509
C191385	Symptoms and Signs	Decreased breath sounds or dullness	C191402	Physical Examination	Diminished breath sounds	C191569	Decreased Breath Sounds		Diminished breath sounds noted during auscultation.	510
C191385	Symptoms and Signs	Rhonchi	C191402	Physical Examination	Abnormal breath sounds similar to snoring heard on auscultation of the bronchial airways, suggesting a partial obstruction due to thick secretions, a muscular spasm, or a neoplasm	C87116	Rhonchi		An abnormal sound similar to snoring heard on auscultation of the bronchial airways, suggesting a partial obstruction due to thick secretions, a muscular spasm, or a neoplasm.	511
C191385	Symptoms and Signs	Wheezing	C191402	Physical Examination	A clinical finding in which there is a raspy high-pitched whistling sound noted on expiration or inspiration associated with obstruction of the lower airways.	C78718	Wheezing	Wheeze	A symptom and a finding during physical examination, characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways. The most common causes of wheezing are asthma, chronic obstructive pulmonary disease, tracheobronchitis, and pulmonary edema.	512
C191385	Symptoms and Signs	Crepitations	C191402	Physical Examination	Crackling sounds typically heard in lung infection or with pulmonary fibrosis	C61454	Basilar Rales	Crackles	Abnormal breath sounds (crackles) heard on auscultation only in the bases of the lungs. They indicate inflammation, fluid, or infection in the air sacs of the lung.	513
C191385	Symptoms and Signs	Pleural friction rub	C191402	Physical Examination	An abnormal lung sound that is caused by inflammation of the pleural layer of the lungs rubbing together. Pleural friction rub is heard on inspiration and expiration and sounds like a low-pitch harsh/grating noise.	C191616	Pleural Friction Rub		A low-pitch harsh, grating sound heard on auscultation of the lungs during inspiration and expiration that is caused by inflamed pleura layers rubbing together.	514
C191385	Symptoms and Signs	Absent breath sounds	C191402	Physical Examination	Absence of breath sounds during auscultation	C191570	Absent Breath Sounds		Absence of breath sounds noted during auscultation.	515
C191385	Symptoms and Signs	Other findings	C191402	Physical Examination		C36295			An additional finding not previously noted.	516
C191385	Symptoms and Signs	Limb edema || Peripheral Edema	C191402	Physical Examination	Increased tissue fluid indicated by perceptible indentation on lower leg or foot after palpation	C78262	Edema Limbs	Limb Edema || Peripheral Edema	Swelling due to an excessive accumulation of fluid in the upper or lower extremities.	517
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	518
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	519
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	520
C191385	Symptoms and Signs	Ascites	C191402	Physical Examination	A clinical finding in which there is accumulation of interstitial fluid in the peritoneal cavity.	C2885	Ascites		The accumulation of fluid in the peritoneal cavity, which may be serous, hemorrhagic, or the result of tumor metastasis to the peritoneum.	521
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	522
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	523
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	524
C191385	Symptoms and Signs	Hepatomegaly	C191402	Physical Examination	A clinical finding in which the liver is found to be enlarged on abdominal palpation.	C3100	Hepatomegaly		Abnormal enlargement of the liver.	525
C191385	Symptoms and Signs	Yes	C191402	Physical Examination		C49488	Yes		The affirmative response to a question.	526
C191385	Symptoms and Signs	No	C191402	Physical Examination		C49487	No		The non-affirmative response to a question.	527
C191385	Symptoms and Signs	Unknown	C191402	Physical Examination	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	528
C191385	Symptoms and Signs	Neurological examination findings	C191402	Physical Examination		C191598	Neurological Examination Finding	Neurologic Examination Finding	A finding noted on examination of the functioning of the nervous system.	529
C191385	Symptoms and Signs	Dizziness	C191402	Physical Examination	A condition in which the sensation of lightheadedness or a feeling of movement within the head occurs.	C37943	Dizziness	Dizzy	A sensation of lightheadedness, unsteadiness, turning, spinning or rocking.	530
C191385	Symptoms and Signs	Headache	C191402	Physical Examination	Pain in any region of the head	C34661	Headache	Cephalalgia || Cephalgia	Pain in various parts of the head, not confined to the area of distribution of any nerve.	531
C191385	Symptoms and Signs	Impaired consciousness	C191402	Physical Examination		C121627	Altered Level of Consciousness	Altered LOC	A level of awareness and arousal other than normal.	532
C191385	Symptoms and Signs	Seizure || Seizures	C191402	Physical Examination	Convulsions, sensory, cognitive disturbances, or loss of consciousness resulting from abnormal electrical discharges in the brain in a patient with probable or confirmed COVID-19	C2962	Seizure	Convulsion	Sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.	533
C191385	Symptoms and Signs	Agitation	C191402	Physical Examination		C79530	Agitation		A state of restlessness associated with unpleasant feelings of irritability and tension. Causes include pain, stress, fever, alcohol and nicotine withdrawal, cocaine and hallucinogenic drugs use, depression, bipolar disorders, and schizophrenia.	534
C191385	Symptoms and Signs	Confusion	C191402	Physical Examination		C37928	Confusion	Disorientation	A mental state characterized by a lack of clear and orderly thought and behavior.	535
C191385	Symptoms and Signs	Visual agnosia	C191402	Physical Examination		C35276	Visual Agnosia		An inability to recognize or interpret objects by sight.	536
C191385	Symptoms and Signs	Encephalopathy	C191402	Physical Examination		C26920	Encephalopathy		A functional and/or structural disorder of the brain caused by diseases (e.g. liver disease, kidney disease), medications, chemicals, and injuries.	537
C191385	Symptoms and Signs	Acute cerebrovascular accident	C191402	Physical Examination		C191433	Acute Stroke		The sudden or severe onset of neurological deficit(s) attributable to an acute focal vascular injury of the central nervous system.	538
C191385	Symptoms and Signs	Corticospinal tract signs: enhanced tendon reflexes	C191402	Physical Examination		C191580	Enhanced Tendon Reflex		Greater than normal deep tendon reflexes.	539
C191385	Symptoms and Signs	Corticospinal tract signs: clonus	C191402	Physical Examination		C34484	Clonus		A form of involuntary muscular movement characterized by alternating contractions and relaxation in rapid succession. In the context of reflex testing, the ability to elicit clonus indicates injury to the nerve tracts above the point at which the reflex was initiated.	540
C191385	Symptoms and Signs	Corticospinal tract signs: hyperreflexia	C191402	Physical Examination		C43248	Hyperreflexia		Autonomic nervous system overreaction to stimuli, most commonly after spinal cord injury at a T-5 level and above.	541
C191385	Symptoms and Signs	Stroke || Stroke not otherwise specified	C191402	Physical Examination	An episode of acute neurological dysfunction presumed to be caused by ischemia or hemorrhage, persisting greater than or equal to 24 h or until death but without sufficient evidence to be classified as one of the above	C3390	Stroke	Cerebrovascular Accident || Stroke Syndrome	A sudden loss of neurological function secondary to hemorrhage or ischemia in the brain parenchyma due to a vascular event.	542
C191385	Symptoms and Signs	Guillain-Barré syndrome	C191402	Physical Examination		C116345	Guillain-Barre Syndrome	Guillain Barre Syndrome || Guillain Barré Syndrome || Guillain-Barré Syndrome	A rapidly progressive autoimmune disorder of the peripheral nervous system characterized by limb paresthesias, areflexia, and generalized muscle weakness or paralysis that often begins in the legs and spreads to the arms, torso, and face.	543
C191385	Symptoms and Signs	Critical illness myopathy	C191402	Physical Examination		C122793	Critical Illness Myopathy		Acute muscle weakness and paralysis that develops in critically ill patients who have been treated with multiple drugs during their intensive care unit stay. It is associated with delayed weaning from mechanical ventilation and prolonged rehabilitation.	544
C191385	Symptoms and Signs	Critical illness polyneuropathy	C191402	Physical Examination		C191601	Critical Illness Polyneuropathy		Polyneuropathy arising in intensive care unit patients. It is a common complication of severe sepsis and is thought to represent a neurologic manifestation of systemic inflammatory response syndrome (SIRS).	545
C191385	Symptoms and Signs	Critical illness polyneuropathy/myopathy	C191402	Physical Examination		C191600	Critical Illness Polyneuromyopathy		Polyneuropathy and myopathy arising in intensive care unit patients.	546
C191385	Symptoms and Signs	Miller-Fisher syndrome	C191402	Physical Examination		C116958	Miller Fisher Syndrome	Fisher Syndrome	An autoimmune process characterized by the clinical triad of ophthalmoplegia, ataxia, and areflexia.	547
C191385	Symptoms and Signs	Other, specify	C191402	Physical Examination		C157106	Specify Other		A directive to indicate a response not listed.	548
C191385	Symptoms and Signs	Frailty	C191402	Physical Examination	Canadian Study of Health and Aging Clinical Frailty Scale score	C185373	Clinical Frailty Scale	CFS	A judgement-based tool to screen for frailty and to broadly stratify degrees of fitness and frailty in elderly people.	549
C191385	Symptoms and Signs	1 (very fit)	C191402	Physical Examination	People who are robust, active, energetic, and motivated. These people commonly exercise regularly. They are among the fittest for their age.	C191486	Clinical Frailty Scale Category 1		A Clinical Frailty Scale category that indicates that an individual is very fit. People who are robust, active, energetic, and motivated. These people commonly exercise regularly. They are among the fittest for their age.	550
C191385	Symptoms and Signs	2 (well)	C191402	Physical Examination	People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally (e.g., seasonally)	C191487	Clinical Frailty Scale Category 2		A Clinical Frailty Scale category that indicates that an individual is fit or well. People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally (e.g., seasonally).	551
C191385	Symptoms and Signs	3 (managing well)	C191402	Physical Examination	People whose medical problems are well controlled but are not regularly active beyond routine walking	C191488	Clinical Frailty Scale Category 3		A Clinical Frailty Scale category that indicates that an individual is managing well. People whose medical problems are well controlled but are not regularly active beyond routine walking.	552
C191385	Symptoms and Signs	4 (vulnerable)	C191402	Physical Examination	Although not dependent on others for daily help, symptoms often limit activities. A common complaint is being "slowed up" or being tired during the day.	C191489	Clinical Frailty Scale Category 4		A Clinical Frailty Scale category that indicates that an individual is living with very mild frailty. Previously denoted as "vulnerable", this category marks the transition from complete independence. Although not dependent on others for daily help, symptoms often limit activities. A common complaint is being "slowed up" or being tired during the day.	553
C191385	Symptoms and Signs	5 (mildly frail)	C191402	Physical Examination	These people often have more evident slowing and need help in high-order instrumental activities of daily living (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation, and housework.	C191490	Clinical Frailty Scale Category 5		A Clinical Frailty Scale category that indicates that an individual is living with mild frailty. These people often have more evident slowing and need help in high-order instrumental activities of daily living (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation, and housework.	554
C191385	Symptoms and Signs	6 (moderately frail)	C191402	Physical Examination	People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cueing, standby) with dressing.	C191491	Clinical Frailty Scale Category 6		A Clinical Frailty Scale category that indicates that an individual is living with moderate frailty. People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cueing, standby) with dressing.	555
C191385	Symptoms and Signs	7 (severely frail)	C191402	Physical Examination	Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~6 mo).	C191492	Clinical Frailty Scale Category 7		A Clinical Frailty Scale category that indicates that an individual is living with severe frailty. Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within about 6 months).	556
C191385	Symptoms and Signs	8 (very severely frail)	C191402	Physical Examination	Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.	C191493	Clinical Frailty Scale Category 8		A Clinical Frailty Scale category that indicates that an individual is living with very severe frailty. Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.	557
C191385	Symptoms and Signs	9 (terminally ill)	C191402	Physical Examination	Approaching the end of life. This category applies to people with a life expectancy <6 mo, who are not otherwise evidently frail.	C191494	Clinical Frailty Scale Category 9		A Clinical Frailty Scale category that indicates that an individual is terminally ill. Approaching the end of life. This category applies to people with a life expectancy of less than 6 months, who are not otherwise evidently frail. Many terminally ill patients can still exercise until very close to death.	558
C191386	Diagnostic Procedures	EF, quantitative			Proportion of blood pumped out of the left ventricle of the heart with each contraction, expressed as a percentage	C80417	Ejection Fraction, Quantitative		The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction.	559
C191386	Diagnostic Procedures	EF, %			The fraction of blood expelled from the left ventricle with each cardiac systole (stroke volume/end diastolic volume)	C99524	Left Ventricular Ejection Fraction		The fraction of the left ventricular end diastolic volume ejected with each beat. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume.	560
C191386	Diagnostic Procedures	EF, qualitative			Proportion of blood pumped out of the left ventricle of the heart with each contraction, expressed as qualitative description. The qualitative estimate of the amount of blood expelled from the left ventricle with each cardiac systole.	C80418	Ejection Fraction, Qualitative		A descriptive adjective assigned to the computed amount of blood ejected during a ventricular contraction of the heart.	561
C191386	Diagnostic Procedures	Normal (i.e., greater than or equal to 50%)				C99513	Normal Ventricular Ejection Fraction		The usual amount of blood that is forced from the heart ventricle to produce cardiac output. Quantitatively, the ejection fraction is considered between 50% to 70%.	562
C191386	Diagnostic Procedures	Mildly reduced (i.e., greater than or equal to 40% and less than 50%)				C99507	Mildly Abnormal Ejection Fraction		Slightly less than normal amount of blood that is forced from the heart ventricle to produce cardiac output. Quantitatively, the ejection fraction is considered between 40% to 49%.	563
C191386	Diagnostic Procedures	Moderately reduced (i.e., greater than or equal to 30% and less than 40%)				C99508	Moderately Abnormal Ejection Fraction		Moderately less than normal amount of blood that is forced from the heart ventricle to produce cardiac output. Quantitatively, the ejection fraction is considered between 30% to 39%.	564
C191386	Diagnostic Procedures	Severely reduced (i.e., less than 30%)				C99509	Severely Abnormal Ventricular Ejection Fraction		Severely less than normal amount of blood that is forced from the heart ventricle to produce cardiac output. Quantitatively, the ejection fraction is considered less than 30%.	565
C191386	Diagnostic Procedures	EF modality			Modality used to determine the EF	C191578	Ejection Fraction Modality	EF Modality	The modality used to determine the ejection fraction.	566
C191386	Diagnostic Procedures	Radionuclide ventriculography			A multigated acquisition scan and a form of radionuclide imaging that provides a comprehensive look at blood flow and the function of the lower chambers of the heart ventricles	C38073	Multigated Acquisition Scan	Blood Pool Scan || Equilibrium Radionuclide Angiography || Gated Blood Pool Imaging || MUGA Scan || Multi-Gated Acquisition Scan || RNVG || Radionuclide Ventriculography || SYMA Scanning || Synchronized Multigated Acquisition Scanning	A diagnostic test used to evaluate the pumping function of the heart's ventricles. A radioactive tracer is injected into a vein and a gamma camera detects the radiation released by the tracer, with image acquisition triggered (gated) at different points of the cardiac cycle.	567
C191386	Diagnostic Procedures	Cardiac MRI			A noninvasive medical imaging technology using magnetic field and radio waves to evaluate the heart's anatomy and function for detection and monitoring of cardiac diseases.	C137915	Magnetic Resonance Imaging of the Heart	Cardiac MRI || Heart MRI	Magnetic resonance imaging of the heart.	568
C191386	Diagnostic Procedures	Echocardiography			A test that uses high-frequency sound waves (ultrasound) to create an image of the heart	C16525	Echocardiography		A procedure that uses high-frequency sound waves (ultrasound) to create an image of the heart.	569
C191386	Diagnostic Procedures	Invasive contrast left ventriculography			A medical imaging test that involves injecting contrast media into the heart's ventricle(s) to determine a patient's cardiac function	C124142	Cardiac Ventriculography		A medical imaging test that involves injecting contrast media into the heart's ventricle(s) to determine a patient's cardiac function.	570
C191386	Diagnostic Procedures	Myocardial perfusion imaging			An imaging procedure that quantifies blood flow throughout the heart muscle	C102676	Myocardial Perfusion Imaging		A procedure that captures pictures of blood flow throughout the heart muscle.	571
C191386	Diagnostic Procedures	Other			A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	572
C191386	Diagnostic Procedures	Echocardiography data elements			Refer to the 2019 ACC/AHA/ASE Key Data Elements and Definitions for Transthoracic Echocardiography.	C191523	Echocardiography Data Element		A data element that is used in the reporting of echocardiography.	573
C191386	Diagnostic Procedures	Electrocardiography elements			12-lead electrocardiography data elements	C191524	Electrocardiography Data Element		A data element that is used in the reporting of electrocardiography.	574
C191386	Diagnostic Procedures	Rhythm				C87081	Heart Rhythm	Cardiac Rhythm	The recurrent, measured movements (rhythm) of a beating heart.	575
C191386	Diagnostic Procedures	Sinus Rhythm			an electrocardiographic finding of a cardiac rhythm that originates in the sinoatrial node	C100076	Sinus Rhythm		An electrocardiographic finding of an atrial rhythm which originates from the sinoatrial node that is considered normal for the population. (CDISC)	576
C191386	Diagnostic Procedures	AF			an arrhythmia characterized by uncoordinated atrial myocardium due to multiple reentry circuits with consequent deterioration of atrial mechanical function. Instead of intermittently contracting, the atria quiver continuously in a chaotic pattern, causing a totally irregular often tachycardic ventricular rate	C111092	Atrial Fibrillation by ECG Finding	Atrial Fibrillation || Atrial Fibrillation by EKG Finding	An electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregularly irregular ventricular response. (CDISC)	577
C191386	Diagnostic Procedures	Atrial flutter			a disorder characterized by an electrocardiographic finding of an organized, regular atrial rhythm with atrial rate of 240-340 bpm. Multiple P waves typically appear in the inferior leads in a sawtooth-like pattern between the QRS complexes.	C111094	Atrial Flutter by ECG Finding	Atrial Flutter || Atrial Flutter by EKG Finding	An electrocardiographic finding of an organized, regular atrial rhythm with atrial rate of 240-340 beats per minute. Multiple P waves typically appear in the inferior leads in a saw tooth like pattern between the QRS complexes. (CDISC)	578
C191386	Diagnostic Procedures	Ventricular arrhythmia			a disorder characterized by an electrocardiographic finding of an atypical cardiac rhythm resulting from a pathological process in the cardiac ventricles	C111101	Ventricular Arrhythmia by ECG Finding	Ventricular Arrhythmia || Ventricular Arrhythmia by EKG Finding	An electrocardiographic finding of an atypical cardiac rhythm resulting from a pathologic process in the cardiac ventricles.	579
C191386	Diagnostic Procedures	Supraventricular tachycardia			a disorder characterized by an electrocardiographic finding of a tachycardia that does not originate in the ventricles or His Purkinje system	C111100	Supraventricular Tachycardia by ECG Finding	Supraventricular Tachycardia || Supraventricular Tachycardia by EKG Finding	An electrocardiographic finding of a tachycardia which does not originate in the ventricles or His Purkinje system. There is an abnormally high heart rate and QRS complexes are typically narrow, but aberration or preexcitation may be present. (CDISC)	580
C191386	Diagnostic Procedures	Paced rhythm			an electrocardiographic finding that the cardiac rhythm is initiated by an electrical impulse from a mechanical cardiac pacemaker	C88140	Paced Rhythm		An electrocardiographic finding in which the cardiac rhythm is controlled by an electrical impulse from an artificial cardiac pacemaker. (CDISC)	581
C191386	Diagnostic Procedures	Other			A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	582
C191386	Diagnostic Procedures	Heart rate || Vital Signs - Heart Rate			A measurement that describes the frequency of rate of contractions of the systemic (often left) ventricle measured within a unit time.	C49677	Heart Rate	HR	The number of heartbeats per unit of time, usually expressed as beats per minute.	583
C191386	Diagnostic Procedures	QRS axis			A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane	C118165	QRS Axis		A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)	584
C191386	Diagnostic Procedures	LBBB			An electrocardiographic finding of delayed conduction to the left ventricle, manifested as a widened QRS complex and absence of Q waves in leads V5, V6, I, and aVL with QRS duration greater than or equal to 120 ms	C62269	Left Bundle Branch Block by ECG Finding	LBBB || Left Bundle Branch Block || Left Bundle Branch Block by EKG Finding	An electrocardiographic finding of a wide QRS complex with evidence of delayed conduction to the left ventricle, manifested as a widened initial portion of the QRS complex in leads V5, V6, I and aVL and with QRS duration greater than or equal to 120 ms. (CDISC)	585
C191386	Diagnostic Procedures	RBBB			An electrocardiographic finding of delayed conduction to the right ventricle, manifested by a widened QRS in V1 and V2, a widened S wave in V5, V6, I and aVL, and with QRS duration greater than or equal to 120 ms. An RsR' complex is typically present in leads V1 and V2	C62270	Right Bundle Branch Block by ECG Finding	RBBB || Right Bundle Branch Block || Right Bundle Branch Block by EKG Finding	An electrocardiographic finding of a wide QRS complex with evidence of delayed conduction to the right ventricle, manifested by a widened initial portion of the QRS in V1 and V2, a widened S wave in V5, V6, I and aVL, and with QRS duration greater than or equal to 120 ms. An RsR' complex is typically present in leads V1 and V2. (CDISC)	586
C191386	Diagnostic Procedures	Nonspecific intraventricular conduction delay			An electrocardiographic finding of a widened QRS duration typically >110 ms that does not meet the morphological criteria for any of the standard bundle branch or fascicular block patterns	C62271	Nonspecific Intraventricular Conduction Delay by ECG Finding	IVCD || Nonspecific Intraventricular Conduction Delay || Nonspecific Intraventricular Conduction Delay by EKG Finding	An electrocardiographic finding of a widened QRS duration typically greater than 110 ms which does not meet the morphologic criteria for any of the standard bundle branch or fascicular block patterns. (CDISC)	587
C191386	Diagnostic Procedures	Presence of abnormal Q waves			greater than or equal to 0.03 s in width and greater than or equal to 1 mm (0.1 mV) in depth in at least 2 contiguous leads	C191644	Q Wave Abnormality by ECG Finding	Q Wave Abnormality || Q Wave Abnormality by EKG Finding	An electrocardiographic finding for the Q wave that is atypical for the duration (greater than or equal to 0.03 seconds) and amplitude (greater than or equal to 1 mm (0.1 mV)) in at least 2 contiguous leads.	588
C191386	Diagnostic Procedures	Mean QRS duration, ms			The mean duration of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize.	C62087	Mean QRS Duration	Summary (Mean) QRS Duration	The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize.	589
C191386	Diagnostic Procedures	PR interval			The time interval between the start of the P wave and the beginning of the QRS complex in the cardiac cycle	C83502	PR Interval		The time interval between the start of the P wave and the beginning of the QRS complex in the cardiac cycle.	590
C191386	Diagnostic Procedures	QTc interval			The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle as corrected with a nonspecified correction formula	C100391	Corrected QT Interval	QTc Interval	The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle as corrected with a non-specified correction formula.	591
C191386	Diagnostic Procedures	AV block			An electrocardiographic finding of blocked cardiac electrical impulses along the fibers normally responsible for impulse conduction	C26703	Atrioventricular Block by ECG Finding	AV Block || Atrioventricular Block || Atrioventricular Block by EKG Finding	An electrocardiographic finding of delayed or blocked cardiac electrical impulse conduction from the atria to the ventricles at the level of the atrioventricular node.	592
C191386	Diagnostic Procedures	ST segment changes			An electrocardiographic finding of ST segment elevation or depression	C71026	ST Segment Abnormality by ECG Finding	ST Segment Abnormality || ST Segment Abnormality by EKG Finding	An electrocardiographic finding of ST segment elevation or depression.	593
C191386	Diagnostic Procedures	Chest radiography			Documented findings from the radiological examination of the chest (chest x-ray)	C38103	Chest Radiography	Chest X-ray	An x-ray examination of the chest.	594
C191386	Diagnostic Procedures	Pulmonary infiltrates			Imaging-defined opacification and consolidation of lungs suggesting injury and substance denser than air, such as pus, blood, or protein, within the parenchyma of the lungs during acute COVID-19	C102531	Pulmonary Infiltrate	Lung Infiltrate	A finding indicating the presence of an inflammatory or neoplastic cellular infiltrate in the lung parenchyma.	595
C191386	Diagnostic Procedures	Pulmonary vascular redistribution			Distension of the pulmonary veins, particularly in the upper lung fields during acute COVID-19	C191483	Pulmonary Vascular Redistribution		Distension of the pulmonary veins, particularly in the upper lung fields.	596
C191386	Diagnostic Procedures	Pulmonary congestion			Imaging findings consistent with increased intravascular blood volume in the lungs	C119217	Pulmonary Congestion by Radiological Technique		Imaging findings consistent with increased intravascular blood volume in the lungs.	597
C191386	Diagnostic Procedures	Pulmonary edema			Accumulation of fluid in the lung tissues	C26868	Pulmonary Edema		Accumulation of fluid in the lung tissues causing disturbance of the gas exchange that may lead to respiratory failure. It is caused by direct injury to the lung parenchyma or congestive heart failure. The symptoms may appear suddenly or gradually. Suddenly appearing symptoms include difficulty breathing, feeling of suffocation, and coughing associated with frothy sputum. Gradually appearing symptoms include difficulty breathing while lying in bed, shortness of breath during activity, and weight gain (in patients with congestive heart failure).	598
C191386	Diagnostic Procedures	Cardiomegaly || Cardiomegaly, chamber enlargement			A clinical finding in which the heart is noted to be larger than normal.	C61453	Cardiomegaly		Abnormal enlargement of the heart.	599
C191386	Diagnostic Procedures	Pleural effusion(s)			Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive HF, pleural and lung tumors, connective tissue disorders, and trauma	C3331	Pleural Effusion		Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.	600
C191386	Diagnostic Procedures	No abnormalities related to cardiovascular diseases || None				C41132	None		No person or thing, nobody, not any.	601
C191386	Diagnostic Procedures	Chest CT			Documented findings from the CT examination of the chest, with or without angiography	C191501	Chest Computed Tomography	Chest CT || Computed Tomography of the Chest	Computed tomography of the chest.	602
C191386	Diagnostic Procedures	Pulmonary embolism			The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung, during acute COVID-19	C50713	Pulmonary Embolism		The obstruction of the pulmonary artery or one of its branches by an embolus, sometimes associated with infarction of the lung.	603
C191386	Diagnostic Procedures	Pulmonary infiltrates			Imaging-defined opacification and consolidation of lungs suggesting injury and substance denser than air, such as pus, blood, or protein, within the parenchyma of the lungs during acute COVID-19	C102531	Pulmonary Infiltrate	Lung Infiltrate	A finding indicating the presence of an inflammatory or neoplastic cellular infiltrate in the lung parenchyma.	604
C191386	Diagnostic Procedures	Pulmonary vascular redistribution			Distension of the pulmonary veins, particularly in the upper lung fields during acute COVID-19	C191483	Pulmonary Vascular Redistribution		Distension of the pulmonary veins, particularly in the upper lung fields.	605
C191386	Diagnostic Procedures	Pulmonary congestion			Imaging findings consistent with increased intravascular blood volume in the lungs	C119217	Pulmonary Congestion by Radiological Technique		Imaging findings consistent with increased intravascular blood volume in the lungs.	606
C191386	Diagnostic Procedures	Pulmonary edema			Accumulation of fluid in the lung tissues	C26868	Pulmonary Edema		Accumulation of fluid in the lung tissues causing disturbance of the gas exchange that may lead to respiratory failure. It is caused by direct injury to the lung parenchyma or congestive heart failure. The symptoms may appear suddenly or gradually. Suddenly appearing symptoms include difficulty breathing, feeling of suffocation, and coughing associated with frothy sputum. Gradually appearing symptoms include difficulty breathing while lying in bed, shortness of breath during activity, and weight gain (in patients with congestive heart failure).	607
C191386	Diagnostic Procedures	Cardiomegaly || Cardiomegaly, chamber enlargement			A clinical finding in which the heart is noted to be larger than normal.	C61453	Cardiomegaly		Abnormal enlargement of the heart.	608
C191386	Diagnostic Procedures	Pleural effusion(s)			Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive HF, pleural and lung tumors, connective tissue disorders, and trauma	C3331	Pleural Effusion		Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.	609
C191386	Diagnostic Procedures	Thrombus			The formation of a blood clot in the lumen of a vessel or heart chamber	C27083	Blood Clot	Thrombus	An aggregation of blood factors, primarily platelets and fibrin with entrapment of cellular elements, frequently causing vascular obstruction at the point of its formation.	610
C191386	Diagnostic Procedures	Coronary artery aneurysm			Focal dilation of a coronary artery (greater than or equal to 1.5' the adjacent normal segment)	C168176	Coronary Artery Aneurysm		Focal dilation of a coronary artery secondary to arterial wall weakening. (ACC/AHA)	611
C191386	Diagnostic Procedures	No abnormalities related to cardiovascular diseases || None				C41132	None		No person or thing, nobody, not any.	612
C191386	Diagnostic Procedures	CCTA			CAD-RADS (Reporting and Data System) score specifically for CCTA, based on degree of maximal coronary stenosis	C191422	Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score	CAD-RADS CCTA Score	A score developed by the Coronary Artery Disease Reporting and Data System (CAD-RADS) to standardize reporting of the extent of coronary artery stenosis in patients undergoing coronary CT angiography (CCTA) and to guide patient management. All vessels greater than 1.5 mm in diameter are assessed for the most clinically relevant (usually highest-grade) stenosis.	613
C191386	Diagnostic Procedures	0			0%	C191503	Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score 0	CAD-RADS CCTA Score 0	A Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score that indicates that no plaque or stenosis is present. Absence of coronary artery disease.	614
C191386	Diagnostic Procedures	1			1%-24%	C191504	Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score 1	CAD-RADS CCTA Score 1	A Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score that indicates that minimal stenosis (1-24%) or plaque with no stenosis is present. Minimal non-obstructive coronary artery disease.	615
C191386	Diagnostic Procedures	2			25%-49%	C191505	Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score 2	CAD-RADS CCTA Score 2	A Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score that indicates that mild stenosis (25-49%) is present. Mild non-obstructive coronary artery disease.	616
C191386	Diagnostic Procedures	3			50%-69%	C191506	Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score 3	CAD-RADS CCTA Score 3	A Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score that indicates that moderate stenosis (50-69%) is present.	617
C191386	Diagnostic Procedures	4			70%-99% or Left main >50% or 3-vessel obstructive disease	C191507	Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score 4	CAD-RADS CCTA Score 4	A Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score that indicates that severe stenosis (70-99%) or left main stenosis greater than or equal to 50% or 3-vessel obstructive (greater than or equal to 70%) disease is present.	618
C191386	Diagnostic Procedures	5			100%	C191508	Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score 5	CAD-RADS CCTA Score 5	A Coronary Artery Disease Reporting and Data System Coronary CT Angiography Score that indicates that total occlusion or subtotal occlusion is present.	619
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	620
C191386	Diagnostic Procedures	Lower extremity ultrasound			Documented findings from the ultrasound examination	C191543	Lower Extremity Doppler Ultrasonography	Doppler Ultrasound of Leg	Ultrasound examination of the blood flow through the vasculature of the lower extremities.	621
C191386	Diagnostic Procedures	DVT			Thrombosis formation within deep veins during acute COVID-19	C49343	Deep Vein Thrombosis		A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.	622
C191386	Diagnostic Procedures	Arterial thrombosis			Formation of a blood clot in the lumen of an artery during acute COVID-19	C98826	Arterial Thrombosis		Formation of a blood clot in the lumen of an artery.	623
C191386	Diagnostic Procedures	Myocardial perfusion imaging			An imaging procedure that quantifies blood flow throughout the heart muscle	C102676	Myocardial Perfusion Imaging		A procedure that captures pictures of blood flow throughout the heart muscle.	624
C191386	Diagnostic Procedures	Coronary angiography			Documented findings from coronary angiography	C100085	Coronary Angiography		The passage of a catheter into the aortic root or other great vessel for the purpose of angiography of the native coronary arteries or bypass grafts supplying native coronary arteries. (ACC)	625
C191386	Diagnostic Procedures	Left heart catheterization			Documented findings from left heart catheterization	C80413	Left Heart Catheterization		The passage of a catheter into the left ventricle for the purposes of angiography, measurement of ventricular pressures, and/or oxygen saturation.	626
C191386	Diagnostic Procedures	Left ventricular end-diastolic pressure (mm Hg)				C120919	Left Ventricular End Diastolic Pressure		The pressure within the left ventricle following the completion of diastolic filling, just prior to systole.	627
C191386	Diagnostic Procedures	Left ventriculography EF				C135374	Calculated Left Ventricular Ejection Fraction		The percent or fraction of the left ventricular end diastolic volume ejected in systole, which is calculated as the left ventricular stroke volume divided by the left ventricular end diastolic volume.	628
C191386	Diagnostic Procedures	RA mean pressure			Mean right atrial pressure measured from pulmonary artery catheter	C191460	Mean Right Atrial Pressure		The average blood pressure within the right atrium as measured from a pulmonary artery catheter.	629
C191386	Diagnostic Procedures	mmHg				C49670	Millimeter of Mercury	Torr	A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.	630
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	631
C191386	Diagnostic Procedures	PA mean pressure			Mean blood pressure in the pulmonary artery	C120935	Mean Pulmonary Arterial Pressure		The average blood pressure reading in the pulmonary artery as calculated through multiple cardiac cycles.	632
C191386	Diagnostic Procedures	mmHg				C49670	Millimeter of Mercury	Torr	A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.	633
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	634
C191386	Diagnostic Procedures	PA systolic pressure			The blood pressure in the pulmonary artery during the contraction of the left ventricle of the heart	C120943	Pulmonary Artery Systolic Pressure		The blood pressure in the pulmonary artery during the contraction of the left ventricle of the heart.	635
C191386	Diagnostic Procedures	mmHg				C49670	Millimeter of Mercury	Torr	A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.	636
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	637
C191386	Diagnostic Procedures	PA diastolic pressure			The blood pressure in the pulmonary artery during ventricular relaxation (diastole)	C120941	Pulmonary Artery Diastolic Pressure		The blood pressure in the pulmonary artery during ventricular relaxation (diastole).	638
C191386	Diagnostic Procedures	mmHg				C49670	Millimeter of Mercury	Torr	A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.	639
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	640
C191386	Diagnostic Procedures	PAPi			Pulse pressure across pulmonary artery divided by RA (calculated systolic pulmonary arterial pressure - diastolic pulmonary pressure)/right atrial pressure)	C191614	Pulmonary Artery Pulsatility Index	PAPi	A predictive measure of right ventricular failure after inferior myocardial infarction and left ventricular assist device implantation. It is calculated from the ratio of the pulmonary artery pulse pressure to right atrial pressure (calculated systolic pulmonary arterial pressure - diastolic pulmonary pressure)/right atrial pressure).	641
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	642
C191386	Diagnostic Procedures	Mean pulmonary capillary wedge pressure			The pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch	C129955	Pulmonary Artery Wedge Pressure	PAOP || PAWP || PCWP || Pulmonary Arterial Wedge Pressure || Pulmonary Artery Occlusion Pressure || Pulmonary Capillary Wedge Pressure	The pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch.	643
C191386	Diagnostic Procedures	mmHg				C49670	Millimeter of Mercury	Torr	A non-SI unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere. Use of this unit is generally deprecated by ISO and IUPAC.	644
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	645
C191386	Diagnostic Procedures	Cardiac output			The total volume of blood pumped by the heart over a set period of time, conventionally 1 min; it is calculated as heart rate times stroke volume and is additionally dependent on preload and afterload for functional output.	C119246	Cardiac Output		The total volume of blood pumped by the heart over a set period of time, conventionally one minute; it is calculated as heart rate times stroke volume (CO= HR x SV), and is additionally dependent on preload and afterload for functional output.	646
C191386	Diagnostic Procedures	liters/min				C67388	Liter per Minute	Cubic Decimeter per Minute || Liter/Minute	A metric unit of volumetric flow rate defined as the rate at which one liter of matter crosses a given surface during the period of time equal to one minute.	647
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	648
C191386	Diagnostic Procedures	Cardiac index			The measure of an individual's cardiac output as divided by their body surface area ). This calculation is a useful function to determine an individual's cardiac performance in relation to their body size, providing an overview of global cardiovascular function.	C119245	Cardiac Index		The measure of an individual's cardiac output as divided by their body surface area (CI= CO/BSA). This calculation is a useful function to determine an individual's cardiac performance in relation to their body size, providing an overview of global cardiovascular function.	649
C191386	Diagnostic Procedures	liters/min/m^2				C105496	Liter Per Minute Per Square Meter	L/min/m2 || Liters per Minute per Square Meter	A unit expressed as one liter of volume per unit of time equal to one minute per square meter of area. (NCI)	650
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	651
C191386	Diagnostic Procedures	Transpulmonary gradient			Difference between mean pulmonary artery pressure and mean pulmonary capillary wedge pressure	C191572	Transpulmonary Gradient		The difference between the mean pulmonary artery pressure and the mean pulmonary capillary wedge pressure.	652
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	653
C191386	Diagnostic Procedures	Pulmonary vascular resistance			Pulmonary vascular resistance is calculated as (mean PA pressure minus mean pulmonary capillary wedge pressure) divided by cardiac output.	C119247	Pulmonary Vascular Resistance		The resistance to blood flow offered by the pulmonary vasculature, which is normally one sixth of SVR. The major determinant of PVR is pulmonary vessel constriction, most often caused by hypoxia and/or hypercarbia. Prolonged elevated PVR can cause right heart failure.	654
C191386	Diagnostic Procedures	Wood units				C150900	Hybrid Resistance Units	Wood Unit || mmHg*min/L	A unit of resistance equal to the number of millimeters of mercury times minutes, per unit of volume equal to one liter.	655
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	656
C191386	Diagnostic Procedures	Systemic vascular resistance			Systemic vascular resistance is calculated as the systemic mean arterial blood pressure minus right arterial pressure divided by cardiac output.	C119248	Systemic Vascular Resistance	Total Peripheral Resistance	The resistance to blood flow offered by all systemic vasculature, excluding pulmonary vasculature. The major determinant of SVR is arteriolar tone, but blood viscosity and vascular capacitance are also contributing factors.	657
C191386	Diagnostic Procedures	Wood units				C150900	Hybrid Resistance Units	Wood Unit || mmHg*min/L	A unit of resistance equal to the number of millimeters of mercury times minutes, per unit of volume equal to one liter.	658
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	659
C191386	Diagnostic Procedures	Mixed venous O2 saturation			Saturation measured via a sample of blood from a pulmonary artery catheter measures the end result of O2 consumption and delivery, used in the ICU as a measure of O2 extraction by the body.	C191583	Mixed Venous Oxygen Saturation	SmvO2	The oxygen content of the venous blood returned to the heart via the superior and inferior vena caval system after perfusing the entire body. The venous blood in the pulmonary artery, measured using a pulmonary artery catheter, represents oxygen extraction from the whole body.	660
C191386	Diagnostic Procedures	%				C25613	Percentage		A fraction or ratio with 100 understood as the denominator.	661
C191386	Diagnostic Procedures	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	662
C191386	Diagnostic Procedures	Cardiac MRI			A noninvasive medical imaging technology using magnetic field and radio waves to evaluate the heart's anatomy and function for detection and monitoring of cardiac diseases.	C137915	Magnetic Resonance Imaging of the Heart	Cardiac MRI || Heart MRI	Magnetic resonance imaging of the heart.	663
C191386	Diagnostic Procedures	Myocardial edema by T2 mapping or T2-weighted imaging			Regional or global myocardial SI increase in T2-weighted images suggestive of edema	C191559	Myocardial Edema by T2 Mapping or T2-weighted Imaging		Regional or global myocardial increase in signal intensity on T2-weighted images suggestive of edema.	664
C191386	Diagnostic Procedures	Myocardial injury by T1 mapping			Regional or global myocardial injury by T1 mapping	C191561	Myocardial Injury by T1 mapping		Regional or global myocardial injury as suggested by T1-weighted images.	665
C191386	Diagnostic Procedures	Myocardial injury by late gadolinium enhancement			Increased global myocardial late gadolinium enhancement in gadolinium-enhanced T1-weighted images	C191560	Myocardial Injury by Late Gadolinium Enhancement of T1 Imaging		Global myocardial increase in signal intensity on gadolinium-enhanced T1-weighted images suggestive of myocardial injury.	666
C191386	Diagnostic Procedures	Myocarditis			Acute viral myocarditis, usually lasting 1-3 d, is characterized by cardiomyocyte necrosis directly triggered by the viral infection. Humoral and cellular immunologic responses in the myocardium may persist for months and may result in a chronic postinfectious autoimmune myocarditis.	C128381	Viral Myocarditis		Myocarditis that is caused by an infection with a viral agent.	667
C191386	Diagnostic Procedures	Pericardial changes			Pericardial effusion, thickening, increased signal intensity on late gadolinium enhancement	C191562	Pericardial Changes on Imaging		Pericardial effusion or thickening as suggested by increased signal intensity or late gadolinium enhancement.	668
C191386	Diagnostic Procedures	Ventricular functional abnormalities			LV systolic or diastolic dysfunction, RV systolic or diastolic dysfunction, functional valvular regurgitation	C111655	Ventricular Dysfunction		Impairment of the ventricle to either fill or eject adequately.	669
C191386	Diagnostic Procedures	Other cardiac structural abnormalities			LV, RV, LA, RA chamber enlargement, wall motion abnormalities, valvular structural abnormalities, cardiac masses	C99538	Structural Heart Abnormality		An anatomic deformity of the heart, ventricles or great vessels.	670
C191386	Diagnostic Procedures	FDG-PET			Documented findings from FDG-PET	C103400	FDG-Positron Emission Tomography	FDG-PET	An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake.	671
C191386	Diagnostic Procedures	Myocarditis				C34831	Myocarditis		Inflammation of the muscle tissue of the heart.	672
C191386	Diagnostic Procedures	Pericarditis				C34915	Pericarditis		An inflammatory process affecting the pericardium.	673
C191386	Diagnostic Procedures	Other			A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	674
C191386	Diagnostic Procedures	Brain CT without contrast			Documented findings from brain CT without contrast	C137897	Computed Tomography of the Brain without Contrast	Brain CT without Contrast || Head CT without Contrast	Computed tomography of the brain without the use of a contrast agent.	675
C191386	Diagnostic Procedures	Hemorrhagic stroke			Brain tissue necrosis due to an intracerebral bleed	C95803	Hemorrhagic Stroke	Hemorrhagic Cerebrovascular Accident	An acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage.	676
C191386	Diagnostic Procedures	Acute ischemic stroke || Ischemic stroke			Acute onset of neurological deficits resulting from a loss of blood supply to brain tissue in an area of arterial distribution.	C95802	Ischemic Stroke	Ischemic Cerebrovascular Accident	An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of brain tissue.	677
C191386	Diagnostic Procedures	Hypoxic ischemic encephalopathy			Injury to the central nervous system that occurs when there is insufficient delivery of oxygen to all or part of the brain	C35549	Hypoxic Ischemic Encephalopathy	Anoxic encephalopathy	Ischemic brain damage in which the entire brain is deprived of oxygen. It may be fatal or lead to long term disabilities including developmental delays, intellectual disability, and seizures.	678
C191386	Diagnostic Procedures	Brain MRI			Documented findings from brain MRI	C137913	Magnetic Resonance Imaging of the Brain with and without Contrast	Brain MRI with and without Contrast || Brain Magnetic Resonance Imaging with and without Contrast || Head MRI with and without Contrast	Magnetic resonance imaging of the brain with and without the use of a contrast agent to enhance the image.	679
C191386	Diagnostic Procedures	Hemorrhagic stroke			Brain tissue necrosis due to an intracerebral bleed	C95803	Hemorrhagic Stroke	Hemorrhagic Cerebrovascular Accident	An acute episode of focal or global cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage.	680
C191386	Diagnostic Procedures	Acute ischemic stroke || Ischemic stroke			Acute onset of neurological deficits resulting from a loss of blood supply to brain tissue in an area of arterial distribution.	C95802	Ischemic Stroke	Ischemic Cerebrovascular Accident	An acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of brain tissue.	681
C191386	Diagnostic Procedures	Hypoxic ischemic encephalopathy			Injury to the central nervous system that occurs when there is insufficient delivery of oxygen to all or part of the brain	C35549	Hypoxic Ischemic Encephalopathy	Anoxic encephalopathy	Ischemic brain damage in which the entire brain is deprived of oxygen. It may be fatal or lead to long term disabilities including developmental delays, intellectual disability, and seizures.	682
C191387	Pharmacological Therapy	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C191470	Preexisting Cardiovascular Disease Therapy		Current or previous treatment received for cardiovascular disease that was present prior to the current presentation.	683
C191387	Pharmacological Therapy	Aldosterone inhibitor (mineralocorticoid receptor antagonist)	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	Spironolactone or eplerenone, which antagonize the action of aldosterone at mineralocorticoid receptors	C101255	Aldosterone Receptor Antagonist	Antimineralocorticoid	A class of agents that act by selectively inhibiting aldosterone receptor activation with diuretic activity. Aldosterone receptor antagonists bind to and block the activation of aldosterone (mineralocorticoid) receptors on the epithelial cells in the late distal tubule and collecting duct of the kidney, thus preventing the synthesis of aldosterone-induced proteins which enhance Na+ retention and K+ and H+ secretion. The enhanced excretion of Na+ produces diuresis ultimately resulting in a reduction in blood pressure without the loss of K+.	684
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	685
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	686
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	687
C191387	Pharmacological Therapy	Angiotensin-converting enzyme (ACE) inhibitor medication	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A medication that inhibits ACE, an enzyme that catalyzes the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in a reduction in angiotensin II and angiotensin II-induced aldosterone secretion, causing vasodilation and natriuresis.	C247	ACE Inhibitor	Angiotensin-Converting Enzyme Inhibitor	Any substance that inhibits angiotensin-converting enzyme (ACE), an enzyme that catalyzes the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in a reduction in angiotensin II and angiotensin II-induced aldosterone secretion, causing vasodilation and natriuresis.	688
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	689
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	690
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	691
C191387	Pharmacological Therapy	Angiotensin II receptor blocker (ARB) medication	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	An angiotensin receptor blocker (ARB) medication, a class of agents that act by selectively inhibiting angiotensin II receptor activation in the renin-angiotensin-aldosterone system. Angiotensin II receptor antagonists bind to and block the activation of angiotensin II type 1 (AT1) receptors, thereby reducing production and secretion of aldosterone, among other actions. The combined effects result in reduction of blood pressure. It is primarily used for the treatment of hypertension or HF.	C66930	Angiotensin II Receptor Antagonist	Angiotensin II Receptor Antagonists || Angiotensin II Receptor Blocker || Angiotensin Receptor Blockers	A class of agents that act by selectively inhibiting angiotensin II receptor activation in the renin-angiotensin-aldosterone system. Angiotensin II receptor antagonists bind to and block the activation of angiotensin II type 1 (AT1) receptors, thereby reducing production and secretion of aldosterone, amongst other actions. The combined effects result in reduction of blood pressure. Although this class of agents is also used in diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure, it is primarily used for the treatment of hypertension in cases where the patient is intolerant of ACE inhibitor therapy.	692
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	693
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	694
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	695
C191387	Pharmacological Therapy	ARNi	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	Combination of an angiotensin receptor blocker (above) and a neprilysin inhibitor (e.g., sacubitril). Additionally, inhibits neprilysin, a neutral endopeptidase that degrades vasoactive peptides, such as bradykinin, and natriuretic peptides.	C190796	Angiotensin Receptor-Neprilysin Inhibitor		A combination agent containing an angiotensin receptor blocker and a neprilysin inhibitor.	696
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	697
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	698
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	699
C191387	Pharmacological Therapy	Beta-adrenergic antagonist (beta blocker) medication	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A beta-adrenergic receptor antagonist (beta blocker) medication. Includes bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate, atenolol.	C29576	Beta-Adrenergic Antagonist	Beta Blocker || Beta-Adrenergic Blocking Agent || Beta-Blockers	Natural or synthetic beta adrenergic antagonists selectively or non-selectively blocking or diminishing physiologic beta-adrenergic agonist actions on the sympathetic system. This group of antagonists are generally used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.	700
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	701
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	702
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	703
C191387	Pharmacological Therapy	Metformin	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A specific agent belonging to the biguanide class of antihyperglycemic agents	C61612	Metformin	N,N-dimethylbiguanide	An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.	704
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	705
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	706
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	707
C191387	Pharmacological Therapy	SGLT2 inhibitor	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	SGLT2 inhibitors inhibit the sodium glucose cotransporter 2 in the kidney, and selected agents in this class have demonstrated benefit in HF, CKD, ASCVD, and diabetes.	C98083	SGLT2 Inhibitor	SLC5A2 Inhibitor	Any inhibitor of the sodium-glucose co-transporter subtype 2 (SGLT2) with antihyperglycemic activity. By binding to and blocking SGLT2, these inhibitors suppress reabsorption of glucose in the proximal tubule within the kidneys and thereby enhancing urinary excretion of glucose. This eventually normalizes blood glucose levels. SGLT2, a transport system exclusively expressed in the proximal renal tubules, mediates about 90% of renal glucose reabsorption from tubular fluid.	708
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	709
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	710
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	711
C191387	Pharmacological Therapy	GLP-1 receptor agonist	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	Select medications in this class have been shown to improve ASCVD outcomes, drive weight loss, and lower glucose.	C98085	GLP-1 Mimetics	GLP-1 Analogue || GLP-1 Receptor Agonist	Any of the analogues of the endogenous gastrointestinal hormone glucagon-like peptide-1 (GLP-1) with antihyperglycemic activity. GLP-1 mimetics mimic the activity of GLP-1 and thereby stimulate glucose-dependent secretion of insulin from pancreatic beta cells, suppress glucagon secretion from alpha cells, increase insulin sensitivity and inhibit gastric emptying thereby slowing absorption of nutrients and creating a satiating effect. Altogether, this lowers blood glucose levels. GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).	712
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	713
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	714
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	715
C191387	Pharmacological Therapy	Statin	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	An HMG-CoA reductase inhibitor ("statin"). Lipid-lowering medications with proven ASCVD benefits.	C1655	HMG-CoA Reductase Inhibitor	Hydroxymethylglutaryl CoenzymeA Reductase Inhibitors || Statin	Any substance that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Inhibition of HMG-CoA reductase acts to lower plasma cholesterol and lipoprotein levels.	716
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	717
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	718
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	719
C191387	Pharmacological Therapy	Ezetimibe	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A cholesterol absorption inhibitor with lipid-lowering activity	C47529	Ezetimibe	Ezedoc	An azetidinone derivative and a cholesterol absorption inhibitor with lipid-lowering activity. Ezetimibe appears to interact physically with cholesterol transporters at the brush border of the small intestine and inhibits the intestinal absorption of cholesterol and related phytosterols. As a result, ezetimibe causes a decrease in the level of blood cholesterol or an increase in the clearance of cholesterol from the bloodstream. Overall, the following effects observed are a reduction of hepatic cholesterol stores and a reduction of total cholesterol, LDL cholesterol, and other triglycerides in the blood.	720
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	721
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	722
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	723
C191387	Pharmacological Therapy	PCSK9 inhibitor	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	Inhibits an enzyme (PCSK9), resulting in a reduction in circulating LDL cholesterol	C190797	PCSK9 Inhibitor	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor	Any agent that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).	724
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	725
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	726
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	727
C191387	Pharmacological Therapy	Bempedoic acid	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	Bempedoic acid decreases LDL cholesterol by inhibiting ATP-citrate lyase.	C166494	Bempedoic Acid		An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity. Upon oral administration, bempedoic acid becomes activated to its thioester form with coenzyme A (CoA) by the enzyme very long-chain acyl-CoA synthetase 1 (ACSVL1; SLC27A2) in the liver. The activated form inhibits ACL, thereby preventing the liver's biosynthesis of cholesterol. This lowers low-density lipoprotein cholesterol (LDL-C) levels. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway.	728
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	729
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	730
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	731
C191387	Pharmacological Therapy	Aspirin	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	Acetylsalicylic acid decreases synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.	C287	Aspirin	Acetylsalicylic Acid	An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.	732
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	733
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	734
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	735
C191387	Pharmacological Therapy	P2Y12 inhibitor	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A nonaspirin P2Y12 inhibitor such as clopidogrel, ticagrelor, prasugrel as an antiplatelet agent	C190801	P2Y12 Inhibitor	P2Y12 Receptor Blocker || Platelet P2Y12 Receptor Antagonist	Any agent that inhibits the adenosine diphosphate (ADP) receptor P2Y12.	736
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	737
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	738
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	739
C191387	Pharmacological Therapy	Warfarin	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A vitamin K antagonist anticoagulant	C945	Warfarin		A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.	740
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	741
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	742
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	743
C191387	Pharmacological Therapy	DOAC	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	Oral anticoagulant that directly inhibits specific proteins within the coagulation cascade (rivaroxaban, apixaban, dabigatran, or edoxaban)	C180619	Direct Oral Anticoagulant	DOAC || DOACs || Direct Oral Anticoagulants || NOAC || Novel Oral Anticoagulant	An agent taken orally to prevent blood clot formation by directly inhibiting certain coagulation factors including thrombin (factor IIa) or factor Xa.	744
C191387	Pharmacological Therapy	Yes	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49488	Yes		The affirmative response to a question.	745
C191387	Pharmacological Therapy	No	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)		C49487	No		The non-affirmative response to a question.	746
C191387	Pharmacological Therapy	Unknown	C191405	Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission)	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	747
C191387	Pharmacological Therapy	SARS-CoV-2 antiviral agents	C191404	Therapies for COVID-19	A prodrug of an ATP analog, with potential antiviral activity against a variety of RNA viruses. Competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase.	C190794	SARS-CoV-2 Antiviral Agent		Any agent that inhibits the SARS-CoV-2 virus by directly interfering with viral replication and/or life cycle.	748
C191387	Pharmacological Therapy	SARS-CoV-2 antiviral agents: remdesivir	C191404	Therapies for COVID-19		C152185	Remdesivir	2-Ethylbutyl (2S)-2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate || L-Alanine, N-((S)-hydroxyphenoxyphosphinyl)-, 2-Ethylbutyl Ester, 6-Ester with 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitrile	A prodrug of an adenosine triphosphate (ATP) analog, with potential antiviral activity against a variety of RNA viruses. Upon administration, remdesivir, being a prodrug, is metabolized into its active form GS-441524. As an ATP analog, GS-441524 competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production.	749
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	750
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	751
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	752
C191387	Pharmacological Therapy	SARS-CoV-2 antiviral agents: molnupiravir	C191404	Therapies for COVID-19		C172633	Molnupiravir	N4-Hydroxycytidine, 5'-Isopropyl Ester || Uridine, 4-Oxime, 5'-(2-Methylpropanoate)	An orally bioavailable prodrug of EIDD-1931, the synthetic ribonucleoside derivative N4-hydroxycytidine and ribonucleoside analog, with potential antiviral activity against a variety of RNA viruses. Upon oral administration, molnupiravir, being a prodrug, is metabolized into its active form EIDD-1931 and converted into its triphosphate (TP) form. The TP form of EIDD-1931 is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production, and viral RNA replication.	753
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	754
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	755
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	756
C191387	Pharmacological Therapy	SARS-CoV-2 protease inhibitors: nirmatrelvir/ritonavir	C191404	Therapies for COVID-19	Nirmatrelvir inhibits the SARS-CoV-2 main protease (Mpro), which results in inhibition of viral replication. Ritonavir has no direct activity against SARS-CoV-2 but is a pharmacokinetic boosting agent that results in higher plasma concentrations of nirmatrelvir.	C188303	Nirmatrelvir/Ritonavir	Ritonavir/Nirmatrelvir	A fixed combination of nirmatrelvir, an inhibitor of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) main protease (Mpro; 3C-like protease; 3CL protease; 3CLpro; nsp5 protease), and ritonavir, an inhibitor of cytochrome P450 3A4 (CYP3A4), that may be used to treat coronavirus disease 2019 (COVID-19). Upon oral administration of nirmatrelvir/ritonavir, nirmatrelvir selectively targets, binds to, and inhibits the activity of SARS-CoV-2 Mpro. This inhibits the proteolytic cleavage of viral polyproteins, thereby inhibiting the formation of viral proteins including helicase, single-stranded-RNA-binding protein, RNA-dependent RNA polymerase, 20-O-ribose methyltransferase, endoribonuclease and exoribonuclease. This prevents viral transcription and replication. Ritonavir inhibits CYP3A4-mediated metabolism of nirmatrelvir, thereby increasing the plasma concentration of nirmatrelvir.	757
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	758
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	759
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	760
C191387	Pharmacological Therapy	Corticosteroids	C191404	Therapies for COVID-19	Hormones synthesized in the cortex of the adrenal gland and consisting of 2 subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation)	C211	Therapeutic Corticosteroid	Corticosteroids		761
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	762
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	763
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	764
C191387	Pharmacological Therapy	IL-6 receptor monoclonal antibodies	C191404	Therapies for COVID-19	An antibody that recognizes and binds the IL-6 receptor	C190830	Anti-IL-6R Monoclonal Antibody	Anti-IL-6 Receptor Monoclonal Antibody || IL-6 Receptor Monoclonal Antibody	Any monoclonal antibody that is directed against interleukin-6 receptor (IL-6R).	765
C191387	Pharmacological Therapy	IL-6 receptor monoclonal antibodies: tocilizumab	C191404	Therapies for COVID-19		C84217	Tocilizumab	Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer	A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.	766
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	767
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	768
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	769
C191387	Pharmacological Therapy	IL-6 receptor monoclonal antibodies: sarilumab	C191404	Therapies for COVID-19		C152302	Sarilumab	Immunoglobulin G1, Anti-Human Interleukin 6 Receptor alpha) (Human REGN88 Heavy Chain), Disulfide with Human REGN88 Light Chain, Dimer	A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), with potential anti-inflammatory activity. Upon intravenous administration of sarilumab, this agent targets and binds to both soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R). This inhibits the binding of the pro-in?ammatory cytokine IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This may inhibit IL-6/IL-6R-mediated inflammation.	770
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	771
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	772
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	773
C191387	Pharmacological Therapy	COVID-19 convalescent plasma	C191404	Therapies for COVID-19	Plasma that has been collected from patients who have recovered from the novel coronavirus disease, COVID-19. This plasma contains antibodies developed against the SARS-CoV-2 virus and is being investigated for the treatment of COVID-19.	C171633	COVID-19 Convalescent Plasma	COVID-19 Plasma	Plasma that has been collected from patients who have recovered from the novel coronavirus disease, COVID-19. This plasma contains antibodies developed against the SARS-CoV-2 virus and is being investigated for the treatment of COVID-19.	774
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	775
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	776
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	777
C191387	Pharmacological Therapy	JAK inhibitors	C191404	Therapies for COVID-19	A substance that inhibits the biological action of tyrosine-protein kinase JAK1, an enzyme that plays a key role in certain types of cancer and cytokine signaling	C172200	JAK Inhibitor	Janus Kinase Inhibitor	Any agent that targets, binds to and inhibits the activity of one or more of the Janus kinase family of enzymes.	778
C191387	Pharmacological Therapy	JAK inhibitors: baricitinib	C191404	Therapies for COVID-19		C127012	Baricitinib		An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.	779
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	780
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	781
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	782
C191387	Pharmacological Therapy	JAK inhibitors: tofacitinib	C191404	Therapies for COVID-19		C95800	Tofacitinib		An orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.	783
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	784
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	785
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	786
C191387	Pharmacological Therapy	Monoclonal antibodies against SARS-CoV-2	C191404	Therapies for COVID-19	Any monoclonal antibody that is directed against the spike (S) protein of SARS-CoV-2	C173741	Anti-spike Protein SARS-CoV-2 Monoclonal Antibody	Anti-SARS-CoV-2 Coronavirus Spike Protein Monoclonal Antibody || Anti-SARS-CoV-2 S Protein Monoclonal Antibody || Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody	Any monoclonal antibody that is directed against the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	787
C191387	Pharmacological Therapy	Monoclonal antibodies against SARS-CoV-2: bamlanivimab	C191404	Therapies for COVID-19		C173742	Bamlanivimab		A neutralizing immunoglobulin G1 (IgG1) monoclonal antibody directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration of bamlanivimab, this agent specifically targets and binds to the SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.	788
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	789
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	790
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	791
C191387	Pharmacological Therapy	Monoclonal antibodies against SARS-CoV-2: etesevimab	C191404	Therapies for COVID-19		C173977	Etesevimab	Anti-COVID-19 Monoclonal Antibody JS016 || Anti-COVID-19 Spike Protein Monoclonal Antibody JS016 || Anti-SARS-CoV-2 Monoclonal Antibody JS016	An Fc-modified neutralizing, recombinant, human monoclonal antibody directed against the spike (S) protein receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against Coronavirus disease 2019 (COVID-19). Upon administration of etesevimab, this agent specifically targets and binds to the RBD of the SARS-CoV-2 S protein. This blocks viral attachment and entry into human host cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may also provide temporary protection against infection with SARS-CoV-2. S-protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.	792
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	793
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	794
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	795
C191387	Pharmacological Therapy	Monoclonal antibodies against SARS-CoV-2: casirivimab/imdevimab	C191404	Therapies for COVID-19		C173743	Casirivimab/Imdevimab	Anti-COVID Cocktail REGN-COV2 || Anti-Spike SARS-CoV-2 Monoclonal Antibodies REGN-COV2 || Casirivimab Plus Imdevimab || Casirivimab and Imdevimab || Casirivimab+Imdevimab || REGN10933 Plus REGN10987 || REGN10933+REGN10987 || REGN10933/REGN10987 || SARS-CoV-2-specific Antibodies REGN10933 and REGN10987	A combination of two monoclonal antibodies, casirivimab and imdevimab, directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab and imdevimab specifically target and bind to non-overlapping regions of the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to two distinct regions of the RBD of SP may decrease the potential for virus escape mutants that occur upon treatment with a single SARS-CoV-2 antibody, and may provide enhanced protection against loss of efficacy.	796
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	797
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	798
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	799
C191387	Pharmacological Therapy	Monoclonal antibodies against SARS-CoV-2: sotrovimab	C191404	Therapies for COVID-19		C177059	Sotrovimab	Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody VIR-7831	A neutralizing human monoclonal antibody directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, sotrovimab specifically targets and binds to an epitope on the SARS-CoV-2 S protein that is shared with SARS-CoV-1, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.	800
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	801
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	802
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	803
C191387	Pharmacological Therapy	Monoclonal antibodies against SARS-CoV-2: tixagevimab/cilgavimab	C191404	Therapies for COVID-19		C175229	Cilgavimab/Tixagevimab	AZD8895 + AZD1061 || AZD8895/AZD1061 || Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody AZD7442 || Monoclonal Antibody AZD7442	A combination of two neutralizing human monoclonal antibodies cilgavimab and tixagevimab, that are isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of cilgavimab/tixagevimab, both antibodies specifically target and bind to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.	804
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	805
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	806
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	807
C191387	Pharmacological Therapy	Monoclonal antibodies against SARS-CoV-2: bebtelovimab	C191404	Therapies for COVID-19		C182122	Bebtelovimab		A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, bebtelovimab specifically targets and binds to the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.	808
C191387	Pharmacological Therapy	Yes	C191404	Therapies for COVID-19		C49488	Yes		The affirmative response to a question.	809
C191387	Pharmacological Therapy	No	C191404	Therapies for COVID-19		C49487	No		The non-affirmative response to a question.	810
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	811
C191387	Pharmacological Therapy	SARS-CoV-2 vaccine	C191404	Therapies for COVID-19	Any vaccine that decreases the risk of acquiring SARS-CoV-2 infection and development of acute COVID-19	C173023	COVID-19 Vaccine	SARS-CoV-2 Vaccine	Any vaccine that may prevent coronavirus disease-2019 (COVID-19) that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	812
C191387	Pharmacological Therapy	Fully vaccinated	C191404	Therapies for COVID-19	>2 wk after completion of the relevant vaccination series (currently 2 doses for the mRNA vaccines)	C189090	Vaccinated for COVID-19		A status indicating that an individual has received a COVID-19 vaccination.	813
C191387	Pharmacological Therapy	Partially vaccinated	C191404	Therapies for COVID-19	>2 wk from the initial dose of a 2-dose series (currently applies only to the mRNA vaccines)	C189098	Partially Vaccinated for COVID-19		A status indicating that an individual has received a COVID-19 vaccination but has not completed a vaccination series.	814
C191387	Pharmacological Therapy	Unvaccinated	C191404	Therapies for COVID-19	No vaccine, or <2 wk from first vaccine dose	C189099	Not Vaccinated for COVID-19		A status indicating that an individual has not received a COVID-19 vaccination.	815
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	816
C191387	Pharmacological Therapy	SARS-CoV-2 vaccine type	C191404	Therapies for COVID-19	Type of SARS-CoV-2 vaccine received	C189190	COVID-19 Vaccine Administered	SARS-CoV-2 Vaccine Administered	A question about which COVID-19 vaccine was administered.	817
C191387	Pharmacological Therapy	BNT162b2 (Pfizer-BioNTech)	C191404	Therapies for COVID-19		C173055	Tozinameran	BNT1162b2 SARS-CoV-2 Vaccine || BNT162b2 COVID-19 Vaccine || Pfizer COVID-19 Vaccine || Pfizer-BioNTech COVID-19 Vaccine || SARS-CoV-2 SP mRNA LNP Vaccine BNT162b2	A formulation consisting of lipid nanoparticle (LNP) encapsulating a nucleoside modified messenger RNA (modRNA) encoding an optimized form of the full-length severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (SP), with potential immunizing and anti-COVID-19 activities. Upon injection of tozinameran, the LNPs bind to the plasma membrane of nearby cells and release SARS-CoV-2 SP mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce SARS-CoV-2 SP. This may stimulate the immune system to induce an antibody and T-cell-mediated immune response. This may provide active immunization against SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.	818
C191387	Pharmacological Therapy	mRNA-1273 (Moderna)	C191404	Therapies for COVID-19		C172736	Elasomeran	LNP-encapsulated mRNA-based SARS-CoV-2 Vaccine mRNA-1273 || Lipid Nanoparticle-encapsulated mRNA-based SARS-CoV-2 Vaccine mRNA-1273 || Moderna COVID-19 Vaccine	A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length, prefusion stabilized spike (S) protein of SARS-CoV-2, with potential immunizing activity against SARS-CoV-2. Upon administration of elasomeran, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNA into the cells. The mRNA is then translated by ribosomes to produce the SARS-CoV-2 S protein. This may activate both humoral and cellular immune responses which may result in protection against SARS-CoV-2 infection.	819
C191387	Pharmacological Therapy	Ad26.COV2.S (Johnson & Johnson/Janssen)	C191404	Therapies for COVID-19		C176055	COVID-19 Vaccine Ad26.COV2.S	Ad26-encoding SARS-CoV-2 Spike Protein Vaccine || Ad26.COV2.S || Ad26COVS1 || Johnson and Johnson COVID-19 Vaccine	A coronavirus vaccine composed of a genetically engineered, replication-incompetent, adenovirus serotype 26 (Ad26) vector expressing the stabilized pre-fusion spike (S) protein of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with potential immunomodulating and anti-COVID-19 activities. Upon intramuscular administration of the COVID-19 vaccine Ad26.COV2.S, the Ad26 infects human cells, which produces SARS-CoV-2 S protein. The released S protein activates the immune system to induce a humoral and cell-mediated immune response against SARS-CoV-2. This may prevent SARS-CoV-2 infection and inhibit viral replication. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.	820
C191387	Pharmacological Therapy	Other, specify	C191404	Therapies for COVID-19		C157106	Specify Other		A directive to indicate a response not listed.	821
C191387	Pharmacological Therapy	Unknown	C191404	Therapies for COVID-19	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	822
C191387	Pharmacological Therapy	Date of SARS-CoV-2 immunization	C191404	Therapies for COVID-19	Date that SARS-CoV-2 immunization was completed. This would be the date of the second dose for a 2-dose series vaccine (currently the mRNA vaccines). Do not use date of booster dose.	C191534	Date of SARS-CoV-2 Immunization	Date of SARS-CoV-2 Vaccination	The date that SARS-CoV-2 immunization was completed. In a vaccine series, this corresponds to the date of the last vaccination but does not include booster doses.	823
C191387	Pharmacological Therapy	Manufacturer of SARS-CoV-2 vaccine received	C191404	Therapies for COVID-19	The manufacturer of the vaccine received	C191571	Manufacturer of SARS-CoV-2 Vaccine Received		The company that produced the COVID-19 vaccine that was received.	824
C191387	Pharmacological Therapy	Pfizer/BioNTech	C191404	Therapies for COVID-19		C191584	Pfizer/BioNTech		The collaboration of two pharmaceutical companies, Pfizer and BioNTech, that together developed COVID-19 mRNA vaccines.	825
C191387	Pharmacological Therapy	Moderna	C191404	Therapies for COVID-19		C177124	Moderna		An American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. The company focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA.	826
C191387	Pharmacological Therapy	Johnson & Johnson	C191404	Therapies for COVID-19		C164191	Janssen Pharmaceuticals	JRD || Janssen || Janssen Pharmaceutica || Janssen Research and Development	A pharmaceutical company providing medicines for an array of health concerns in several therapeutic areas. The company conducts research and development into oncology, mental illness, neurological disorders, gastrointestinal disorders, fungal infection, and allergies.	827
C191387	Pharmacological Therapy	Date of SARS-CoV-2 booster dose	C191404	Therapies for COVID-19	Date that SARS-CoV-2 booster was given	C191533	Date of SARS-CoV-2 Booster Dose	Date of SARS-CoV-2 Booster Vaccination	The date that SARS-CoV-2 booster vaccination was received.	828
C191387	Pharmacological Therapy	IVIG	C191404	Therapies for COVID-19	Blood product derived from pooled Ig antibodies extracted from donor plasma delivered intravenously	C121331	Intravenous Immunoglobulin Therapy	Gamma Globulin Therapy || IVIG Therapy || Immune Globulin Therapy	The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.	829
C191387	Pharmacological Therapy	COVID-19 Supportive Care	C191406	Therapies for Supportive Care During COVID-19 Infection		C191628	COVID-19 Supportive Care		Non-curative therapy given to treat symptomatic SARS-CoV-2 infection.	830
C191387	Pharmacological Therapy	IV vasopressors	C191406	Therapies for Supportive Care During COVID-19 Infection	IV vasopressor agents are a group of medicines that augment blood pressure predominantly through an increase in vascular tone.	C126567	Vasopressor	Anti-hypotensive Agent || Antihypotensive Agent	Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.	831
C191387	Pharmacological Therapy	Norepinephrine	C191406	Therapies for Supportive Care During COVID-19 Infection	Norepinephrine is a sympathomimetic drug that increases blood pressure and enhances ventricular contractility.	C62098	Norepinephrine, DL-	(+/-)-Noradrenaline || Arterenol || Noradrenaline || Norepinephrine	A synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine. Norepinephrine acts directly on the alpha- and beta-adrenergic receptors. Clinically, norepinephrine is used as a peripheral vasoconstrictor that causes constriction of arterial and venous beds via its alpha-adrenergic action. It is also used as a potent inotropic and chronotropic stimulator of the heart mediated through its beta-1 adrenergic action.	832
C191387	Pharmacological Therapy	Epinephrine	C191406	Therapies for Supportive Care During COVID-19 Infection	Epinephrine is a sympathomimetic drug that increases blood pressure and enhances ventricular contractility.	C473	Therapeutic Epinephrine	Adrenaline || Epinephrine	The synthetic form of the naturally occurring sympathomimetic amine with vasoconstricting, intraocular pressure-reducing, and bronchodilating activities. By stimulating vascular alpha-adrenergic receptors, epinephrine causes vasoconstriction, thereby increasing vascular resistance and blood pressure. When administered in the conjunctiva, this agent binds to alpha-adrenergic receptors in the iris sphincter muscle, resulting in vasoconstriction, a decrease in the production of aqueous humor, and a lowering of intraocular pressure. Through its beta1 receptor-stimulating actions, epinephrine increases the force and rate of myocardial contraction and relaxes bronchial smooth muscle, resulting in bronchodilation.	833
C191387	Pharmacological Therapy	Dopamine	C191406	Therapies for Supportive Care During COVID-19 Infection	Dopamine is a sympathomimetic drug that increases blood pressure and enhances ventricular contractility.	C81078	Dopa, DL-		The racemic mixture of the precursor of dopamine L-DOPA (levodopa) and D-DOPA, with antiparkinsonian properties. L-DOPA is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier (BBB). When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors, thereby compensating for the depleted supply of endogenous dopamine seen in Parkinson's disease.	834
C191387	Pharmacological Therapy	Vasopressin	C191406	Therapies for Supportive Care During COVID-19 Infection	Vasopressin is a vasoactive hormone used synergistically with another sympathomimetic drug (typically norepinephrine) to increase and maintain peripheral vascular tone in patients with distributive shock.	C184932	Vasopressin, Unspecified		An unspecified form of vasopressin, with antidiuretic property. Synthesized in the hypothalamus and stored in and released from the posterior lobe of the pituitary, vasopressin regulates extracellular fluid volume, acts as a vasoconstrictor, and increases blood pressure and systemic vascular resistance.	835
C191387	Pharmacological Therapy	Phenylephrine	C191406	Therapies for Supportive Care During COVID-19 Infection	Phenylephrine is a sympathomimetic drug whose primary activity results from stimulation of the alpha receptors of the vasculature, resulting in vasoconstriction while producing comparatively mild direct cardiac effects.	C62067	Phenylephrine		A direct-acting sympathomimetic amine chemically related to adrenaline and ephedrine with potent vasoconstrictor property. Phenylephrine is a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, increases systolic/diastolic pressures, reflex bradycardia, and stroke output.	836
C191387	Pharmacological Therapy	Other	C191406	Therapies for Supportive Care During COVID-19 Infection	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	837
C191387	Pharmacological Therapy	No abnormalities related to cardiovascular diseases || None	C191406	Therapies for Supportive Care During COVID-19 Infection		C41132	None		No person or thing, nobody, not any.	838
C191387	Pharmacological Therapy	IV inotropic agent	C191406	Therapies for Supportive Care During COVID-19 Infection	IV positive inotropic agents are a group of medicines that stimulate and increase the force of contraction of the heart muscle.	C78322	Cardiotonic Agent	Cardiotonic Inotropic Agent	any agent having a favorable effect on the function of the heart.	839
C191387	Pharmacological Therapy	Milrinone	C191406	Therapies for Supportive Care During COVID-19 Infection	Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility, decrease pulmonary vascular resistance, and as a systemic vasodilator.	C61848	Milrinone		A cardiovascular bipyridine agent and phosphodiesterase (PDE) III inhibitor, with positive inotropic and vasodilator activities. Upon administration, milrinone selectively inhibits PDE-mediated degradation of cyclic adenosine monophosphate (cAMP) in the heart and vascular muscles, thereby increasing cAMP and activates protein kinase A (PKA). This leads to phosphorylation of calcium ion channels and improve myocardium contractile force. Milrinone also causes vasodilation in arteriolar and venous vascular smooth muscle.	840
C191387	Pharmacological Therapy	Dobutamine	C191406	Therapies for Supportive Care During COVID-19 Infection	Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ? receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.	C61733	Dobutamine		A synthetic catecholamine with sympathomimetic activity. Dobutamine is a direct-acting inotropic agent and an adrenergic agonist that stimulates primarily the beta-1 adrenoceptor, with lesser effect on beta-2 or alpha receptors. Via beta-1 adrenoceptor of the heart, this agent induces positive inotropic effect with minimal changes in chronotropic activities or systemic vascular resistance. Dobutamine also causes vasodilation by stimulating beta-2 adrenergic receptors in blood vessels, augmented by reflex vasoconstriction resulting in increased cardiac output.	841
C191387	Pharmacological Therapy	Other	C191406	Therapies for Supportive Care During COVID-19 Infection	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	842
C191387	Pharmacological Therapy	No abnormalities related to cardiovascular diseases || None	C191406	Therapies for Supportive Care During COVID-19 Infection		C41132	None		No person or thing, nobody, not any.	843
C191387	Pharmacological Therapy	COVID-19-specific intermediate- or full-dose anticoagulation	C191406	Therapies for Supportive Care During COVID-19 Infection	Intermediate- or full-dose anticoagulation used to prevent VTE complications due to SARS-CoV-2 specifically and not because of documented VTE or another noninfectious indication. Note that this excludes the low-dose prophylactic anticoagulation often given to inpatients for VTE prophylaxis (see below).	C191450	COVID-19-specific Anticoagulation		Medical prophylactic anticoagulation therapy given to COVID-19 patients to prevent adverse outcomes.	844
C191387	Pharmacological Therapy	Heparin || Unfractionated heparin	C191406	Therapies for Supportive Care During COVID-19 Infection	Heparin is an indirect thrombin inhibitor composed of a mixture of heterogeneous mucopolysaccharides with a molecular weight of 5-30 kDa.	C539	Heparin	Unfractionated Heparin	A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.	845
C191387	Pharmacological Therapy	Low-molecular-weight heparin	C191406	Therapies for Supportive Care During COVID-19 Infection	Low-molecular-weight heparin compounds are fractions of heparin that primarily act by inhibiting the activated clotting factor X. Examples include enoxaparin and dalteparin.	C2578	Low Molecular Weight Heparin		Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.	846
C191387	Pharmacological Therapy	DOAC	C191406	Therapies for Supportive Care During COVID-19 Infection	Oral anticoagulant that directly inhibits specific proteins within the coagulation cascade (rivaroxaban, apixaban, dabigatran, or edoxaban)	C180619	Direct Oral Anticoagulant	DOAC || DOACs || Direct Oral Anticoagulants || NOAC || Novel Oral Anticoagulant	An agent taken orally to prevent blood clot formation by directly inhibiting certain coagulation factors including thrombin (factor IIa) or factor Xa.	847
C191387	Pharmacological Therapy	Warfarin	C191406	Therapies for Supportive Care During COVID-19 Infection	A vitamin K antagonist anticoagulant	C945	Warfarin		A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.	848
C191387	Pharmacological Therapy	Yes	C191406	Therapies for Supportive Care During COVID-19 Infection		C49488	Yes		The affirmative response to a question.	849
C191387	Pharmacological Therapy	No	C191406	Therapies for Supportive Care During COVID-19 Infection		C49487	No		The non-affirmative response to a question.	850
C191387	Pharmacological Therapy	Unknown	C191406	Therapies for Supportive Care During COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	851
C191387	Pharmacological Therapy	COVID-19-specific anticoagulation dosing strategy	C191406	Therapies for Supportive Care During COVID-19 Infection	For patients receiving intermediate- or full-dose anticoagulation because of SARS-CoV-2 specifically and not because of documented VTE or another noninfectious indication.	C191425	COVID-19-specific Anticoagulation Dosing Strategy		A scheme to approach the prophylactic anticoagulation of COVID-19 patients.	852
C191387	Pharmacological Therapy	Full dose	C191406	Therapies for Supportive Care During COVID-19 Infection	Standard treatment dose	C191521	COVID-19-specific Full Anticoagulation Dose		A dosing strategy that targets a standard treatment dose of an anticoagulant for the treatment of COVID-19.	853
C191387	Pharmacological Therapy	Intermediate dose	C191406	Therapies for Supportive Care During COVID-19 Infection	Intermediate dose is defined here as a dosing strategy targeting levels of anticoagulation less than standard treatment doses but greater than standard VTE prophylaxis doses.	C191522	COVID-19-specific Intermediate Anticoagulation Dose		A dosing strategy that targets a less than standard treatment dose but greater than a standard prophylactic dose of an anticoagulant for the treatment of COVID-19.	854
C191387	Pharmacological Therapy	Unknown	C191406	Therapies for Supportive Care During COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	855
C191387	Pharmacological Therapy	Anticoagulation for VTE prophylaxis	C191406	Therapies for Supportive Care During COVID-19 Infection	Administration of a prophylactic dose (not therapeutic dose) of anticoagulant to prevent VTE during hospitalization for COVID-19	C116684	Thromboembolism Prophylaxis		The use of medication to prevent the formation of clots and emboli.	856
C191387	Pharmacological Therapy	Yes	C191406	Therapies for Supportive Care During COVID-19 Infection		C49488	Yes		The affirmative response to a question.	857
C191387	Pharmacological Therapy	No	C191406	Therapies for Supportive Care During COVID-19 Infection		C49487	No		The non-affirmative response to a question.	858
C191387	Pharmacological Therapy	Unknown	C191406	Therapies for Supportive Care During COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	859
C191387	Pharmacological Therapy	Anticoagulant medication administered for VTE prophylaxis	C191406	Therapies for Supportive Care During COVID-19 Infection	Name of the anticoagulant medication administered to prevent VTE during hospitalization for COVID-19	C263	Anticoagulant Agent	Anticoagulant Drugs || Anticoagulants	Any agent capable of preventing blood clot formation.	860
C191387	Pharmacological Therapy	Heparin || Unfractionated heparin	C191406	Therapies for Supportive Care During COVID-19 Infection	Heparin is an indirect thrombin inhibitor composed of a mixture of heterogeneous mucopolysaccharides with a molecular weight of 5-30 kDa.	C539	Heparin	Unfractionated Heparin	A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.	861
C191387	Pharmacological Therapy	Low-molecular-weight heparin	C191406	Therapies for Supportive Care During COVID-19 Infection	Low-molecular-weight heparin compounds are fractions of heparin that primarily act by inhibiting the activated clotting factor X. Examples include enoxaparin and dalteparin.	C2578	Low Molecular Weight Heparin		Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.	862
C191387	Pharmacological Therapy	Fondaparinux	C191406	Therapies for Supportive Care During COVID-19 Infection	Fondaparinux is a synthetic anticoagulant based on the pentasaccharide sequence that makes up the minimal antithrombin-binding region of heparin.	C73142	Fondaparinux	Natural Heparin Pentasaccharide	A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.	863
C191387	Pharmacological Therapy	Bivalirudin	C191406	Therapies for Supportive Care During COVID-19 Infection	Bivalirudin is a semisynthetic derivative of hirudin and is a highly specific inhibitor of thrombin.	C47415	Bivalirudin	Hirulog	A 20 amino acid long synthetic peptide with thrombin-specific anticoagulant properties. Bivalirudin reversibly binds thrombin, free as well as clot bound, at the catalytic site and the anion-binding exosite, thereby preventing the formation and activation of fibrin, factor XIIIa, and other coagulation factors. This drug is primarily used during coronary angioplasty procedures, in combination with aspirin, in patients with unstable angina.	864
C191387	Pharmacological Therapy	Other	C191406	Therapies for Supportive Care During COVID-19 Infection	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	865
C191387	Pharmacological Therapy	Unknown	C191406	Therapies for Supportive Care During COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	866
C191387	Pharmacological Therapy	Renal replacement therapy	C191406	Therapies for Supportive Care During COVID-19 Infection	Use of renal replacement therapy during hospitalization for COVID-19 in a patient without end-stage renal disease prior to such hospitalization. These therapies may include CRRT, prolonged intermittent renal replacement therapy, IHD, or other forms of renal replacement therapy.	C126400	Renal Replacement Therapy	RRT	Treatments that substitute for the blood-filtering function of the kidneys. It includes dialysis (hemodialysis or peritoneal dialysis), hemofiltration, and hemodiafiltration. Kidney transplant may also be considered a renal replacement therapy.	867
C191387	Pharmacological Therapy	Yes	C191406	Therapies for Supportive Care During COVID-19 Infection		C49488	Yes		The affirmative response to a question.	868
C191387	Pharmacological Therapy	No	C191406	Therapies for Supportive Care During COVID-19 Infection		C49487	No		The non-affirmative response to a question.	869
C191387	Pharmacological Therapy	Unknown	C191406	Therapies for Supportive Care During COVID-19 Infection	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	870
C191388	Therapeutic and Supportive Procedures for COVID-19	MCS	C191401	Mechanical Support	MCS required. MCS is circulatory support using implanted devices most commonly used to supplement vasopressors and inotropes in the management of patients with low cardiac output and cardiogenic shock.	C99540	Mechanical Circulatory Support		Use of a device to replace the function of a cardiac ventricle. This includes use of cardiopulmonary bypass, left ventricular assist device (LVAD), intra-aortic balloon pump (IABP) and/or extracorporeal membrane oxygenation (ECMO).	871
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191401	Mechanical Support		C49488	Yes		The affirmative response to a question.	872
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191401	Mechanical Support		C49487	No		The non-affirmative response to a question.	873
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191401	Mechanical Support	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	874
C191388	Therapeutic and Supportive Procedures for COVID-19	Implantation of temporary MCS device	C191401	Mechanical Support	MCS device used. MCS devices are the implanted devices used to supplement vasopressors and inotropes in the management of patients with low cardiac output and cardiogenic shock.	C191468	Implantation of Temporary Mechanical Circulatory Support Device	Implantation of Temporary MCS Device	Placement of a short-term device used to supplement medical therapy (vasopressors and inotropes) in the management of patients with low cardiac output and cardiogenic shock.	875
C191388	Therapeutic and Supportive Procedures for COVID-19	IABP	C191401	Mechanical Support		C100087	Intra-Aortic Balloon Pump		A medical device that increases myocardial oxygen perfusion while at the same time increasing cardiac output. (ACC)	876
C191388	Therapeutic and Supportive Procedures for COVID-19	Impella	C191401	Mechanical Support		C191592	Catheter-based Miniaturized Left Ventricular Assist Device	Impella (BR)	A percutaneously implanted miniaturized heart pump.	877
C191388	Therapeutic and Supportive Procedures for COVID-19	TandemHeart	C191401	Mechanical Support		C191428	Percutaneous Ventricular Assist Device	PVAD || TandemHeart (BR)	A percutaneously implanted heart pump.	878
C191388	Therapeutic and Supportive Procedures for COVID-19	VA ECMO	C191401	Mechanical Support	ECMO, in which a venous cannula is usually placed in the right or left common femoral vein for extraction, and an arterial cannula is usually placed into the right or left femoral artery for infusion, with an oxygenator between the extraction and infusion cannulae. Used to provide circulatory support and to facilitate gas exchange.	C191550	Veno-Arterial Extracorporeal Membrane Oxygenation	VA ECMO || Venoarterial Extracorporeal Membrane Oxygenation	Extracorporeal membrane oxygenation (ECMO) in which a venous cannula is typically placed in the right or left common femoral vein for extraction, and an arterial cannula is usually placed into the right or left femoral artery for infusion, with an oxygenator between the extraction and infusion cannulae.	879
C191388	Therapeutic and Supportive Procedures for COVID-19	VV ECMO	C191401	Mechanical Support	ECMO to provide adequate gas exchange, usually in respiratory failure/ARDS. The access cannula is usually placed in the inferior vena cava via the femoral vein. The tip of the return cannula should sit close to the right atrium, and it may be placed via the femoral or internal jugular vein.	C191553	Veno-Venous Extracorporeal Membrane Oxygenation	VV ECMO || Venovenous Extracorporeal Membrane Oxygenation	Extracorporeal membrane oxygenation (ECMO) to provide adequate gas exchange, usually in respiratory failure/ARDS. The access cannula is usually placed in the inferior vena cava via the femoral vein. The tip of the return cannula is placed close to the right atrium, and it may be placed via the femoral or internal jugular vein.	880
C191388	Therapeutic and Supportive Procedures for COVID-19	Other	C191401	Mechanical Support	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	881
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191401	Mechanical Support	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	882
C191388	Therapeutic and Supportive Procedures for COVID-19	Implantation of a long-term durable MCS device performed	C191401	Mechanical Support	Mechanical pump to help pump blood from the ventricle(s) to the body, used in the management of patients with low cardiac output and cardiogenic shock	C191467	Implantation of Long Term Durable Mechanical Circulatory Support Device	Implantation of Long Term Durable MCS Device	Placement of a permanent device used to supplement medical therapy (vasopressors and inotropes) in the management of patients with low cardiac output and cardiogenic shock.	883
C191388	Therapeutic and Supportive Procedures for COVID-19	LVAD	C191401	Mechanical Support		C80473	Left Ventricular Assist Device		A mechanical pump which also includes a control system and an energy supply. It receives blood from the left ventricle and delivers it to the aorta, thus helping the heart to pump sufficient blood to the body.	884
C191388	Therapeutic and Supportive Procedures for COVID-19	RVAD	C191401	Mechanical Support		C80472	Right Ventricular Assist Device		A mechanical pump which also includes a control system and an energy supply. It receives blood from the right ventricle and delivers it to the pulmonary artery, thus helping the heart to pump sufficient blood to the body.	885
C191388	Therapeutic and Supportive Procedures for COVID-19	BiVAD	C191401	Mechanical Support		C191574	Biventricular Assist Device	BiVAD	A mechanical pump that is implanted to augment the function of both ventricles of the heart, typically as a bridge to transplantation.	886
C191388	Therapeutic and Supportive Procedures for COVID-19	Total artificial heart	C191401	Mechanical Support		C191576	Total Artificial Heart		A prosthetic device used to replace the function of both cardiac ventricles and all four cardiac valves, typically as a bridge to transplantation.	887
C191388	Therapeutic and Supportive Procedures for COVID-19	No abnormalities related to cardiovascular diseases || None	C191401	Mechanical Support		C41132	None		No person or thing, nobody, not any.	888
C191388	Therapeutic and Supportive Procedures for COVID-19	Date of MCS	C191401	Mechanical Support	Date that MCS was used	C191531	Date of Mechanical Circulatory Support	Date of MCS	The date that mechanical circulatory support was utilized.	889
C191388	Therapeutic and Supportive Procedures for COVID-19	MCS Time	C191401	Mechanical Support	Time that MCS was used	C191639	Time of Mechanical Circulatory Support	Time of MCS	The time that mechanical circulatory support was utilized.	890
C191388	Therapeutic and Supportive Procedures for COVID-19	Noninvasive mechanical ventilatory support	C191401	Mechanical Support	A type of mechanical ventilation procedure that uses a noninvasive means, such as a face mask or nasal mask, to deliver oxygenated air into the lungs	C171457	Non-Invasive Mechanical Ventilation	NIV || Non-Invasive Ventilation	A type of mechanical ventilation procedure that uses a non-invasive means, such as a face mask or nasal mask, to deliver oxygenated air into the lungs.	891
C191388	Therapeutic and Supportive Procedures for COVID-19	CPAP	C191401	Mechanical Support	A form of noninvasive mechanical pressure support ventilation that uses a CPAP level to support spontaneous breathing activity	C124040	Continuous Positive Airway Pressure		A form of non-invasive mechanical pressure support ventilation that uses a continuous positive airway pressure level to support spontaneous breathing activity.	892
C191388	Therapeutic and Supportive Procedures for COVID-19	BiPAP	C191401	Mechanical Support	A type of noninvasive mechanical ventilation procedure that that uses BiPAP to support spontaneous breathing activity	C124039	Biphasic Positive Airway Pressure	Bilevel Positive Airway Pressure Ventilation	A form of non-invasive mechanical pressure support ventilation that uses a time-cycled change of the applied positive airway pressure level to support spontaneous breathing activity.	893
C191388	Therapeutic and Supportive Procedures for COVID-19	No abnormalities related to cardiovascular diseases || None	C191401	Mechanical Support		C41132	None		No person or thing, nobody, not any.	894
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191401	Mechanical Support	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	895
C191388	Therapeutic and Supportive Procedures for COVID-19	Invasive mechanical ventilatory support	C191401	Mechanical Support	Artificial ventilation to assist or replace spontaneous breathing through tracheostomy or endotracheal tubes	C191573	Invasive Mechanical Ventilation		A type of mechanical ventilation procedure that uses an endotracheal or tracheostomy tube to deliver pressurized oxygenated air into the lungs.	896
C191388	Therapeutic and Supportive Procedures for COVID-19	Mechanical ventilation	C191401	Mechanical Support	Mechanical ventilation technique is a life-sustaining technique through which gas is moved toward and from the lungs through an external device connected directly to the patient.	C70909	Mechanical Ventilation		A method to mechanically assist or replace spontaneous breathing in patients by use of a powered device that forces oxygenated air into the lungs.	897
C191388	Therapeutic and Supportive Procedures for COVID-19	Adaptive servo-ventilation	C191401	Mechanical Support	Positive airway pressure therapy in which air pressure target is adjusted according to the patient's breathing patterns	C191582	Adaptive Servo-Ventilation	ASV || Adaptive Servo Ventilation	A non-invasive ventilatory treatment that continuously adjusts positive airway pressure (PAP) to prompt breathing when needed based on a patient's breathing pattern.	898
C191388	Therapeutic and Supportive Procedures for COVID-19	No abnormalities related to cardiovascular diseases || None	C191401	Mechanical Support		C41132	None		No person or thing, nobody, not any.	899
C191388	Therapeutic and Supportive Procedures for COVID-19	Oxygen therapy	C191401	Mechanical Support	The administration of oxygen to an individual, usually to aid in respiration	C94624	Oxygen Therapy		The administration of oxygen to an individual, usually to aid in respiration.	900
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191401	Mechanical Support		C49488	Yes		The affirmative response to a question.	901
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191401	Mechanical Support		C49487	No		The non-affirmative response to a question.	902
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191401	Mechanical Support	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	903
C191388	Therapeutic and Supportive Procedures for COVID-19	Maximum fraction of inspired oxygen (FiO2)	C191401	Mechanical Support	Maximum molar fraction of oxygen in an inhaled gas	C38082	Fraction of Inspired Oxygen		The molar fraction of oxygen in an inhaled gas.	904
C191388	Therapeutic and Supportive Procedures for COVID-19	PEEP	C191401	Mechanical Support	The maximum end-expiratory alveolar pressure above atmospheric pressure supplied to patients on invasive or noninvasive ventilation	C191605	Positive End-Expiratory Pressure	PEEP	The pressure applied by the ventilator at the end of each breath to ensure that the alveoli are not so prone to collapse.	905
C191388	Therapeutic and Supportive Procedures for COVID-19	FiO2/PEEP ratio	C191401	Mechanical Support	Ratio of FiO2 to PEEP used to achieve desired arterial oxygenation	C191613	FiO2/PEEP		The ratio of fraction of inspired oxygen (FiO2) to positive end-expiratory pressure (PEEP). This measured value may be adjusted on a mechanical ventilator to optimize treatment.	906
C191388	Therapeutic and Supportive Procedures for COVID-19	VA ECMO	C191401	Mechanical Support	ECMO, in which a venous cannula is usually placed in the right or left common femoral vein for extraction, and an arterial cannula is usually placed into the right or left femoral artery for infusion, with an oxygenator between the extraction and infusion cannulae. Used to provide circulatory support and to facilitate gas exchange.	C191550	Veno-Arterial Extracorporeal Membrane Oxygenation	VA ECMO || Venoarterial Extracorporeal Membrane Oxygenation	Extracorporeal membrane oxygenation (ECMO) in which a venous cannula is typically placed in the right or left common femoral vein for extraction, and an arterial cannula is usually placed into the right or left femoral artery for infusion, with an oxygenator between the extraction and infusion cannulae.	907
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191401	Mechanical Support		C49488	Yes		The affirmative response to a question.	908
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191401	Mechanical Support		C49487	No		The non-affirmative response to a question.	909
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191401	Mechanical Support	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	910
C191388	Therapeutic and Supportive Procedures for COVID-19	VV ECMO	C191401	Mechanical Support	ECMO to provide adequate gas exchange, usually in respiratory failure/ARDS. The access cannula is usually placed in the inferior vena cava via the femoral vein. The tip of the return cannula should sit close to the right atrium, and it may be placed via the femoral or internal jugular vein.	C191553	Veno-Venous Extracorporeal Membrane Oxygenation	VV ECMO || Venovenous Extracorporeal Membrane Oxygenation	Extracorporeal membrane oxygenation (ECMO) to provide adequate gas exchange, usually in respiratory failure/ARDS. The access cannula is usually placed in the inferior vena cava via the femoral vein. The tip of the return cannula is placed close to the right atrium, and it may be placed via the femoral or internal jugular vein.	911
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191401	Mechanical Support		C49488	Yes		The affirmative response to a question.	912
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191401	Mechanical Support		C49487	No		The non-affirmative response to a question.	913
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191401	Mechanical Support	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	914
C191388	Therapeutic and Supportive Procedures for COVID-19	Prone positioning in ventilated patient	C191401	Mechanical Support	Positioning of a mechanically ventilated patient so that their anterior chest is dependent, which allows for improved oxygenation by ameliorating the ventral-dorsal transpulmonary pressure difference, reducing dorsal lung compression, and improving lung perfusion.	C173751	Prone Ventilation		Positioning of a mechanically ventilated patient so that their anterior chest is dependent which allows for improved oxygenation by ameliorating the ventral-dorsal transpulmonary pressure difference, reducing dorsal lung compression, and improving lung perfusion.	915
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191401	Mechanical Support		C49488	Yes		The affirmative response to a question.	916
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191401	Mechanical Support		C49487	No		The non-affirmative response to a question.	917
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191401	Mechanical Support	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	918
C191388	Therapeutic and Supportive Procedures for COVID-19	Cardiac arrest requiring CPR	C191401	Mechanical Support	Cardiac arrest that is treated by CPR or defibrillation, regardless of outcome	C141268	Cardiac Arrest Requiring Cardiopulmonary Resuscitation		Cardiac arrest that is treated by CPR and/or defibrillation, regardless of outcome.	919
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191401	Mechanical Support		C49488	Yes		The affirmative response to a question.	920
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191401	Mechanical Support		C49487	No		The non-affirmative response to a question.	921
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191401	Mechanical Support	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	922
C191388	Therapeutic and Supportive Procedures for COVID-19	Date of CPR for cardiac arrest	C191401	Mechanical Support	Date that CPR for cardiac arrest was performed	C191525	Date of Cardiopulmonary Resuscitation for Cardiac Arrest	Date of CPR for cardiac arrest	The date that cardiopulmonary resuscitation (CPR) for cardiac arrest was performed.	923
C191388	Therapeutic and Supportive Procedures for COVID-19	Time of CPR for cardiac arrest	C191401	Mechanical Support	Time that CPR for cardiac arrest was performed	C191640	Time of Cardiopulmonary Resuscitation for Cardiac Arrest	Time of CPR for cardiac arrest	The time that cardiopulmonary resuscitation (CPR) for cardiac arrest was performed.	924
C191388	Therapeutic and Supportive Procedures for COVID-19	Electrophysiological Procedure	C191399	Electrophysiological Procedures		C191466	Electrophysiological Procedure		A procedure that is used to correct aberrant electrical impulses associated with cardiac arrhythmias.	925
C191388	Therapeutic and Supportive Procedures for COVID-19	Insertion of a temporary transvenous pacing wire	C191399	Electrophysiological Procedures	Temporary transvenous pacing wire was inserted. Indications for temporary transvenous pacing are similar to indications for permanent pacing. Typically, temporary transvenous pacing is performed via a pacing wire placed in the RV from a central venous access site.	C191469	Temporary Transvenous Pacing Wire Placement		Placement of a short-term pacing wire via a central vein to correct for inconsistent and/or ineffective electric impulses to the heart.	926
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191399	Electrophysiological Procedures		C49488	Yes		The affirmative response to a question.	927
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191399	Electrophysiological Procedures		C49487	No		The non-affirmative response to a question.	928
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191399	Electrophysiological Procedures	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	929
C191388	Therapeutic and Supportive Procedures for COVID-19	Date of temporary transvenous pacing wire insertion	C191399	Electrophysiological Procedures	Date temporary transvenous pacing wire was inserted	C191535	Date of Temporary Transvenous Pacing Wire Insertion		The date that the temporary transvenous pacing wire was inserted.	930
C191388	Therapeutic and Supportive Procedures for COVID-19	Implantation of a cardioverter-defibrillator performed	C191399	Electrophysiological Procedures	A battery-powered electrical impulse generator implanted in patients at risk of sudden cardiac death to detect cardiac arrhythmia and correct it by delivering a jolt of electricity, implanted during current encounter	C80435	Implantable Cardioverter-Defibrillator Placement		A surgical procedure in which a small, battery-powered device is placed in the chest wall to detect arrhythmias and correct them by delivering a jolt of electricity.	931
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191399	Electrophysiological Procedures		C49488	Yes		The affirmative response to a question.	932
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191399	Electrophysiological Procedures		C49487	No		The non-affirmative response to a question.	933
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191399	Electrophysiological Procedures	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	934
C191388	Therapeutic and Supportive Procedures for COVID-19	Type of permanent cardioverter-defibrillator implanted	C191399	Electrophysiological Procedures	A battery-powered electrical impulse generator implanted in patients at risk of sudden cardiac death to detect cardiac arrhythmia and correct it by delivering a jolt of electricity, implanted during current encounter	C191499	Type of Permanent Cardioverter-Defibrillator Implanted		A question about which type of permanent cardioverter-defibrillator was implanted.	935
C191388	Therapeutic and Supportive Procedures for COVID-19	Transvenous	C191399	Electrophysiological Procedures		C191564	Transvenous Cardioverter-Defibrillator		A cardioverter-defibrillator implanted via a central vein.	936
C191388	Therapeutic and Supportive Procedures for COVID-19	Subcutaneous	C191399	Electrophysiological Procedures		C191563	Subcutaneous Cardioverter-Defibrillator		A cardioverter-defibrillator implanted under the skin.	937
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191399	Electrophysiological Procedures	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	938
C191388	Therapeutic and Supportive Procedures for COVID-19	Date of ICD implantation	C191399	Electrophysiological Procedures	Date that ICD was implanted	C191530	Date of Cardioverter-Defibrillator Implantation		The date that the cardioverter-defibrillator was implanted.	939
C191388	Therapeutic and Supportive Procedures for COVID-19	Insertion of a permanent pacemaker	C191399	Electrophysiological Procedures	A cardiac pacemaker where the generator is implanted inside the body	C80434	Pacemaker Placement		A surgical procedure in which a small, battery-powered device is placed in the chest wall to transmit electrical impulses to the heart muscles to stimulate contraction.	940
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191399	Electrophysiological Procedures		C49488	Yes		The affirmative response to a question.	941
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191399	Electrophysiological Procedures		C49487	No		The non-affirmative response to a question.	942
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191399	Electrophysiological Procedures	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	943
C191388	Therapeutic and Supportive Procedures for COVID-19	Electric cardioversion	C191399	Electrophysiological Procedures	The administration of electric current to correct abnormal heart rhythm	C99948	Electric Cardioversion		The administration of electric current to correct abnormal heart rhythm. (ACC)	944
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191399	Electrophysiological Procedures		C49488	Yes		The affirmative response to a question.	945
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191399	Electrophysiological Procedures		C49487	No		The non-affirmative response to a question.	946
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191399	Electrophysiological Procedures	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	947
C191388	Therapeutic and Supportive Procedures for COVID-19	Date of electric cardioversion	C191399	Electrophysiological Procedures	Date that DC cardioversion was performed	C191527	Date of Electric Cardioversion		The date that direct current cardioversion was performed.	948
C191388	Therapeutic and Supportive Procedures for COVID-19	Cardiac arrest requiring defibrillation	C191399	Electrophysiological Procedures	The sudden cessation of cardiac activity in an individual who becomes unresponsive, without normal breathing and no signs of circulation. Certain forms of cardiac arrest (e.g., ventricular fibrillation) may be reversed by defibrillation.	C191461	Cardiac Arrest Requiring Defibrillation		Cardiac arrest that is treated by defibrillation, regardless of outcome.	949
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191399	Electrophysiological Procedures		C49488	Yes		The affirmative response to a question.	950
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191399	Electrophysiological Procedures		C49487	No		The non-affirmative response to a question.	951
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191399	Electrophysiological Procedures	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	952
C191388	Therapeutic and Supportive Procedures for COVID-19	Date of defibrillation	C191399	Electrophysiological Procedures	Date that defibrillation was performed	C191526	Date of Defibrillation		The date that defibrillation was performed.	953
C191388	Therapeutic and Supportive Procedures for COVID-19	Invasive Revascularization Therapy	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C191567	Invasive Revascularization Therapy		A procedure undertaken to re-establish blood flow through a vessel via introduction of a medical device.	954
C191388	Therapeutic and Supportive Procedures for COVID-19	PCI	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Any attempt (successful or unsuccessful) to treat a stenosis by any technique, or even failed attempts to cross the stenosis with a wire or device.	C99521	Percutaneous Coronary Intervention		The placement of an angioplasty guide wire, balloon, or other device (e.g. stent, atherectomy, brachytherapy, or thrombectomy catheter) into a native coronary artery or coronary artery bypass graft for the purpose of mechanical coronary revascularization.	955
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49488	Yes		The affirmative response to a question.	956
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49487	No		The non-affirmative response to a question.	957
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	958
C191388	Therapeutic and Supportive Procedures for COVID-19	Date of PCI	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Date that PCI was performed	C191532	Date of Percutaneous Coronary Intervention	Date of PCI	The date that percutaneous coronary intervention (PCI) was performed.	959
C191388	Therapeutic and Supportive Procedures for COVID-19	Time of PCI	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Time that PCI was performed	C191641	Time of Percutaneous Coronary Intervention	Time of PCI	The time that percutaneous coronary intervention (PCI) was performed.	960
C191388	Therapeutic and Supportive Procedures for COVID-19	PCI Status	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Classification of the urgency of PCI procedure at the time the operator decides to perform the PCI	C191577	Percutaneous Coronary Intervention Status	PCI Status || PCI Type	The classification of the urgency of percutaneous coronary intervention (PCI) at the time the operator decides to perform the procedure.	961
C191388	Therapeutic and Supportive Procedures for COVID-19	Elective	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	The procedure can be performed on an outpatient basis or during a subsequent hospitalization without significant risk of infarction or death. For stable inpatients, the procedure is being performed during this hospitalization for convenience and ease of scheduling and NOT because the patient's clinical situation demands the procedure before discharge. If the diagnostic catheterization was elective and there were no complications, the PCI would also be elective.	C191588	Elective Percutaneous Coronary Intervention	Elective PCI	A percutaneous coronary intervention (PCI) that is performed on an outpatient basis or during a subsequent hospitalization without significant risk of infarction or death. For stable inpatients, the procedure is being performed during their hospitalization for convenience and ease of scheduling but not because the patient's clinical situation demands the procedure before discharge. If the diagnostic catheterization was elective and there were no complications, the PCI would also be considered elective.	962
C191388	Therapeutic and Supportive Procedures for COVID-19	Urgent	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	The procedure is performed on an inpatient basis and before discharge because of significant concerns that there is risk of ischemia, infarction, or death. Patients who are outpatients or in the emergency department at the time that the cardiac catheterization is requested would warrant an admission based on their clinical presentation.	C191591	Urgent Percutaneous Coronary Intervention	Urgent PCI	A percutaneous coronary intervention (PCI) that is performed on an inpatient basis and before discharge because of significant concerns that there is risk of ischemia, infarction, or death. Patients who are outpatients or in the emergency department at the time that the cardiac catheterization is requested would warrant an admission based on their clinical presentation.	963
C191388	Therapeutic and Supportive Procedures for COVID-19	Emergency	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	The procedure is performed as soon as possible because of substantial concerns that ongoing ischemia or infarction could lead to death. "As soon as possible" refers to a case of sufficient acuity that a scheduled case would be cancelled to perform this procedure immediately in the next available room during business hours, or the on-call team would be activated if this were to occur during off-hours.	C191589	Emergency Percutaneous Coronary Intervention	Emergency PCI	A percutaneous coronary intervention (PCI) that is performed as soon as possible because of substantial concerns that ongoing ischemia or infarction could lead to death. "As soon as possible" refers to a case of sufficient acuity that a scheduled case would be cancelled to perform this procedure immediately in the next available room during business hours, or the on-call team would be activated if this were to occur during off-hours.	964
C191388	Therapeutic and Supportive Procedures for COVID-19	Salvage	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	The procedure is a last resort in a patient with cardiogenic shock when the PCI begins (i.e., at the time of introduction into a coronary artery or bypass graft of the first guidewire or intracoronary device for the purpose of mechanical revascularization). Within the last 10 min before the start of the case or during the diagnostic portion of the case, the patient may have received chest compressions for a total of at least 60 s or have been on unanticipated extracorporeal circulatory support (e.g., extracorporeal mechanical oxygenation, or cardiopulmonary support).	C191590	Salvage Percutaneous Coronary Intervention	Salvage PCI	A percutaneous coronary intervention (PCI) that is a last resort in a patient with cardiogenic shock when the PCI begins (i.e., at the time of introduction into a coronary artery or bypass graft of the first guidewire or intracoronary device for the purpose of mechanical revascularization). Within the last 10 minutes before the start of the case, or during the diagnostic portion of the case, the patient may have received chest compressions for a total of at least 60 seconds or have been on unanticipated extracorporeal circulatory support (e.g., extracorporeal mechanical oxygenation (ECMO), or cardiopulmonary support).	965
C191388	Therapeutic and Supportive Procedures for COVID-19	Stent used	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A small stainless steel expandable mesh tube, inserted within the lumen of tubular body structures, to help keep it open	C50190	Stent Device	Stent	A device designed to support a tubular structure, especially the small stainless steel expandable mesh tube inserted within an artery.	966
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49488	Yes		The affirmative response to a question.	967
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49487	No		The non-affirmative response to a question.	968
C191388	Therapeutic and Supportive Procedures for COVID-19	Stent type	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Type of stent used to treat lesion	C191496	Type of Stent Used		A question about which type of stent was used to treat the lesion.	969
C191388	Therapeutic and Supportive Procedures for COVID-19	Bare-metal	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Metallic coronary stent without a polymer or antiproliferative drug coating	C80464	Bare Metal Stent		A vascular metal mesh tube without a coating.	970
C191388	Therapeutic and Supportive Procedures for COVID-19	Drug-eluting	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Metallic coronary stent with or without a polymer but with an antiproliferative drug coating	C80465	Drug Eluting Stent		A vascular metal mesh tube coated with medication. The drug coating is intended to lessen the likelihood of restenosis.	971
C191388	Therapeutic and Supportive Procedures for COVID-19	Drug-eluting with bioabsorbable polymer	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Metallic coronary stent with a bioabsorbable polymer with an antiproliferative drug coating	C191544	Bioabsorbable Polymer-Coated Drug Eluting Stent		A biodegradable drug-eluting vascular stent that is coated with a polymer that releases an anti-proliferative drug to inhibit intimal growth and prevent restenosis after implantation. The polymer degrades after completion of drug release, leaving an inert metal scaffold in place.	972
C191388	Therapeutic and Supportive Procedures for COVID-19	Bioabsorbable	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Stent struts composed of bioabsorbable materials also containing an antiproliferative drug	C191622	Bioabsorbable Vascular Stent	BVS || Bioresorbable Vascular Stent	A type of vascular stent that is biodegradable.	973
C191388	Therapeutic and Supportive Procedures for COVID-19	Covered	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Metallic coronary stent scaffold incorporating fabric or graft material, such as PTFE or polyurethane as a membrane component	C191623	Covered Stent		A metallic vascular stent encased by a synthetic membrane, often polytetrafluoroethylene or polyurethane, developed to prevent restenosis from proliferation of tissue as may be the case with uncovered stents.	974
C191388	Therapeutic and Supportive Procedures for COVID-19	Multiple types	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Treatment of several arteries using different stent types	C191495	Multiple Stent Types Used		A response indicating that arteries were treated for stenosis by using different stent types.	975
C191388	Therapeutic and Supportive Procedures for COVID-19	Other	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	976
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI flow prior to PCI	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Indicate if the previously treated and stented lesion is being treated for in-stent restenosis.	C191498	TIMI Flow prior to PCI	Thrombolysis in Myocardial Infarction Flow prior to Percutaneous Coronary Intervention	A question about the Thrombolysis in Myocardial Infarction (TIMI) flow grade of the previously treated lesion which is now being treated again for in-stent restenosis.	977
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI 0	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	No flow/no perfusion	C100040	Thrombolysis in Myocardial Infarction Flow-0	TIMI Flow-0	No perfusion: No antegrade flow beyond the point of occlusion. (www.TIMI.org accessed 21SEP2011) (ACC)	978
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI 1	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Slow penetration without perfusion	C100041	Thrombolysis in Myocardial Infarction Flow-1	TIMI Flow-1	Penetration without perfusion: The contrast material passes beyond the area of obstruction, but fails to opacify the entire coronary bed distal to the obstruction for the duration of the cine run. (www.TIMI.org accessed 21SEP2011) (ACC)	979
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI 2	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Partial flow/partial perfusion (>TIMI 1 but <TIMI 3)	C100042	Thrombolysis in Myocardial Infarction Flow-2	TIMI Flow-2	Partial reperfusion: The contrast material passes across the obstruction and opacifies the entire coronary bed distal to the obstruction. However, the rate of entry of contrast into the vessel distal to the obstruction and/or its rate of clearance from the distal bed are perceptibly slower than its entry into and/or clearance from comparable areas not perfused by the culprit vessel (e.g., the opposite coronary artery or coronary bed proximal to the obstruction).(www.TIMI.org accessed 21SEP2011) (ACC)	980
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI 3	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Complete and brisk flow/complete perfusion	C100043	Thrombolysis in Myocardial Infarction Flow-3	TIMI Flow-3	Complete perfusion: Antegrade flow into the bed distal to the obstruction occurs as promptly as into the bed proximal to the obstruction and clearance of contrast material from the involved bed is as rapid as from an uninvolved bed in the same vessel or the opposite artery. (www.TIMI.org accessed 21SEP2011) (ACC)	981
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	982
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI flow after PCI	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Indicate the postintervention TIMI flow.	C191497	TIMI Flow after PCI	Thrombolysis in Myocardial Infarction Flow after Percutaneous Coronary Intervention	A question about the post-interventional Thrombolysis in Myocardial Infarction (TIMI) flow grade.	983
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI 0	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	No flow/no perfusion	C100040	Thrombolysis in Myocardial Infarction Flow-0	TIMI Flow-0	No perfusion: No antegrade flow beyond the point of occlusion. (www.TIMI.org accessed 21SEP2011) (ACC)	984
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI 1	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Slow penetration without perfusion	C100041	Thrombolysis in Myocardial Infarction Flow-1	TIMI Flow-1	Penetration without perfusion: The contrast material passes beyond the area of obstruction, but fails to opacify the entire coronary bed distal to the obstruction for the duration of the cine run. (www.TIMI.org accessed 21SEP2011) (ACC)	985
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI 2	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Partial flow/partial perfusion (>TIMI 1 but <TIMI 3)	C100042	Thrombolysis in Myocardial Infarction Flow-2	TIMI Flow-2	Partial reperfusion: The contrast material passes across the obstruction and opacifies the entire coronary bed distal to the obstruction. However, the rate of entry of contrast into the vessel distal to the obstruction and/or its rate of clearance from the distal bed are perceptibly slower than its entry into and/or clearance from comparable areas not perfused by the culprit vessel (e.g., the opposite coronary artery or coronary bed proximal to the obstruction).(www.TIMI.org accessed 21SEP2011) (ACC)	986
C191388	Therapeutic and Supportive Procedures for COVID-19	TIMI 3	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Complete and brisk flow/complete perfusion	C100043	Thrombolysis in Myocardial Infarction Flow-3	TIMI Flow-3	Complete perfusion: Antegrade flow into the bed distal to the obstruction occurs as promptly as into the bed proximal to the obstruction and clearance of contrast material from the involved bed is as rapid as from an uninvolved bed in the same vessel or the opposite artery. (www.TIMI.org accessed 21SEP2011) (ACC)	987
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	988
C191388	Therapeutic and Supportive Procedures for COVID-19	% stenosis prior to PCI	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Percent diameter stenosis immediately before the treatment of this lesion. Percentage diameter reduction, ranging from 0 to 100, associated with the identified vessels. Percent stenosis at its maximal point is estimated to be the amount of reduction in the diameter of the "normal" reference vessel proximal to the lesion. In instances where multiple lesions are present, enter the single highest percent stenosis noted.	C191587	Percent Diameter prior to PCI	Percent Stenosis prior to Percutaneous Coronary Intervention	The percent diameter stenosis immediately before the treatment of the lesion.	989
C191388	Therapeutic and Supportive Procedures for COVID-19	% stenosis after PCI	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Percent diameter stenosis after treatment of this lesion. Percentage diameter reduction, ranging from 0 to 100, associated with the identified vessels. Percent stenosis at its maximal point is estimated to be the amount of reduction in the diameter of the "normal" reference vessel proximal to the lesion. In instances where multiple lesions are present, enter the single highest percent stenosis noted.	C191586	Percent Stenosis after PCI	Percent Stenosis after Percutaneous Coronary Intervention	The percent diameter stenosis after the treatment of the lesion.	990
C191388	Therapeutic and Supportive Procedures for COVID-19	Percutaneous arterial access	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Arterial access site(s)	C100056	Arterial Access Site		Anatomical location where an artery was accessed for a diagnostic or therapeutic procedure.	991
C191388	Therapeutic and Supportive Procedures for COVID-19	Femoral || Femoral artery	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	The artery of the groin that supplies the lower extremity, including the anterior and anteromedial surfaces of the thigh, whose pulse is palpable below the inguinal ligament, midway between the anterior superior iliac spine and the symphysis pubis.	C12715	Femoral Artery		An artery that starts within the inguinal region and extends to the lower extremities.	992
C191388	Therapeutic and Supportive Procedures for COVID-19	Brachial || Brachial artery	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	The artery of the upper arm, whose pulse can be palpated on the inner surface of the upper arm between the bodies of the biceps and triceps muscles.	C12681	Brachial Artery		An artery originating at the axillary artery and branching into the radial and ulnar arteries.	993
C191388	Therapeutic and Supportive Procedures for COVID-19	Radial || Radial artery	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	The artery of the lower arm that supplies muscles of lateral portions of both the anterior and posterior compartment of the forearm, lateral aspect of the wrist, skin of the dorsum hand and proximal portions of digits, and deep muscles of pain whose pulsations can be palpated on the flexor surface of the wrist laterally.	C12838	Radial Artery		The branch of the brachial artery that passes down the forearm.	994
C191388	Therapeutic and Supportive Procedures for COVID-19	Other	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17649	Other	Other or Miscellaneous	Different than the one(s) previously specified or mentioned.	995
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	996
C191388	Therapeutic and Supportive Procedures for COVID-19	Thrombectomy for pulmonary embolism	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Interventional procedure to remove a blood clot from a pulmonary artery in a patient with acute pulmonary embolism	C191634	Thrombectomy for Pulmonary Embolism		An interventional procedure to remove a blood clot from a pulmonary artery in a patient with acute pulmonary embolism.	997
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49488	Yes		The affirmative response to a question.	998
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49487	No		The non-affirmative response to a question.	999
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1000
C191388	Therapeutic and Supportive Procedures for COVID-19	Thrombectomy for stroke	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Interventional procedure to remove a blood clot from an artery in a patient with acute ischemic stroke	C191635	Thrombectomy for Stroke		An interventional procedure to remove a blood clot from an artery in a patient with acute ischemic stroke.	1001
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49488	Yes		The affirmative response to a question.	1002
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49487	No		The non-affirmative response to a question.	1003
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1004
C191388	Therapeutic and Supportive Procedures for COVID-19	Thrombectomy for peripheral arterial thrombus	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Interventional procedure to remove a blood clot from a peripheral artery, excluding acute ischemic stroke	C191633	Thrombectomy for Peripheral Arterial Thrombus		An interventional procedure to remove a blood clot from a peripheral artery, excluding acute ischemic stroke.	1005
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49488	Yes		The affirmative response to a question.	1006
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49487	No		The non-affirmative response to a question.	1007
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1008
C191388	Therapeutic and Supportive Procedures for COVID-19	Thrombolysis for pulmonary embolism	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Treatment to remove a blood clot from a pulmonary artery in a patient with acute ischemic stroke	C191636	Thrombolysis for Pulmonary Embolism		Medical treatment to break up a blood clot from a pulmonary artery in a patient with acute pulmonary embolism.	1009
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49488	Yes		The affirmative response to a question.	1010
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49487	No		The non-affirmative response to a question.	1011
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1012
C191388	Therapeutic and Supportive Procedures for COVID-19	Thrombolysis for stroke	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	Treatment to remove a blood clot from an artery in a patient with acute ischemic stroke	C191637	Thrombolysis for Stroke		Medical treatment to break up a blood clot from an artery in a patient with acute ischemic stroke.	1013
C191388	Therapeutic and Supportive Procedures for COVID-19	Yes	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49488	Yes		The affirmative response to a question.	1014
C191388	Therapeutic and Supportive Procedures for COVID-19	No	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment		C49487	No		The non-affirmative response to a question.	1015
C191388	Therapeutic and Supportive Procedures for COVID-19	Unknown	C191400	Invasive Coronary/Vascular/Neurovascular Revascularization Treatment	A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1016
C191389	End-of-Life Management	Limitation of resuscitation			Any documented order or decision regarding patient request to limit a component of emergency therapy to restore circulation or ventilation (e.g., no intubation, no shocking, no chest compressions)	C191445	Limitation of Resuscitation		A documented order or decision regarding a patient's request to limit a component of emergency therapy to restore circulation or ventilation (e.g., no intubation, no shocking, no chest compressions).	1017
C191389	End-of-Life Management	Yes				C49488	Yes		The affirmative response to a question.	1018
C191389	End-of-Life Management	No				C49487	No		The non-affirmative response to a question.	1019
C191389	End-of-Life Management	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1020
C191389	End-of-Life Management	DNR			Explicit documentation by health care provider or patient indicating that no resuscitative efforts are to be performed in the event of circulatory or respiratory arrest	C93313	Do Not Resuscitate Order	DNR || Do Not Resuscitate		1021
C191389	End-of-Life Management	Yes				C49488	Yes		The affirmative response to a question.	1022
C191389	End-of-Life Management	No				C49487	No		The non-affirmative response to a question.	1023
C191389	End-of-Life Management	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1024
C191389	End-of-Life Management	Inactivation of ICD defibrillation mode			Inactivation of ICD defibrillation mode without plans to reactivate (excludes inactivation for specific surgical procedures)	C191444	Inactivation of ICD Defibrillation Mode		A documented order or decision to inactivate the ICD defibrillation mode without plans for reactivation (excludes inactivation for specific surgical procedures).	1025
C191389	End-of-Life Management	Yes				C49488	Yes		The affirmative response to a question.	1026
C191389	End-of-Life Management	No				C49487	No		The non-affirmative response to a question.	1027
C191389	End-of-Life Management	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1028
C191389	End-of-Life Management	Advance care planning			The process of clarifying goals of care, communicating wishes and goals for medical care in the event of an emergency, and documenting those wishes or plan in an advance directive	C191599	Advance Care Planning		The process of clarifying the aims of care, communicating wishes and goals for medical care in the event of an emergency, and documenting those wishes or plan in an advance directive.	1029
C191389	End-of-Life Management	Yes				C49488	Yes		The affirmative response to a question.	1030
C191389	End-of-Life Management	No				C49487	No		The non-affirmative response to a question.	1031
C191389	End-of-Life Management	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1032
C191389	End-of-Life Management	Medical order for life-sustaining treatment			A written medical order by a physician, advanced practice registered nurse, or physician assistant that records a patient's treatment preferences as to life-sustaining treatment	C176984	Physician Orders for Life Sustaining Treatment		A medical order form, signed by a medical professional, that outlines a plan for end of life care that reflects both a patient's preferences concerning care at life's end and a physician's judgment based on a medical evaluation.	1033
C191389	End-of-Life Management	Yes				C49488	Yes		The affirmative response to a question.	1034
C191389	End-of-Life Management	No				C49487	No		The non-affirmative response to a question.	1035
C191389	End-of-Life Management	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1036
C191389	End-of-Life Management	Discharge to hospice			Discharge to either home hospice or to a facility with hospice care	C191585	Discharge to Hospice		The disposition of a patient to hospice care.	1037
C191389	End-of-Life Management	Yes				C49488	Yes		The affirmative response to a question.	1038
C191389	End-of-Life Management	No				C49487	No		The non-affirmative response to a question.	1039
C191389	End-of-Life Management	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1040
C191389	End-of-Life Management	Palliative care consultation			Consultation with a palliative care provider	C191566	Palliative Care Consultation		The evaluation of a patient's care with the focus on minimizing their discomfort and maximizing their quality of life rather than curing their disease.	1041
C191389	End-of-Life Management	Yes				C49488	Yes		The affirmative response to a question.	1042
C191389	End-of-Life Management	No				C49487	No		The non-affirmative response to a question.	1043
C191389	End-of-Life Management	Unknown			A proper value is applicable but not known.	C17998	Unknown	Not Known || Unknown/Not Stated	Not known, observed, recorded; or reported as unknown by the data contributor.	1044